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Summary 
Inflammatory bowel disease (IBD) is a chronic, relapsing inflammatory condition of the gastro-
intestinal tract comprising two subtypes; Crohn’s disease and ulcerative colitis (UC). The aetiology of 
IBD is not completely understood but the general consensus is that it is a multifactorial disease in 
which an inappropriate immune response is mounted in genetically susceptible individuals as a result 
of a complex interplay between unknown environmental triggers, the gut microbiome, and the 
intestinal immune system. A major hallmark of IBD is increased intestinal permeability caused mainly 
by tight junction (TJ) deregulation and intestinal epithelial cell (IEC) apoptosis. Directly targeting 
epithelial dysfunction in IBD would restore intestinal barrier integrity, which forms the structural 
basis of mucosal healing; a key treatment goal in IBD management that predicts sustained clinical 
remission and resection-free survival of patients. 
In this thesis, we investigated the therapeutic potential of intervening in two pathways directly 
involved in maintenance and regulation of barrier integrity; increasing colonic butyrate levels 
through oral administration of Butyricicoccus pullicaecorum (B. pullicaecorum) 25-3T, and Rho-
associated kinase (ROCK) inhibition using an inhibitor that was specifically designed to have a 
localised action in the gut. 
In the first part of this thesis (chapter III), we investigated the barrier-protective properties of B. 
pullicaecorum 25-3T; a potentially probiotic bacterial strain. This anaerobic butyrate-producer 
belongs to the clostridial cluster IV, a bacterial community that is particularly depleted in the 
dysbiotic IBD microbiota. Given the severe butyrate deficiency in IBD patients and the well-known 
barrier-protective properties of butyrate, B. pullicaecorum 25-3T could be used as a pharmabiotic to 
promote mucosal healing in IBD. First, Butyricicoccus was found to be mucosa-adherent and reduced 
in UC patients with active disease compared to healthy controls. Next, we found that butyrate-
responsive TJ gene expression was severely deregulated in inflamed colonic mucosal biopsies 
collected from UC patients, in particular claudin-1 (CLDN1) whose mRNA levels were, counter-
intuitively, increased. These elevated CLDN1 levels correlated with a reduced Butyricicoccus activity 
in the colonic mucosa. Administration of butyrate to IEC monolayers of differentiated epithelial Caco-
2 cells decreased tumor necrosis factor (TNF)/interferon gamma (IFNγ)-induced CLDN1 levels, which 
coincided with a restoration of barrier integrity. Interestingly, the conditioned medium of B. 
pullicaecorum 25-3T reduced CLDN1 levels in inflamed colonic mucosal biopsies from UC patients. 
In the second part of this thesis (chapter IV), we investigated the effect of ROCK inhibition on 
intestinal epithelial barrier dysfunction. The involvement of ROCK in inflammation-induced loss of 
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barrier integrity and the elevated ROCK activity observed in mucosa of patients with active IBD, has 
prompted research into the use of ROCK inhibitors to counteract epithelial dysfunction in IBD. In this 
thesis, we evaluated a locally acting ROCK inhibitor, AMA0825, which does not display the adverse 
effects of current inhibitors due to its degradation upon systemic exposure. Despite its efficient 
inhibition of myosin light chain phosphorylation, AMA0825 did not affect TNF/IFNγ-induced loss of 
barrier integrity or nuclear factor-κB activation in intestinal epithelial cells. AMA0825 did not 
attenuate the occurrence of epithelial erosions or the associated mucosal inflammation during 
experimental colitis. Finally, AMA0825 did not prevent TNF/IFNγ-induced epithelial caspase-
activation, nor in vivo lipopolysaccharide-mediated enterocyte apoptosis or the ensuing intestinal 
permeability and mucosal pro-inflammatory response. Research from our lab demonstrated that 
AMA0825 prevents and resolves intestinal fibrosis via effects that combine a reduction in fibroblast 
activation with an increase in the autophagic response in these cells. 
In a the third and final part of this thesis (chapter V), we sought to further define the differences 
between two colonic epithelial cell lines; T84 and Caco-2. Both differentiate spontaneously at 
confluence into a monolayer of structurally and functionally mature absorptive epithelial cells and 
are used interchangeably as model systems for human intestinal epithelium, despite evidence 
suggesting that differentiated Caco-2 cells closely resemble small intestinal enterocytes, while 
mature T84 cells have been less well described. We demonstrated that differentiated T84 
monolayers have - in contrast to differentiated Caco-2 monolayers - shorter microvilli, a lack of brush 
border-associated enzyme expression, exhibit high levels of colon-specific markers and show a dose-
responsive improvement of barrier function towards butyrate. This led us to conclude that 
differentiated T84 cells do not acquire the signature of mature small intestinal enterocytes like Caco-
2 cells, but retain much of their original colonic characteristics throughout differentiation. 
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Samenvatting 
Inflammatoir darmlijden (inflammatory bowel disease, IBD) is een chronische, terugkerende 
ontsteking van het gastro-intestinaal stelsel met twee subtypes; de ziekte van Crohn en colitis 
ulcerosa (ulcerative colitis, UC). De etiologie van IBD is niet volledig gekend maar de algemeen 
aanvaarde definitie is dat het een multifactoriële ziekte is, waarbij een overdreven immuunrespons 
wordt opgewekt in individuen met een genetische aanleg die het resultaat is van een complexe 
interactie tussen ongekende omgevingsfactoren, de darmflora, en het intestinale immuunsysteem. 
Een belangrijk kenmerk van IBD is een verhoogde intestinale permeabiliteit die voornamelijk 
veroorzaakt wordt door een ontregeling van de zonula occludens (tight junctions, TJ) structuur en 
door apoptose van intestinale epitheelcellen (IEC). Het direct remediëren van epitheel-dysfunctie in 
IBD zou het herstel van de intestinale barrière bewerkstelligen, hetgeen de structurele basis vormt 
voor mucosale heling dat een belangrijk einddoel is in de behandeling van IBD. Mucosale heling 
voorspelt nl. langdurige klinische remissie van de ziekte en een verminderde nood aan chirurgisch 
ingrijpen. 
Tijdens deze thesis onderzochten we het therapeutisch potentieel van de interventie in twee 
pathways die rechtstreeks betrokken zijn bij behoud en regulatie van barrière-integriteit; het 
verhogen van de butyraat-niveaus in het colon door orale toediening van Butyricicoccus 
pullicaecorum (B. pullicaecorum) 25-3T, en inhibitie van Rho-geassocieerde kinasen (ROCK) d.m.v. een 
inhibitor die specifiek ontwikkeld werd voor een lokale werking in de darm.  
In het eerste deel van deze thesis (hoofdstuk III) onderzochten we de barrière-protectieve 
eigenschappen van B. pullicaecorum 25-3T; een potentieel probiotische bacterie. Deze anaerobe 
boterzuur-produceerder behoort tot de Clostridium cluster IV, een bacteriële groep die sterk 
gereduceerd is in de dysbiotische IBD microbiota. Gezien de uitgesproken boterzuur-deficiëntie in 
IBD patiënten en de gekende barrière-protectieve eigenschappen van boterzuur, lijkt B. 
pullicaecorum 25-3T interessant voor gebruik als een zgn. pharmabioticum ter bevordering van 
mucosale heling in IBD. Ten eerste konden wij aantonen dat Butyricicoccus mucosa-adherent was en 
gereduceerd in patiënten met actieve UC in vergelijking met gezonde controles. Vervolgens 
demonstreerden we dat boterzuur-responsieve TJ genexpressie sterk ontregeld was in 
geïnflammeerde mucosale colonbiopten van UC patiënten, in het bijzonder claudine-1 (CLDN1) 
waarvan de mRNA niveaus verhoogd waren; een tegenstrijdig gegeven gezien de verstoorde 
barrière-integriteit in IBD. Deze verhoogde CLDN1 niveaus correleerden met een verlaagde 
Butyricicoccus activiteit in de colon-mucosa. Toediening van boterzuur aan IEC monolagen van 
gedifferentieerde epitheliale Caco-2 cellen verlaagde de tumor necrosis factor (TNF)/interferon 
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gamma (IFNγ)-geïnduceerde CLDN1 niveaus, hetgeen samenviel met een herstel van de barrière-
integriteit. Interessant was dat het geconditioneerd medium van B. pullicaecorum 25-3T de CLDN1 
niveaus in geïnflammeerde mucosale colonbiopten van UC patiënten deed dalen. 
In het tweede deel van deze thesis (hoofdstuk IV) onderzochten we het effect van ROCK inhibitie op 
intestinale epitheliale barrière-dysfunctie. De betrokkenheid van ROCK’s bij inflammatie-
geïnduceerde intestinale permeabiliteit en de verhoogde ROCK activiteit in de mucosa van patiënten 
met actieve IBD, heeft het onderzoek gestimuleerd naar het gebruik van ROCK inhibitoren ter 
behandeling van epitheel-dysfunctie in IBD. In deze thesis evalueerden wij een lokaal werkende 
ROCK inhibitor, AMA0825, die niet de neveneffecten vertoont van de huidige ROCK inhibitoren 
wegens zijn degradatie bij systemische blootstelling. Ondanks zijn efficiënte inhibitie van myosin light 
chain fosforylatie, had AMA0825 geen effect op TNF/IFNγ-geïnduceerd verlies van barrière-integriteit 
of nuclear factor-κB activatie in intestinale epitheelcellen. Behandeling met AMA0825 gaf geen 
vermindering van epitheliale erosies of de geassocieerde mucosale inflammatie tijdens 
experimentele colitis. Tot slot kon AMA0825 de TNF/IFNγ-geïnduceerde epitheliale caspase-activatie 
niet verhinderen, noch de in vivo lipopolysaccharide-gemedieerde enterocyt apoptose of de daaruit 
volgende intestinale permeabiliteit en mucosale pro-inflammatoire respons. Onderzoek uit ons lab 
heeft aangetoond dat AMA0825 de ontwikkeling van intestinale fibrose kan verhinderen en omkeren 
door een combinatie van zowel een reductie van fibroblast-activatie als een verhoging van de 
autofagische respons in deze cellen. 
In het derde en laatste deel van deze thesis (hoofdstuk V) hebben we getracht de verschillen tussen 
twee colonepitheel cellijnen, T84 en Caco-2, verder te definiëren. Deze cellijnen differentiëren 
spontaan na confluentie tot een monolaag van structureel en functioneel mature, absorptieve IEC’en 
en worden beide gebruikt als model systemen voor humaan intestinaal epitheel ondanks het feit dat 
gedifferentieerde Caco-2 cellen eerder lijken op dunne darm enterocyten, terwijl mature T84 cellen 
minder goed gekarakteriseerd zijn. We konden aantonen dat gedifferentieerde T84 monolagen - in 
tegenstelling tot gedifferentieerde Caco-2 monolagen - volgende kenmerken hebben: kortere 
microvilli, een gebrek aan brush border-geassocieerde enzym expressie, hoge concentraties colon-
specifieke merkers en een dosis-afhankelijke verbetering van de barrière functie na stimulatie met 
boterzuur. Hieruit concludeerden we dat gedifferentieerde T84 cellen niet de kenmerken verkrijgen 
van dunne darm enterocyten zoals Caco-2 cellen, maar dat zij hun originele colon-karakter behouden 
tijdens differentiatie. 
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1.1 INTRODUCTION TO INFLAMMATORY BOWEL DISEASE 
In the first part of this introduction, we will focus on the pathology of inflammatory bowel disease 
(IBD). We will elaborate on the clinical and pathophysiological differences between its subtypes 
Crohn’s disease and ulcerative colitis, its etiology and risk factors, and its clinical management. We 
will also touch upon future treatment options to address the unmet needs in current disease 
therapy, in particular those related to our research topic; restoration of intestinal epithelial barrier 
integrity through butyrate-producing bacteria and Rho kinase inhibition. 
1.1.1 Crohn’s disease versus ulcerative colitis 
Inflammatory bowel disease is the common denominator used to describe two related, chronic and 
relapsing inflammatory afflictions of the gastro-intestinal tract, i.e. Crohn’s disease (CD) and 
ulcerative colitis (UC). Inflammatory bowel disease occurs worldwide but the incidence and 
prevalence are the highest in western, developed countries.1 The main clinical symptoms of IBD are 
abdominal pain, fever, weight loss and bloody diarrhea.2 Although both forms of IBD share many 
similarities, several important clinical and pathophysiological differences do exist. CD can manifest 
itself along the entire length of the gastro-intestinal tract but the terminal ileum and colon are the 
most frequently affected areas. UC on the other hand, occurs exclusively in the colon with the 
occasional case of backwash ileitis in patients with pancolitis. Disease complications of IBD include 
fistulae and obstruction due to stenosis in CD, and perforation and toxic megacolon in UC.3 In up to 
40% of IBD patients, extra-intestinal disease manifestations in the joints, eyes and skin also occur.4 
On endoscopy, CD presents itself as a patchy inflammation where multiple affected bowel segments 
are interspersed with unaffected “skip” areas, whereas UC is characterised by a continuous colonic 
involvement. Histologically, inflammation in CD and UC is characterised by ulceration, infiltration of 
acute (granulocytes, macrophages) and chronic (lymphocytes, plasma cells) inflammatory cells, and 
architectural distortions. In UC, inflammation is limited to the mucosal layers and ulcers are 
superficial, while in CD, inflammation is transmural with granulomas and deep, linear ulcers.5 
1.1.2 Etiology and risk factors 
The etiology of IBD is not completely understood but the general consensus is that it is a 
multifactorial disease in which an inappropriate immune response is mounted in genetically 
susceptible individuals as a result of the complex interaction between unknown environmental 
triggers, the gut microbiome, and the intestinal immune system (Figure 1).6,7 
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Figure 1. Etiopathogenesis of IBD. IBD is a multifactorial disease in which an inappropriate intestinal immune 
response is mounted as a result of the complex interplay between the gut microbiota (“microbiome”), unknown 
environmental triggers collectively termed the “exposome” (e.g. diet, smoking, drugs, etc.), and the genome of 
the susceptible host (IBD loci correlating with genes involved in innate immunity, barrier function, etc.). 
Evidence for a genetic contribution to IBD pathogenesis is well-established; 15% of IBD patients have 
a first-degree relative who also has IBD, and twin studies revealed a 20 to 50% concordance rate for 
CD in monozygotic twins and a concordance rate of less than 10% in dizygotic twins. The evidence 
from twin studies in UC showed a concordance rate of 16% and 4% in monozygotic and dizygotic 
twins, respectively. Collectively, these data suggest an important hereditary component to disease 
expression, which is stronger in CD than in UC.8 Genetic association studies have identified over 200 
IBD susceptibility loci so far; a meta-analysis combining genome-wide association studies and 
Immunochip data identified 163 loci associated with IBD, and a more recent trans-ethnic analysis 
identified an additional 38 new IBD loci.9,10 Of those 163 loci identified in the first study, 110 
conferred risk to both IBD subtypes, whereas 30 and 23 loci were unique to CD and UC, respectively. 
IBD susceptibility loci share a significant overlap with other immune-mediated disorders (e.g. 
psoriasis) and, interestingly, also with primary immunodeficiencies like Mendelian susceptibility to 
mycobacterial disease, which is characterised by a predisposition to clinical disease caused by weakly 
virulent mycobacteria.9 Indeed, a substantial amount of IBD loci correlate with genes involved in 
bacterial response. A textbook example of genetic association in IBD is nucleotide-binding 
oligomerisation domain-containing protein 2 (NOD2), a gene encoding an intracellular pattern 
recognition receptor for bacterial muramyl dipeptide and the first ever CD susceptibility gene to be 
discovered.11 However, the total disease variance explained by these 163 loci amounts to 13.6% in 
CD and 7.5% in UC.9 Combined with the IBD concordance rate in identical twins of maximum 50%, 
these data underscore the importance of the contribution of external factors to IBD pathogenesis. 
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In the second half of the 20th century, IBD incidence started to rise in Northern America and Europe. 
Recent data indicate that the incidence rate in these countries may have reached a plateau, whereas 
incidence has started to increase in newly developing countries in Asia and South America.12 This 
distinct geographical distribution pattern of IBD prevalence gave rise to the so-called “hygiene 
hypothesis”, which postulates that the growing frequency in immunological disorders like IBD could 
be partially attributable to a lack of exposure to infectious agents during early childhood, as is the 
case in urban areas of industrialised countries, thus impairing the development of immune tolerance 
to microbial antigens.13 An array of other environmental risk factors characteristic of a western 
lifestyle have also been identified as possible contributors to the onset and subsequent flare-ups of 
IBD, and are collectively termed the “exposome”. Examples include dietary factors, air and water 
pollution, food additives (e.g. aluminium, TiO2), lifestyle factors (e.g. smoking), stress, drug use (oral 
contraceptives, non-steroidal anti-inflammatory drugs and antibiotics), infections and gut microbial 
composition.14 Unfortunately, population-based studies supporting the involvement of these factors 
in disease expression often yield inconsistent findings, making causal relationships difficult to 
establish. The most intensively researched external factor to date is the gut microbiome. There is 
solid evidence that its composition, which is modified to a great extent by dietary intake, is severely 
altered in IBD patients, which could modulate immunological responses and will be discussed in 
more detail in §1.2 of this introduction. 
1.1.3 Unmet needs in current management of IBD 
1.1.3.1 Current approach to managing active IBD 
Given the lack of an obvious causative agent for IBD, the main goal of current IBD management is the 
induction of remission of clinical symptoms, including cessation of rectal bleeding, normalisation of 
stool frequency and consistency, absence of abdominal pain and improved general wellbeing. 
However, evidence suggests that, even during periods of clinical remission, persistent inflammation 
can be seen, as demonstrated by elevation of serum and fecal biomarkers and/or endoscopic signs of 
mucosal inflammation. Persistent inflammation is believed to lead to progressive bowel damage, 
higher relapse risk and complications.15 Achieving deep remission, encompassing besides the 
traditional clinical improvement also more objective parameters of inflammation control, such as 
mucosal healing on endoscopy, histological remission and biomarker normalisation, may therefore 
greatly improve disease outcomes.16 Mucosal healing in particular has emerged as a key treatment 
goal in IBD, with several studies suggesting that the attainment of mucosal healing predicts lower 
hospitalisation rates, sustained clinical remission and resection-free survival of patients.17-22 
The conventional strategy for inducing remission in IBD consists of a step-up approach in which 
corticosteroids are used, alone or in combination with aminosalicylates, as the first treatment option. 
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In case of a lack of improvement, medication is switched to - in sequence - immunosuppressant drug 
therapy (e.g. mercaptopurine, azathioprine, cyclosporine), biologicals against tumor necrosis factor 
(TNF) (e.g. infliximab, adalimumab, certolizumab) or integrin homing receptors (e.g. vedolizumab), 
and surgical resection of the afflicted bowel segment as the final treatment option. The focus of 
subsequent maintenance therapy is the withdrawal of corticosteroids and the prevention of 
symptom recurrence. Several of the drugs described above have been shown to induce mucosal 
healing but there are substantial differences between CD and UC in terms of the effect of different 
drugs on mucosal healing. For example, azathioprine and anti-TNF therapy promote mucosal healing 
in both CD and UC, whereas corticosteroids are able to induce mucosal healing in subsets of patients 
with UC but have little or no positive effect on the induction of mucosal healing in CD patients.23-27 
1.1.3.2 Future directions in IBD therapy 
Despite available treatment modalities, complete and sustained remission is not guaranteed, even 
for the most advanced therapies like anti-TNF biologicals. The most important clinical issues with 
current therapeutics include a lack of response (primary non-response and secondary loss of 
response), systemic adverse effects related to dose and duration of therapy, opportunistic infections 
due to the immunosuppressive nature of most drugs, infusion/injection reactions and antibody 
formation in the case of biologicals, and long-term complications like fibrostenosis.28-32 The need for 
a more effective disease control is evident from this, but next-generation IBD therapy is still largely 
focused on antibody-mediated blocking of effector immune responses. 
However, identification of microbial dysbiosis and impaired barrier function as major hallmarks of 
IBD, have opened up novel therapeutic approaches that do not involve the traditional 
immunosuppressive mode of action. Targeting these primary defects instead of the underlying 
inflammatory processes would not only bypass the adverse effects associated with immune 
suppression but would also directly promote mucosal healing, leading to better clinical outcomes. 
In the next three paragraphs, a brief overview will be given of the future directions in IBD 
management currently under investigation; immunomodulatory strategies in clinical development, 
microbiota modulation, and identification of targets for mucosal healing that are directly involved in 
the restoration of epithelial barrier integrity. 
1.1.3.2.1 Immunomodulatory strategies 
In the following section, a short overview will be given of the next-generation therapeutic strategies 
focussing on abrogating inflammatory immune responses that are currently being evaluated in 
clinical trials, as reviewed by D’Haens et al.33 
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The introduction of TNF-neutralising agents was a breakthrough in IBD management but primary 
non-response and secondary loss of response to anti-TNF antibody therapy is common and presents 
a major clinical problem.34 Other means of blocking TNF are therefore being investigated, including 
anti-TNF vaccination, TNF gene silencing and TNF-neutralising nanobodies. For example, vaccination 
of mice transgenic for human TNF (hTNF) (TTg mice) with a hTNF-kinoid vaccine elicited high titers of 
antibodies that neutralised hTNF bioactivities but did not result in a cellular response to hTNF. The 
vaccine was found to be safe and effective in two experimental models of hTNF exposure: 
immunised TTg mice resisted acute hTNF-driven lethal shock, and were protected from development 
of chronic, spontaneous arthritis.35 The safety, immune responses, and clinical effects of active 
immunisation against TNF using the hTNF-kinoid vaccine has been evaluated in a phase II trial in CD 
patients.36 Immunisation with hTNF-kinoid safely induced anti-TNF antibodies with indication of a 
positive clinical response, suggesting that active immunisation against TNF could represent a new 
therapeutic strategy in IBD. The idea of reducing TNF levels in IBD patients by selectively silencing the 
TNF gene using RNA interference is still in preclinical development but McCarthy et al. reported on 
the clinical potential of a cyclodextrin-based TNF siRNA delivery system for the treatment of IBD.37 
They showed that intrarectal administration of TNF siRNA in C57BL/6 mice with dextran sulfate 
sodium (DSS)-induced colitis resulted in a mild amelioration of clinical signs of colitis as well as a 
significant reduction in colon weight and colonic Tnf levels. Also the use of TNF-neutralising 
nanobodies (derived from fragments of heavy-chain camelid antibodies that are more stable than 
conventional antibodies) as therapeutic proteins in IBD is still in the preclinical phases of 
development, but promising results were obtained with Lactococcus lactis bacteria that were 
engineered to secrete murine (m) TNF-neutralising nanobodies.38 Oral administration of nanobody-
secreting Lactococcus lactis resulted in local delivery of anti-mTNF nanobodies at the colon and 
significantly reduced inflammation in mice with chronic DSS-induced colitis.  
Besides TNF, other pro-inflammatory cytokines, such as interleukin (IL)-12, IL-23 and IL-6, have also 
been reported to play a key role in IBD pathogenesis39,40 and the therapeutic potential of targeting 
these cytokines is currently being evaluated. In the case of IL-6, elevated serum levels are considered 
to be a clinically relevant parameter in patients with active CD and a neutralising antibody against the 
IL-6 receptor suppressed established experimental colitis in various animal models of CD.41 Recently, 
the therapeutic efficacy of a monoclonal antibody (mAb) against IL-6 (PF-04236921) was evaluated in 
a phase II, randomised, double-blind, placebo-controlled, dose-ranging study in subjects with 
refractory CD, which revealed statistically significant clinical response and remission rates in this 
patient population.42 The heterodimeric cytokines IL-12 and IL-23, which share a common p40 
subunit, are both increased in the intestine of patients with CD43 and anti-inflammatory effects of a 
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genetic deletion or antibody-mediated neutralisation of IL-12 and IL-23 in mouse models of intestinal 
inflammation have provided a rationale for the therapeutic targeting of both these cytokines. More 
specifically, administration of mAbs against IL-12 in a murine model of chronic 2,4,6-trinitrobenzene 
sulfonic acid-induced colitis led to an improvement of both the clinical and histopathological aspects 
of disease and frequently abrogated the established colitis completely.44 Also antibodies against p19, 
the subunit specific to IL-23, suppressed chronic intestinal inflammation in a T cell-deficient, 
Helicobacter hepaticus-infected RAG knockout mouse model of IBD.45 The clinical efficacy of 
ustekinumab, a mAb directed against the p40 subunit of IL-12 and IL-2346, as an induction and 
maintenance therapy in refractory CD was recently evaluated in a phase III study, which revealed 
that patients with moderately to severely active CD receiving intravenous ustekinumab had a 
significantly higher response rate than those receiving placebo, and that subcutaneous ustekinumab 
maintained remission in patients who had a clinical response to the intravenous induction therapy.47 
Another targetable mechanism of action is the homing and endothelial transcytosis of immune cells 
towards the site of inflammation. Examples of anti-migration agents include mAbs against the 
leukocyte α4β7 integrin receptor and its endothelial ligand, mucosal vascular addressin cell adhesion 
molecule 1 (MAdCAM-1), as well as mAbs against chemokines (e.g. CXCL-10) and selective, small-
molecule antagonists of chemokine receptors (e.g. CCR9). The anti-α4β7 mAb vedolizumab has 
recently been approved for treatment of moderate to severe UC and CD based on the encouraging 
results from a series of phase III, randomised, placebo-controlled clinical trials performed in patients 
who have failed TNF antagonist therapy.48 These studies showed that vedolizumab is effective in the 
induction of clinical response and remission in moderately to severely active UC and CD patients as 
well as in the maintenance of remission in patients who achieved an initial response to therapy.49 
Safety and efficacy of an anti-MAdCAM-1 mAb (PF-00547659) was recently evaluated in active, 
refractory CD and UC patients in two separate randomised, double-blind, placebo-controlled studies. 
In the UC study, the primary endpoint (remission at week 12) was met50, whereas in the CD study, 
the primary endpoint (clinical response at week 8 or 12) was not met but PF-00547659 was 
pharmacologically active, as shown by a sustained dose-related decrease in MAdCAM-1 levels.51 A 
mAb against CXCL-10 (BMS-936557), a chemokine involved in inflammatory cell migration whose 
expression is elevated in colonic tissue and plasma of UC patients, was evaluated for safety and 
efficacy during a phase II study in patients with active UC. Endpoints of prespecified rates of clinical 
response, clinical remission and mucosal healing were not met, but a higher drug exposure 
correlated with increasing clinical response and histological improvement, warranting further dose-
response studies.52 A pharmacological antagonist of the chemokine receptor CCR9 (CCX282-B), which 
is selectively expressed on gut-homing T cells and on mucosal lymphocytes in the small intestine, 
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thus suggesting that CCR9 plays a role in the recruitment and/or retention of lymphocytes to this 
site53, was recently evaluated in phase II and III clinical trials in patients with active CD. However, 
although CCX282-B showed efficacy in inducing and maintaining clinical response in a randomised, 
placebo-controlled phase II trial54, these results were not confirmed in the ensuing phase III trial.55 
Also modulation of the sphingosine-1-phosphate (S1P) signalling axis has recently emerged as a novel 
therapeutic target for the treatment of IBD. S1P is a bioactive lipid that regulates inflammation via its 
impact on the trafficking, differentiation, and effector functions of bone marrow-derived immune 
cells.56 Targeting S1P signalling in preclinical models of IBD has yielded promising results. For 
example, functional antagonists of the S1P receptor are able to dampen inflammation in murine 
models of colitis induced by IL-10 deficiency, DSS treatment, and adoptive T cell transfer by 
decreasing the number of CD4+ T lymphocytes in the colonic lamina propria, which is associated with 
a reduction in interferon gamma (IFNγ) production.56 The S1P receptor modulator RPC-1063 is 
currently undergoing safety and efficacy evaluation in phase II and phase III trials in patients with 
moderately to severely active UC, and in a phase II trial in patients with moderately to severely active 
CD.57 
A signalling pathway that is also implicated in IBD pathogenesis is the Janus kinase/signal transducer 
and activator of transcription (JAK/STAT) pathway, which regulates immune functions in response to 
various cytokines and growth factors.58 So far, only data from tofacitinib, a novel selective oral JAK 
inhibitor, are available. Tofacitinib has been shown to inhibit a range of innate and adaptive immune 
responses, including the acute response to lipopolysaccharide (LPS) as well as T cell activation and 
differentiation.58-60 A recent randomised, placebo-controlled, dose-ranging phase II study indicated 
that patients with moderately to severely active UC treated with tofacitinib over a period of 8 weeks 
had better clinical as well as endoscopic response and remission rates than those receiving placebo. 
Tofacitinib thus seems to show promise as a new therapeutic agent for the treatment of UC.58,61 
Excessive innate immune responses are a major hallmark of IBD and lead to sustained immune 
activation and tissue damage. For example, NKG2D (KLRK1, killer cell lectin like receptor K1) is an 
innate immunity receptor expressed predominantly on natural killer (NK) cells, which recognises 
multiple stress-induced, cell-associated ligands presented by damaged cells, and whose activation 
potentiates the effector functions of certain T cell populations. The expression pattern of the NKG2D 
receptor and its ligands on mucosal and circulating innate immunity populations was found to be 
severely disturbed in IBD.62 Safety and efficacy of an anti-NKG2D mAb was recently evaluated in a 
randomised, placebo-controlled phase II trial in subjects with moderately to severely active CD, 
which revealed that treatment with a subcutaneous dose of anti-NKG2D significantly reduced disease 
activity versus placebo, supporting further development of anti-NKG2D in IBD.63 Stimulation of Toll-
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like receptor (TLR) 9, also a key activator of innate immunity that recognises unmethylated CpG 
dinucleotides present in bacterial DNA, has been shown to suppress the severity of experimental 
colitis64, and the clinical efficacy of an oral TLR9 agonist (BL-7040) was evaluated in a phase IIa trial in 
patients with moderately active UC. Results from this study indicate that BL-7040 is safe and 
effective in treating UC, as demonstrated by the improved clinical response achieved in 50% of the 
patients enrolled in the study.65 Deregulated immune behaviour in IBD is also in part due to a lack of 
suppression by immunomodulatory cell populations such as regulatory T cells (Tregs). Treg 
suppressor activity of the induction and proliferation of effector s mediated by anti-inflammatory 
cytokines such as transforming growth factor β (TGFβ), whose inhibitory capacity is abrogated due to 
Smad7 overexpression.66 The safety and efficacy of an oral Smad7 antisense oligonucleotide 
(mongersen) was recently evaluated in a double-blind, placebo-controlled, phase II trial in patients 
with active CD, which showed that study participants who received mongersen had significantly 
higher rates of clinical remission and clinical response than those who received placebo.67 A more 
drastic way of inducing anergy in the inflammatory environment is through transplantation of bone 
marrow hematopoietic stem cells (HSC). Myeloablation first eliminates detrimental T cell 
populations, and subsequent HSC transplantation generates naive cells via de novo haematopoiesis. 
Patients essentially undergo an immune system reboot, which will hopefully bring about long-lasting 
remission. Trials designed to investigate the potential clinical benefit of autologous HSC 
transplantation have shown encouraging results in patients with severe, refractory CD. However, 
existing studies are still inconclusive, so the next few years will be decisive for defining the role of 
this therapy in the management of IBD.68 
1.1.3.2.2 Microbiota modulation 
IBD patients display substantial intestinal dysbiosis and depletion of key commensal bacteria is 
thought to be associated with inflammation. The rationale behind therapeutically manipulating the 
diseased microbiota is the idea that reshaping the gut microbiome to a less pro-inflammatory state 
would aid in induction and/or maintenance of clinical remission. This can be achieved either through 
administration of bacterial strains with known anti-inflammatory properties (probiotics), by a diet 
that selectively promotes the growth of these strains (prebiotics), or by transplanting the fecal 
microbiota (FMT) from a healthy individual to the patient.  
IBD-associated dysbiosis involves various functional groups of commensal bacteria across different 
taxonomical levels. The most well-defined change that has been noted in patients is the reduced 
abundance of the phylum Firmicutes.69 Spread across several families within this phylum is a large 
community of butyrate-producing species, whose numbers are severely depleted during intestinal 
inflammation. These butyrate-producing bacteria are of specific interest as a new treatment strategy 
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to promote mucosal healing in IBD patients given the barrier-protective properties of butyrate. The 
different bacterial communities implicated in IBD-associated dysbiosis, in particular that of the 
butyrate-producers, the role of butyrate in colonic homeostasis, and the potential application of 
butyrate-producing commensals as pharmabiotics for IBD, are discussed in more detail in §1.2 of this 
chapter. 
1.1.3.2.3 New targets for the restoration of intestinal epithelial barrier integrity 
As mentioned above, several of the currently used IBD therapeutics induce mucosal healing but 
whether this is due to a direct barrier-protective effect, remains unclear. For example, anti-TNF 
therapy rapidly induces mucosal healing but several lines of evidence suggest that its key mechanism 
of action is the induction of T cell apoptosis.70 Aminosalicylates on the other hand, directly affect 
barrier integrity in vitro; the 5-aminosalicylic acid (5-ASA) precursor, sulfasalazine, is able to prevent 
TNF-induced barrier dysfunction and morphological tight junction disruption in Caco-2 cells.71 Up to 
now, the term mucosal healing refers to endoscopic remission, which includes o.a. the resolution of 
visible ulcers. However, this definition does not take into account the microscopic and ultrastructural 
components of the intestinal barrier that are also affected during active disease. Restoration of 
epithelial barrier integrity following injury involves epithelial restitution (intestinal epithelial cell (IEC) 
migration into the eroded area), followed by proliferation and differentiation. These processes are 
regulated by environmental signals like growth factors, cytokines and bacterial products that activate 
transcription factors such as nuclear factor κB (NF-κB) and STAT3, which mediate anti-apoptotic and 
proliferative effects in IECs. For example, ameliorating effects on mucosal healing in experimental 
colitis have been described for targeted modulation of Smad5, protein kinase C (PKC), p53-
upregulated modulator of apoptosis (PUMA) and apical TLR9 stimulation.23 Whether microscopic 
healing has an added clinical benefit compared to endoscopic resolution of inflammation, remains to 
be determined but these experimental data demonstrate that targeting signalling pathways involved 
in epithelial restitution represent possible novel approaches for future therapeutic interventions. 
One such a signalling pathway, that of the Rho-associated kinases which are involved in 
inflammation-induced loss of epithelial barrier integrity, was investigated during this thesis. The role 
of Rho-associated kinases during intestinal inflammation and their targeting as a potential new 
treatment option for restoring epithelial barrier integrity, are discussed in more detail in §1.3 of this 
chapter. 
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1.2 MICROBIAL DYSBIOSIS IN IBD: A ROLE FOR BUTYRATE-PRODUCING BACTERIA? 
In the second part of this introduction, we will elaborate on the role of the gut microbiome in IBD 
pathogenesis. We will describe its biogeography and modulating factors, its role in the development 
of the mucosal immune system as well as in the maintenance of gut immune homeostasis, and its 
altered composition in IBD patients. We will focus specifically on butyrate-producing bacteria, a 
community affected by intestinal inflammation, the barrier-protective and anti-inflammatory 
properties of their butyrate metabolite, and their potential application as pharmabiotics for IBD. 
1.2.1 Composition of the human gut microbiome 
1.2.1.1 Bacterial colonisation of the gut 
In utero, our entire gastro-intestinal tract is completely sterile. Bacterial colonisation of the gut starts 
during birth with a first inoculation by the vaginal microbiota. Initial bacterial composition is not very 
diverse and highly dynamic. Once we start consuming solid food, the microbiota composition gains in 
richness and diversity and by the age of 3, the adult gut microbiome has taken shape with 
Bacteroidetes and Firmicutes as the predominant bacterial phyla.72,73 Throughout life, the microbial 
composition is fairly robust with major alterations only occurring as a result of antibiotic therapy, 
infection by gut pathogens or immune-mediated intestinal disorders like IBD. The average bacterial 
load of the entire gastro-intestinal tract amounts to 1014 micro-organisms, outnumbering the human 
cells 10 to 1. Besides microbes, other micro-organisms like viruses and fungi also abundantly colonise 
the gut and are collectively referred to as the enteric virome and fungome, respectively. 
Interestingly, disease-specific alterations in the composition of the enteric virome and fungal 
microbiota have also been observed in IBD. Norman et al. recently demonstrated that the fecal 
virome in CD and UC patients is characterised by a significant expansion of Caudovirales 
bacteriophages compared to healthy controls. Importantly, it did not appear that the expansion and 
diversification of the enteric virome in IBD patients was secondary to changes in bacterial 
populations, suggesting that alterations to the virome composition may contribute to intestinal 
inflammation and bacterial dysbiosis in IBD.74 Also the fecal fungal microbiota was shown to be 
dysbiotic in IBD, displaying an increased Basidiomycota/Ascomycota ratio, a decreased proportion of 
Saccharomyces cerevisiae, and an increased proportion of Candida albicans compared to healthy 
subjects.75 Additionally, the observation that correlations between bacterial and fungal components 
differed between IBD patients and healthy controls implies the existence of disease-specific inter-
kingdom alterations, suggesting that, beyond bacteria, fungi might also play a role in IBD 
pathogenesis. 
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1.2.1.2 Spatial bacterial variation within the gut 
In the gut, the spatial distribution of intestinal microbes occurs along two basic axes; longitudinally 
from proximal to distal, and radially from the central lumen to the mucosal surface (Figure 2).76 A 
general observation for the longitudinal variation is that both load and diversity increase towards the 
rectum; total load in the small intestine varies between 103 and 107 with Lactobacillaceae and 
Enterobacteriaceae as the predominant families, while the total amount of colonic microorganisms 
amounts to 109-1012. The predominant families represented in the colon are the Bacteroidaceae, 
Prevotellaceae, Rikenellaceae, Lachnospiraceae and Ruminococcaceae.77,78 
Radial bacterial variation is determined by autochthonous (resident) microbes that are closely 
associated with the intestinal mucosa and the allochthonous (transient) microbes that are located in 
the central lumen as part of the fecal stream or digesta. The mucosa-associated surface of the colon 
is predominantly colonised by the Lachnospiraceae and Ruminococcaceae families of the Firmicutes 
phylum, whereas the Prevotellaceae, Bacteroidaceae and Rikenellaceae families of the Bacteroidetes 
phylum are enriched in the digesta. This difference in composition between both environments 
suggest that mucosa-associated microbial communities have evolved a symbiotic relationship with 
their human host, which allowed them to colonise a hazardous niche equipped with numerous 
endogenous antimicrobial defence mechanisms while at the same time remaining innocuous to their 
host.76,77 
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Figure 2. Gut biogeography of the microbiota in the human lower gastro-intestinal tract. Intestinal microbes 
are spatially distributed along two basic axes; longitudinal and radial, which is determined by local 
environmental factors. The dominant bacterial phyla in the gut are Bacteroidetes, Firmicutes, Actinobacteria, 
Proteobacteria and Verrucomicrobia. The dominant bacterial families of the small intestine and colon reflect the 
physiological differences along the length of the gut; longitudinal gradients of oxygen, antimicrobial peptides 
and pH limit the bacterial density in the small intestinal community, whereas the colon carries high bacterial 
loads. In the small intestine, the families Lactobacillaceae and Enterobacteriaceae dominate, whereas the colon 
is characterised by the presence of species from the families Bacteroidaceae, Prevotellaceae, Rikenellaceae, 
Lachnospiraceae and Ruminococcaceae. A radial cross-section of the colon shows the digesta, which is 
dominated by Bacteroidaceae, Prevotellaceae and Rikenellaceae, and the inter-fold regions of the lumen, which 
are dominated by Lachnospiraceae and Ruminococcaceae. Colours correspond with the relevant phyla. cfu; 
colony-forming units. Adapted from Donaldson et al. 2016. 
  
CHAPTER I 
29 
1.2.1.3 The enterotype concept 
Despite this obvious bacterial diversity within the gut, a recent fecal metagenomic, cross-country 
study revealed that intestinal microbiota variation between individuals is not continuous. It can be 
stratified into three robust clusters or enterotypes that are not nation- or continent-specific, and are 
identifiable by the variation in the levels of one of three genera; Bacteroides (enterotype 1), 
Prevotella (enterotype 2) and Ruminococcus (enterotype 3). These enterotypes do not correlate with 
host properties like nationality, gender, age or body mass index, although several significant 
functional correlations with each of the studied host properties were found. Interestingly, despite 
being mostly based on species composition, these enterotypes also reveal functional differences, e.g. 
in the metabolic routes used to convert complex carbohydrates in the colon into absorbable 
substrates. This study thus indicates the existence of a limited number of well-balanced host-
microbial symbiotic states that differ both phylogenetically and functionally, and which might 
respond differently to diet and drug intake.79 
Enterotypes were also detected in common laboratory mice, enterotype 1 and enterotype 2, whose 
compositional and community structure properties are strikingly similar to those of the 
Ruminococcus and Bacteroides human enterotypes, respectively.80 An important remark is that this 
stratified intestinal microbiota variation in mice and humans was observed in caecal content and 
fecal samples, respectively, which are not representative of the variation within the mucosa-
associated microbiome. 
1.2.1.4 Major modulators of gut bacterial biogeography 
Several internal and external factors influence both longitudinal and radial bacterial variation within 
the gut. Internal factors, or host factors, include antimicrobial peptides, mucus and the host immune 
system, which create different physiological environments along both axes. The external factors 
affecting gut microbial composition are often members of the aforementioned exposome, of which 
dietary intake is the most important one. 
1.2.1.4.1 Host factors 
Host factors are the main determinators of radial variation by limiting bacterial access to the gut 
epithelium. A protective mucus layer serves as the primary barrier to tissue adherence by the 
microbiota. This mucus layer is made up of different types of mucin proteins (MUC) that are rich in 
serine, threonine and proline amino acid residues. These residues are extensively glycosylated, giving 
the mucins their extended and stiff conformation. There are two different types of mucins; 
transmembrane mucins (e.g. MUC3, MUC12, MUC13, MUC17) and secreted, gel-forming mucins (e.g. 
MUC2, MUC6).81 Transmembrane mucins are densely packed on the apical surface of the IECs, 
forming a first protective layer or glycocalyx. Above this glycocalyx lies a net-like structure of 
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secreted mucus produced by specialised goblet cells, which consists mainly of MUC2 glycopeptides. 
The mucus of the small intestine only has one layer, is not attached to the epithelium, and is 
colonised by adherent bacterial species, including segmented filamentous bacteria (SFB), members of 
the Lactobacillaceae family, and Helicobacter species. Colonic mucus, on the other hand, is two-
layered; a dense, inner mucus layer that remains attached to the IECs and a loose, outer layer that is 
similar to the small intestinal mucus layer. The outer mucus layer is colonised by mucin-degrading 
bacteria, such as Akkermansia muciniphila, whereas the inner mucus layer is penetrated at low 
bacterial density by a more restricted community that includes, for example, the well-characterised 
symbiont Bacteroides fragilis.77,81 Bacteria penetrate these mucus layers by means of flagella-
mediated motility, or secretion of mucus-degrading enzymes or mucinases (e.g., glycosidases, 
proteases, sulphatases, sialidases).82 Physical adherence of bacteria to the epithelial surface occurs 
through appendices like pili, fimbriae and membrane proteins that target ligands on the epithelial 
surface.77 Interestingly, interaction with mucus and adherence to IECs seem to be adaptations used 
both by pathogens during infection and by commensals during persistent colonisation, challenging 
the dogma that intestinal microorganisms only come into contact with the epithelium during disease. 
Secondly, in order to persist near the host tissue, bacteria must be able to tolerate the large amounts 
of immunoglobulin A (IgA) that are secreted into the mucus layer. Secretory IgA physically interacts 
with the microbiota and this may contribute to mucosal biofilm formation, which prevents bacterial 
adherence to the epithelium. Finally, bacterial mucosal adhesion is also limited by secretion of 
antimicrobial peptides (defensins, cathelicidins and histatins)83 and aerobic host metabolism, which 
creates a steep, radial oxygen gradient that influences the type of bacteria capable of surviving close 
to the epithelial surface. Oxygen and antimicrobials concentration also affect longitudinal variation 
since the gradient of both decreases from proximal to distal as well as from tissue to lumen.77 
1.2.1.4.2 Dietary intake 
Several studies have highlighted the influence of dietary factors on the composition of the intestinal 
microbiota and have demonstrated that diet-induced alterations result in significant biological 
changes to the host. A study by Zhang et al. aimed at assessing the relative contributions of host 
genetics and diet in shaping the gut microbiota, revealed that microbial composition strongly 
correlated with diet.84 They administered a long-term high-fat (HF) diet to Apoa-I knockout mice, 
which have impaired glucose tolerance and increased body fat, and their wild-type counterparts. 
Interestingly, diet changes explained 57% of the total structural variation in the gut microbiota, 
whereas the genetic mutation accounted for no more than 12%. Most notably, barrier-protecting 
Bifidobacterium species85 were nearly absent in all animals on the HF diet, regardless of genotype. 
The dominant role of our diet in shaping the gut microbiome was further emphasised by Carmody et 
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al. who showed that a high-fat, high-sugar (HFHS) diet induced the same alterations to the gut 
microbiota in different mouse strains despite pre-existing genotype-related differences in gut 
microbial composition.86 The perturbing effect of this these HF and HFHS diets on the gut microbiota 
is particularly interesting since these types of diets represent the modern day dietary regime of the 
Western world, which is characterised by a high intake of proteins, fat and simple sugars and a 
reduced intake of complex plant carbohydrates or fiber. The implications of a HFHS diet for the 
human gut ecosystem was demonstrated by Turnbaugh et al. who created humanised gnotobiotic 
mice by transplanting human fecal microbial communities into germ-free mice. When these 
transplanted mice were switched from a low-fat, plant polysaccharide-rich diet to a HFHS diet, the 
microbiota composition shifted within a single day to an overgrowth of Firmicutes, including 
Clostridium innocuum, Eubacterium dolichum, Catenibacterium mitsuokai, and Enterococcus species 
as well as a significant reduction in several Bacteroides species.87 The functional consequence of the 
alterations in microbial composition induced by these carbohydrate-reduced diets is apparently a 
shift in the gut microbiome towards a more pro-inflammatory profile in which a decrease in 
beneficial Clostridium cluster XIVa species and a concomitant reduction in fecal butyrate levels are 
observed as well as an overgrowth of colitogenic mucosa-associated Escherichia coli (E. coli) 
bacteria.88-90 On the other hand, diets specifically enriched for complex carbohydrates show less 
pathogenic species, such as Mycobacterium avium subspecies paratuberculosis and 
Enterobacteriaceae, than diets higher in fat or protein as well as increased levels of beneficial 
Bifidobacteria species.91 In conclusion, these studies indicate that dietary factors have a dominating 
role in shaping the gut microbiota and that changes in its composition induced by a Western diet 
may transform a healthy microbiome into a disease-inducing entity. 
1.2.2 Mucosal immunoregulation by the gut microbiota 
Besides their role in host nutrition as part of the digestive system, the gut microbiota also plays a 
crucial role in the development of the intestinal immune system as well as in the maintenance of 
immune homeostasis. The importance of the microbiome in shaping host mucosal immunity was 
highlighted by several earlier studies using germ-free animals, which have revealed that 
development of immunological capacity is impaired under germ-free conditions.92 More specifically, 
germ-free animals display a decrease in IgA-secreting cells, which reduced the maintenance of oral 
tolerance to ovalbumin93,94, a decreased number of intraepithelial lymphocytes95, and 
underdeveloped lymphoid tissues characterised by smaller Peyer’s patches, isolated lymphoid 
follicles with fewer germinal centers, reduced lamina propria cellularity, and decreased epithelial 
production of mucus and antimicrobial peptides.96,97 Conversely, administration of a sterile, LPS-rich 
diet to germ-free mice drives the expansion of B and T cells in the Peyer’s patches and mesenteric 
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lymph nodes, with the most prominent expansion being that of the CD4+ T cells, including Tregs.98 
The microbiota thus shapes the host’s mucosal immune system and actively regulates the 
maintenance of gut immune homeostasis under normal conditions by inducing intestinal 
accumulation of specific immune cell populations necessary for a tolerogenic mucosal response to 
the commensal microbiota. This accumulation of Tregs in the gut lamina propria is induced by 
specific immunomodulatory commensal populations.91,97 For example, the immunomodulatory 
molecule polysaccharide A associated with the prominent human commensal Bacteroidetes fragilis 
was proposed to activate CD4+ T helper cells and direct the establishment of a proper Th1/Th2 
balance.99 Monocolonisation of germ-free mice with B. fragilis promotes Treg development and 
induces anti-inflammatory cytokine IL-10 production exclusively from these cells, which results in 
protection from chemically induced colitis.100 Also adherent SFB have been shown to increase the 
number of Tregs in both the small intestine and colon101 as well as induce Th17 responses102. Another 
key commensal group of potent Treg inducers are Clostridium species belonging to clusters IV and 
XIVa.91,97 Monocolonisation with 46 Clostridium species from these clusters in germ-free mice 
strongly promotes IL-10-producing Tregs.103 Together, these data demonstrate the vital role of our 
gut microbiome in the development, maturation and function of the mucosal immune system by 
promoting the expansion of specific immune cell populations that actively induce mucosal tolerance, 
thus contributing to intestinal homeostasis. Alterations to the composition of the commensal 
microbiota may therefore result in a disruption of immune homeostasis between the host and the 
microbiota, which could contribute to the pathogenesis of chronic, immune-mediated intestinal 
inflammation.  
1.2.3 Characterisation of microbial dysbiosis in IBD 
Circumstantial evidence for the pivotal role of gut microbes in the induction and propagation of 
mucosal inflammation has been substantiated by several observations. For example, surgical 
diversion of the fecal stream can induce remission in refractory colonic CD and the majority of 
patients relapse after stoma reversal.104 Also, antibiotics alleviate both human105 and murine106 
intestinal inflammation, and mice developing intestinal disease in a conventional or specific-
pathogen free environment, generally do not do so in a germ-free one106-108, with the exception of a 
few models, including DSS-induced colitis.109 However, the relationship between bacteria and IBD is 
more intricate than that; it not simply the presence of a gut microbiome that is associated with 
disease but rather its particular composition. Indeed, the intestinal microbiotic profile of IBD patients 
has been shown to be severely altered compared to healthy subjects – a condition termed dysbiosis. 
Dysbiosis is generally defined as a deviation from the normal microbial community, such as an 
imbalance in the abundance, membership or localisation of micro-organisms. In the context of IBD, 
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intestinal dysbiosis entails a decrease in both bacterial load and richness.77 However, despite the 
abundant evidence on IBD-associated dysbiosis, the crucial question remains whether changes in gut 
microbial composition precede, follow, cause or only correlate with the onset of disease. 
Numerous studies have described the nature of intestinal dysbiosis in IBD patients and a few general 
observations can be made. Fecal microbiota composition in both CD and UC patients is characterised 
by a significant depletion of the Firmicutes phylum, particularly members of the Clostridium clusters 
IV and XIVa, while Enterobacteriaceae of the Proteobacteria phylum are increased in relative 
abundance, with Escherichia coli (E. coli) specifically being enriched in feces of CD patients. Data on 
the Bacteroidetes phylum are more ambiguous; inconsistent findings have been reported for their 
presence in IBD patients compared to healthy individuals.110-112 The same dysbiotic signatures are 
also observed when analysing the mucosa-associated microbiota isolated from surgically resected 
mucosal tissue of IBD patients; abundances of Bacteroidetes and Firmicutes were reduced compared 
to non-IBD controls, and the loss of Firmicutes was primarily due to a reduction in the abundances of 
species that belong to the bacterial order Clostridiales, particularly members of the Clostridium 
clusters XIVa and IV.113,114 Also the ileal mucosa of CD patients was found to be selectively enriched 
for invasive E. coli, which correlated with the severity of ileal disease.115 This observation supports 
earlier findings of a higher prevalence of adherent-invasive E. coli (AIEC) strains cultured from the 
ileal mucosa of patients with Crohn's ileitis.116 
Most studies report on dysbiosis during the active phases of disease but the microbiota composition 
of patients in remission still differs from that of healthy individuals. For example, a dysbiotic 
signature was shown to persist during clinical remission in UC, which was characterised by a low 
diversity and temporal instability, and a decrease in bacterial richness prior to relapse.117,118 A 
subclinical dysbiosis has also been reported in unaffected relatives of UC and CD patients.119,120 These 
observations suggest that an initial abnormal gut microbiome composition might, in combination 
with other genetic and environmental factors, contribute to the onset and/or flare-ups of intestinal 
inflammation in IBD. 
The intestinal depletion of Clostridium clusters XIVa and IV species in IBD is of particular significance 
since most of the butyrate-producing bacteria cultured so far belong to these clusters, including 
Roseburia and Faecalibacterium species, which are two abundant gut colonisers.121 In accordance 
with these general findings, a decrease in both Roseburia hominis and Faecalibacterium prausnitzii 
(F. prausnitzii) has been documented in the stool of UC patients, with both species showing an 
inverse correlation with disease activity.122 Other studies have also reported that F. prausnitzii was 
particularly depleted in the ileocolonic mucosa-associated microbiota of IBD patients, and Sokol et al. 
additionally showed that a low proportion of F. prausnitzii in resected ileal CD mucosa is associated 
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with a higher risk of post-operative disease recurrence.123 Also fecal levels of the butyrate-producing 
Butyricicoccus genus are reduced in both CD and UC patients compared to healthy controls.124 This 
depletion of mucosa-associated butyrate producers most likely results in lower butyrate levels near 
the IECs. Indeed, fecal butyrate concentrations were shown to be significantly decreased in IBD 
patients compared to healthy subjects.125-127 The combination of diminished intestinal butyrate levels 
and the inflammation-induced impaired uptake and metabolism of butyrate128,129 causes severe 
epithelial butyrate deficiency, which negatively affects colonic homeostasis. 
1.2.4 Contribution of butyrate metabolism to intestinal homeostasis 
1.2.4.1 Functions of butyrate within the colon 
Butyrate exerts potent effects on a variety of colonic mucosal functions and, although the exact 
underlying mechanisms of action have not yet been elucidated, butyrate is thought to influence cell 
function primarily through epigenetic regulation of butyrate-responsive gene expression by acting as 
a histone deacetylase inhibitor (HDACi).130 Most importantly, butyrate is the main energy source for 
colonocytes, stimulates ion absorption, protects against mucosal oxidative stress, stimulates non-
specific intestinal defence mechanisms and increases intestinal motility. Butyrate also regulates cell 
growth by stimulating cell proliferation of normal colonocytes while inducing differentiation and 
apoptosis in neoplastic cells, a contradictory pattern called the butyrate paradox.130-133 
Immunomodulation by the gut microbiota is also mediated in part by butyrate; commensal-derived 
butyrate has been described to induce differentiation of colonic Tregs.134 Especially indigenous 
Clostridium species belonging to clusters XIVa and IV are potent inducers of IL-10-producing Tregs135, 
which is a way for commensals to promote their own immunological tolerance. Finally, butyrate also 
functions as an anti-inflammatory mediator and is involved in maintenance of intestinal epithelial 
barrier integrity; two functions pertaining to the subject matter of this thesis, which are described in 
more detail below. 
1.2.4.1.1 Anti-inflammatory effects 
Butyrate has been shown to ameliorate intestinal inflammation in several murine models of acute 
colitis. Administration of butyrate enemas during DSS-induced colitis in rats had a clear 
cytoprotective effect on colonocytes, as evidenced by increased cell viability and reduced 
permeability, which was mediated in part through a reduction of NF-κB activation.136 Butyrate 
enemas also stimulated colonic repair during 2,4,6 trinitrobenzene sulfonic acid (TNBS)-induced 
colitis in rats, as demonstrated by a clinical recovery, decreased mucosal inflammation and 
restoration of electrolyte absorption.137 Also oral butyrate administration improved mucosal lesions 
and attenuated the inflammatory profile of the intestinal mucosa and local lymph nodes in DSS-
induced colitis in mice.138 NF-κB activation and the concomitant production of pro-inflammatory 
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cytokines is also increased in the intestinal mucosa of CD patients, and ex vivo butyrate 
administration to intestinal biopsies, lamina propria mononuclear cells (LPMCs) and peripheral blood 
mononuclear cells (PBMCs) collected from CD patients, resulted in reduced TNF production and pro-
inflammatory cytokine mRNA expression in intestinal biopsies and LPMCs. Butyrate also abolished 
LPS-induced expression of cytokines by PBMCs and nuclear translocation of NF-κB. Butyrate thus 
dampens mucosal inflammatory responses in part through inhibition of NF-κB activity.139 
An NF-κB-independent mechanism through which butyrate supresses inflammation in human colonic 
epithelial cells is by inhibiting IFNγ signalling - one of the main cytokines produced in inflamed IBD 
mucosa - at the level of STAT1 phosphorylation; the main transcription factor in the INFγ signalling 
cascade, whose expression and activation is elevated in mucosal samples from IBD patients.140,141 
1.2.4.1.2 Effect on epithelial tight junction integrity 
The anti-inflammatory effect of butyrate indirectly strengthens intestinal barrier integrity by reducing 
expression and signalling of the pro-inflammatory cytokines that cause barrier dysfunction during 
intestinal inflammation. But butyrate can also directly improve barrier function by modulating the 
assembly tight junctions (TJ), the main determinants of intestinal epithelial barrier integrity, and 
expression of TJ proteins, which is reflected by an increase in transepithelial electrical resistance 
(TEER).142 Butyrate facilitates normal TJ assembly; treatment of IEC monolayers with butyrate 
resulted in an accelerated membrane enrichment of TJ proteins occludin (OCLN) and tight junction 
protein 1 (TJP1) after calcium switch-induced TJ assembly.143 Butyrate has also been shown to 
upregulate protein expression of TJP1 in Rat-1 fibroblasts and of OCLN in HeLa cells, which was 
attributable to the HDACi activity of butyrate.144 Butyrate likewise increased transcription of claudin-
1 (CLDN1), a pore-sealing TJ protein, in a monolayer of rat small intestinal epithelial cells by 
facilitating the association between the SP1 transcription factor and the CLDN1 promoter, which 
resulted in an enhanced intestinal barrier function.145 Besides increasing epithelial protein levels of 
pore-sealing claudins, butyrate also reduces those of the pore-forming CLDN2.146 This butyrate-
induced decrease in CLDN2 expression was also confirmed in a microarray study in HT-29 human 
colonic epithelial cells and is dependent on a reduced binding affinity of transcription factors within 
the CLDN2 promoter.147,148 
1.2.4.2 Colonic butyrate production and uptake 
Anaerobic microbial communities of the colon produce the three major short-chain fatty acids (SCFA) 
acetate, proprionate and butyrate as their main non-gaseous fermentation end products.121 Butyrate 
is the least abundant SCFA, making up 15% of the total SCFA concentration in the colonic lumen.131 
Fecal butyrate concentrations range from 11 to 25 mM, but this may be an underestimation of the 
total colonic butyrate production since approximately 95% is rapidly absorbed and metabolised by 
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the colonocytes.132 Fermentable substrates with butyrate as end product are mainly indigestible 
plant fibers like cellulose, starch and other complex polysaccharides.133 
Bacteria produce butyrate through four known pathways; the glutarate, acetyl-CoA, lysine and 4-
aminobutyrate/succinate pathway, with the acetyl-CoA pathway being the predominant one.149 In 
this pathway, acetyl-CoA is converted into butyryl-CoA through a series of intermediate metabolites. 
Acetyl-CoA itself is derived from pyruvate, the end product of glycolysis. Butyryl-CoA is further 
converted to butyrate via either butyrate kinase or butyryl-CoA:acetate CoA transferase. The latter 
route is shown to be more dominant in human butyrate-producing bacteria.133 Indirect butyrate 
production also occurs through conversion of fermentation products such as acetate and lactate, 
which are produced by primary substrate degraders, in a process called cross-feeding.121 
Colonocytes absorb butyrate across their apical membranes through different mechanisms; non-ionic 
diffusion, SCFA/HCO3
- exchange, and active transport by SCFA transporters. The transport proteins 
involved are monocarboxylate transporter isoform 1 (MCT1 or SLC16A1), which is coupled to a 
transmembrane H+-gradient and SLC5A8, which is a Na+-coupled co-transporter.131,132 
1.2.4.3 Taxonomy of butyrate-producing bacteria within the gut 
Culture-independent methods have revealed that the Firmicutes phylum dominates the butyrate-
producing ecosystem in the gut, but members of nine other phyla, including o.a. Bacteroidetes and 
Fusobacteria, were also identified as potential butyrate producers.149 Within the Firmicutes, 
significant populations of known butyrate-producing species are included in the Eubacterium and 
Roseburia genera of the Lachnospiraceae family, in the Clostridium genus of the Clostridiaceae family 
and in the Faecalibacterium genus of the Ruminococcaceae family.121,149 Interestingly, these butyrate-
producing species are phylogenetically interspersed with other species that are not known to 
produce butyrate, making intestinal butyrate producers a functional cohort rather than a 
monophyletic group. 
The butyrate-producing bacteria cultured so far are strictly anaerobic and generally regarded as 
difficult to grow in vitro. They are widely distributed across several clusters that contain species of 
several genera belonging to the Clostridiaceae, Eubacteriaceae, Lachnospiraceae and 
Ruminococcaceae families within the order Clostridiales (Figure 3). These so-called clostridial clusters 
(I–XIX) form a new nomenclature that rearranges the clostridial species into groups, or clusters, 
based on the similarity of their 16S rRNA gene sequences.150 The bulk of butyrate producers belong 
to the Clostridium cluster IV (or Clostridium leptum cluster) and the Clostridium cluster XIVa (or 
Clostridium coccoides cluster), which include some potentially important butyrogenic species related 
to F. prausnitzii and Eubacterium rectale/Roseburia species, respectively.151 In humans, the butyrate-
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producing bacteria related to F. prausnitzii comprise 5-15% of the total microbiota and 5–10% of the 
total microbiota species are related to Eubacterium rectale and Roseburia species.152,153 
 
Figure 3. Distribution of butyrate-producing species across different clostridial clusters within the order 
Clostridiales. Cultural and molecular studies indicate that most of the butyrate-producing bacteria found in 
human feces so far, are highly oxygen-sensitive Clostridium-related anaerobes that are widely distributed across 
several clostridial clusters. This phylogenetic tree shows the inter-relationship of 16S rRNA sequences from 
butyrate- (red) and non-butyrate-producing (black) bacteria. Bootstrap values (expressed as percentages of 
1000 replications) are shown at branch points. The scale bar represents genetic distance (10 substitutions per 
100 nucleotides). Adapted from Pryde et al. 2002. 
One butyrate producer in particular, Butyricicoccus pullicaecorum (B. pullicaecorum), was extensively 
researched during this thesis because of its ability to produce high concentrations of butyrate. It was 
first identified as a novel isolate obtained from the caecal content of a 4-week-old broiler chicken. 
This isolate was shown to represent a single novel species within a novel genus, for which the name 
Butyricicoccus pullicaecorum gen. nov., sp. nov. was proposed.154,155 Cells are Gram-positive, 
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anaerobic, non-motile, coccoid and usually arranged in pairs (occasionally in short chains). The type 
strain B. pullicaecorum 25-3T utilises acetate and small amounts of proprionate to produce H2, CO2 
and butyrate. With a secretion of 18.6±1.2 mM butyrate after overnight growth at 42°C in anaerobic 
M2GSC broth, B. pullicaecorum 25-3T classifies as a high-concentration butyrate producer. 
Phylogenetic analysis based on 16S rRNA gene sequences demonstrated that B. pullicaecorum 
represents a novel lineage within the Clostridium cluster IV in the phylum Firmicutes, with 
Eubacterium desmolans as its closest phylogenetic neighbour (about 93% similarity). A human B. 
pullicaecorum 1.20 isolate has since also been isolated. The abundance of the genus Butyricicoccus in 
human fecal samples is low: 0.05% to 0.4% of total fecal microbiota.156 
1.2.5 Butyrate-producing bacteria as pharmabiotics for IBD 
Given its prominent anti-inflammatory and barrier-protective properties, there is increasing interest 
in using butyrate to restore mucosal homeostasis in IBD. However, its routine clinical application has 
been impeded by practical issues. Oral butyrate administration in the form of enteric-coated tablets 
has shown promising results in a small study of patients with mild to moderate CD157, but the use of 
tablets does not guarantee controlled release at the intended location and butyrate might not reach 
the colon in sufficient amounts due to its rapid absorption. Besides, butyrate has a very unpleasant 
taste and smell. Butyrate enemas have proven to be effective in treating distal UC158,159, but they are 
cumbersome for the patient and exposure of the colonic mucosa to the butyrate is brief and 
discontinuous. The administration of naturally colonising butyrate-producing bacteria that would 
continuously secrete butyrate into the colonic lumen is an alternative strategy to locally increase 
butyrate concentrations. 
Research into the use of probiotics to treat IBD has been ongoing for almost two decades and results 
from clinical studies have generated considerable excitement, despite a relative lack of rigorously 
designed, randomised, placebo-controlled trials. Data from these studies show that probiotics are 
capable of preventing relapse and some can even treat mildly active IBD.160 Most studies report 
prolonged maintenance of remission in UC patients69,105,160 and, although the use of probiotics in 
prevention and treatment of CD is less substantiated than for UC, some trials in CD patients also 
show promising results.105,160,161 The most convincing evidence of the clinical efficacy of probiotics in 
IBD to date, is a prolonged remission time of chronic pouchitis in post-operative UC patients using 
the probiotic cocktail VSL#3.162-164 VSL#3 is a multispecies mix of o.a. lactate-producing lactobacilli 
and bifidobacteria. In fact, most probiotics tested in these clinical trials are lactate-producing 
bacteria that may indirectly affect butyrate levels in the gut by cross-feeding butyrate producers that 
are capable of using lactate. 
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Clinical trials with butyrate producers in particular are scarce. Efficacy of a Clostridium butyricum 
strain with a proven ameliorating effect in experimental colitis165, and which is already being used in 
a clinical setting as a probiotic for patients with functional gastro-intestinal disorders166, is currently 
under evaluation in two clinical trials for irritable bowel syndrome. F. prausnitzii is currently not 
being evaluated in clinical trials despite potent anti-inflammatory effects in PBMCs, Caco-2 IECs and 
two models of acute experimental colitis.123,167 Finally, Butyricicoccus bacteria are also conceptually 
attractive as probiotics given their natural occurrence within the human gut, their decreased 
abundance in stool samples of IBD patients, the ability of a specific Butyricicoccus strain (B. 
pullicaecorum 25-3T) to decrease lesion sizes and inflammation in a rat colitis model, and the capacity 
of B. pullicaecorum 25-3T conditioned medium to prevent cytokine-induced increase in epithelial 
permeability in vitro.124 
1.3 EPITHELIAL DYSFUNCTION IN IBD: A ROLE FOR RHO KINASE INHIBITION? 
In the third part of this introduction, we will elaborate on the morphology and functions of the 
intestinal epithelium and on the crucial role of tight junctions in maintaining barrier integrity. We will 
describe deregulated tight junction gene expression and Rho kinase-mediated tight junction protein 
internalisation as determinants of pathophysiological tight junction deregulation in IBD and discuss 
the potential of targeting Rho kinases to preserve tight junction integrity. 
1.3.1 Morphology of the intestinal epithelium 
The epithelium is crucial to intestinal homeostasis by forming both a physical and a functional barrier 
between the gut lumen and the underlying mucosal compartment (Figure 4). This physical barrier is 
made up of a single layer of intestinal epithelial cells (IECs) tightly held together through apical 
junctional complexes, which restricts translocation of luminal antigens and other macromolecules 
into the underlying interstitium while at the same time allowing selective passage of water, 
electrolytes and nutrients. Junctional complexes also polarise the IECs by separating the apical from 
the basolateral membrane compartments.168 
Within the epithelial layer, four types of IECs can be discriminated, all of which originate from stem 
cells at the base of the crypts and differentiate upwards along the crypt-villus axis. Absorptive cells, 
called enterocytes in the small intestine and colonocytes in the colon, are responsible for digestion 
and absorption of nutrients, water and electrolytes. Enteroendocrine cells secrete peptide hormones 
that regulate cellular homeostasis, and Paneth cells control bacterial growth by producing 
antimicrobial peptides. Finally, goblet cells secrete glycosylated mucins that form a protective mucus 
layer that physically shields the IECs from the luminal environment.169,170 
CHAPTER I 
40 
 
Figure 4. Intestinal epithelial barrier anatomy and components. The intestinal mucosa comprises a layer of 
polarised, columnar epithelial cells and a subepithelial region that contains the lamina propria, enteric nervous 
system, connective tissue, and muscular layers. The epithelium includes enterocytes, goblet cells (which 
synthesise and release mucin), Paneth cells (which synthesise antimicrobial peptides), enterochromaffin cells 
(which produce hormones and other substances), and intestinal stem cells. Above the epithelial barrier lies the 
inner mucus layer; this layer in turn underlies the outer mucus layer, which contains microbiota, secretory IgA, 
mucins, and antimicrobial peptides. Intraepithelial lymphocytes are above the basement membrane, underlying 
the tight junctions. The lamina propria includes a diffuse lymphoid tissue made up of macrophages, dendritic 
cells, plasma cells, lamina propria lymphocytes, and on occasion neutrophils, and a structured lymphoid tissue 
made up of Peyer’s patches, which contain M cells, dendritic cells, and lymphocytes. CNS, central nervous 
system; ENS, enteric nervous system; IEC, intestinal epithelial cell; ECC, enterochromaffin cell; IESC, intestinal 
epithelial stem cell; DC, dendritic cell; PC, plasma cell, sIgA, secretory IgA. Adapted from Salvo-Romero et al. 
2015. 
1.3.2 Intestinal epithelial cells as sentinels of innate immunity 
The intestinal epithelium is not merely a static barrier against intruders but a dynamic, sensory 
apparatus necessary for host nutrition, defence and immune system development. This is why IECs 
are equipped with membrane and intracellular receptors that recognise various microbe-associated 
molecular patterns (MAMPs). Under normal conditions, routine detection of commensal MAMPs 
does not elicit an acute inflammatory response and serves to educate the mucosal immune system 
towards oral tolerance. More specialised antigen-presenting cells (APCs) positioned in-between the 
IECs, such as ileal M cells, intraepithelial lymphocytes, and resident dendritic cells (DCs) and 
macrophages, also assist in immune surveillance by actively sampling luminal antigens and inducing 
tolerogenic, regulatory T cell responses.171 Indirect luminal sampling and antigen presentation to 
mucosal lymphocytes can also occur via the major histocompatibility complex class II molecules 
expressed constitutively on the basolateral membranes of the IECs, which allows them to act as non-
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professional APCs.170,172 In contrast, when invasive pathogens are detected, an acute pro-
inflammatory response is mounted, involving bacterial clearance and epithelial restitution. One of 
the ways in which IECs distinguish commensal detection from pathogen invasion, is through spatial 
expression of TLRs on their membranes. Although the role of epithelial TLRs in innate immunity is 
beyond the scope of this introduction, we will include TLR5 as a prime example of the physiological 
relevance of spatial TLR expression on IECs. Under normal circumstances, this receptor for bacterial 
flagellin is expressed exclusively on the basolateral side of polarised human IECs in vitro and native 
human colonic mucosa. Only flagellin exposure to the basolateral, but not the apical, surface of intact 
epithelium elicits the secretion of pro-inflammatory cytokines like IL-8, whereas flagellin exposure to 
an injured colonic mucosa due to DSS administration in mice does result in a TLR5-associated 
response.173,174 This divergent response would explain how TLR signalling only elicits a pro-
inflammatory response when TJ integrity is compromised and invasive bacteria have actually crossed 
the epithelial barrier while TLR stimulation by commensals on the apical side of an intact epithelial 
monolayer induces a homeostatic, anti-inflammatory response.175 
Besides modulating mucosal microbial responses through induction of soluble mediators for local 
and systemic immune control, TLR signalling in the gut is also actively involved in maintenance of 
epithelial barrier homeostasis. Secretion of antimicrobial peptides by Paneth cells, increasing barrier 
tightness through affecting TJ gene expression by IECs, and production of trefoil factors essential to 
epithelial restitution by goblet cells are all dependent on bacterial TLR activation. The beneficial role 
of TLR signalling in maintaining epithelial barrier function is evidenced o.a. by the observation that 
mice deficient in TLR4 or the TLR adaptor protein MyD88, are both more susceptible to DSS-induced 
colitis and show increased bacterial translocation.175-179 
1.3.3 Tight junctions as determinants of intestinal epithelial barrier integrity 
There are three types of junctional complexes that link IECs together: tight junctions (TJ), adherens 
junctions (AJ) and desmosomes (Figure 5). All three are made up of transmembrane protein 
complexes that interact with their counterparts on the adjacent cell membrane and are linked to 
cytoskeletal filaments via peripheral adaptor proteins. Adherens junctions and desmosomes are 
located in the lateral membrane of IECs and are thought to be important in mechanically linking cells 
at a particular distance (~20 nm apart). The TJs are the apical-most junctional complexes located at 
the border between the apical and lateral membrane regions. They create an impermeable epithelial 
barrier by physically sealing off the intercellular space and regulate selective paracellular ionic solute 
transport.  
Within the TJ structure, there are four known families of transmembrane proteins: occludin (OCLN), 
claudins (CLDN), junctional adhesion molecules (JAM) and tricellulin. Homo- and heterophilic 
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interactions among these proteins are made between adjacent cells, but also within the same 
membrane. Usually, several so-called TJ strands are present at the apical membrane, which are 
interconnected through interlocking junctional complexes. These strands form a circumferential belt-
like ring around the IECs. Integral TJ proteins are linked to the cytoskeletal actin filaments through a 
cytosolic plaque made up of adaptor proteins, such as cingulin and zonula occludens (ZO) proteins. 
This cytoplasmatic plaque also contains signalling proteins like Rho GTPases that are involved in 
junctional assembly and barrier regulation.168,180,181 The three tight junction proteins relevant to this 
work; zonula occludens 1 (ZO-1), OCLN and claudin-1 (CLDN1) are discussed in more detail below. 
 
Figure 5. A representation of epithelial intercellular junctions. Absorptive enterocytes primarily focus on 
nutrient absorption, and water and chlorine secretion into the intestinal lumen. Substances in the intestinal 
lumen may move across the epithelium via the transcellular pathway or the paracellular pathway. Intercellular 
junctional complexes, including tight junctions, adherens junctions, gap junctions and desmosomes, are 
dynamic structures that restrict the passage of macromolecules. The integrity and structure of epithelial cells 
are mostly modulated by the cytoskeleton, mainly by actomyosin and intermediate filaments. Cells adhere to 
the basement membrane through hemidesmosomes. The apical junctional complex is highlighted: tight 
junctions are primarily made up of claudins, occludins and JAM proteins, which are linked to the actin 
cytoskeleton via adaptor proteins like zonula occludens. Adherens junctions include cadherins such as E-
cadherin, which is linked to the actin cytoskeleton via the catenin adaptor protein. Desmosomes are mainly 
comprised of desmocollin and desmoglein, which are linked to the intermediate filaments via the desmoplakin 
protein. TJ; tight junction, AJ; adherens junction; D, desmosome; ZO, zonula occludens; JAM, junctional adhesion 
molecules. Adapted from Salvo-Romero et al. 2015. 
1.3.3.1 Zonula occludens 1 
Zonula occludens 1 or tight junction protein 1 (TJP1) (~220 kDa) contains 3 PDZ (PSD95, Dlg and ZO-1) 
-containing domains in its N-terminus through which interactions with other TJ proteins occur. The 
proline-rich C-terminal half binds to the actin filaments. Two different isoforms of ZO-1, alpha-minus 
and alpha-plus, have been described which result from alternative mRNA splicing. The alpha-plus 
isoform contains an 80 amino acids motif called alpha which is not present in the alpha-minus 
isoform. Only the alpha-containing isoform is found in epithelial cell junctions.182 In epithelial cells, 
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claudin assembly into TJ strands is dependent on expression of ZO proteins, and cells lacking ZO-1 
and ZO-2 fail to form TJs at all. It would seem that interaction between claudins and the PDZ-domain 
of ZO proteins is necessary for efficient junctional claudin delivery.183 
1.3.3.2 Occludin 
Occludin (60-82 kDa) was the first TJ protein to be identified and is a tetraspanning integral 
membrane protein with 2 extracellular loops, a short cytoplasmatic N-terminus and a long 
cytoplasmatic C-terminus. Several OCLN isoforms exist due to alternative mRNA splicing. Subcellular 
distribution and interaction with other TJ proteins is determined by the type of splice variant.184 
Functional analysis indicated that the transmembrane domains and extracellular loops regulate 
selective paracellular permeability, while the intracellular C-terminus interacts with the PDZ-
containing domains of ZO-1.168 Despite the fact that OCLN overexpression increases TEER, neither TJ 
formation nor paracellular barrier function is dependent on OCLN, as demonstrated by the fact that 
Ocln-/- mice show no changes in TJ appearance or intestinal permeability and that OCLN is not by 
itself sufficient to form TJ strands. However, occludin function within the TJ can be modulated 
through phosphorylation. For example, inhibition of PKCη-mediated phosphorylation of OCLN at 
specific threonine residues in the C-terminal domain disrupted junctional distribution of OCLN, 
abolished interactions with ZO-1, and compromised paracellular barrier function.168,181 
1.3.3.3 Claudins 
Claudins (20-27 kDa) also contain 4 transmembrane domains, 2 extracellular loops and cytoplasmatic 
N- and C-terminal domains, but do not show any sequence similarity to occludin.181 The extracellular 
loops are critical for homo- and heterophilic interactions with other TJ proteins and for the formation 
of ion-selective paracellular pores. The C-terminal end anchors the protein to the cytoskeleton 
through interactions with PDZ domain-containing adaptor proteins. Up to now, 27 members of the 
claudin family have been identified in humans that are expressed in a tissue-specific manner.168 
Unlike OCLN, the 2 extracellular loops in claudins have a variable number and distribution of several 
charged amino acid residues, which are crucial to determining paracellular ionic charge and size 
selectivity of the TJ.185 Differences in permeability between claudins has led to the identification of 
pore-forming and pore-sealing claudins, which respectively increase paracellular permeability by 
creating channels, or decrease it by sealing off the TJ.186 Claudins forming paracellular channels 
exhibit 3 types of selectivity; anion, cation and water selectivity. Pore-sealing claudins exhibit strict 
barrier properties in either an almost charge and size non-selective way, or with higher effectivity for 
one or the other charge.187 An example of a cation-selective, pore-forming claudin is CLDN2, which 
acts as a paracellular water channel and is typically expressed in leaky, water-transporting epithelia 
like the small intestine.188,189 CLDN1 on the other hand, is a pore-sealing claudin, which contributes to 
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barrier tightness by increasing TEER and reducing paracellular flux, and is typically expressed in tight 
epithelia such as the skin.190,191 This combination of pore-sealing and pore-forming claudins within 
the same protein complex allows modulation of the degree of barrier permeability and enables TJs to 
perform their so-called “gate function”, by acting both as a barrier that prevents unlimited passage 
of water, solutes and luminal antigens while at the same time functioning as a channel that still 
allows selective transport through the TJ. Like with OCLN, claudin function is further modified 
through phosphorylation, e.g. CLDN1 phosphorylation by mitogen-activated protein kinases (MAPK) 
is required to enhance the barrier function of CLDN1-based TJs.192 
1.3.4 Pathophysiological deregulation of tight junction integrity in IBD 
Whether epithelial barrier dysfunction is a consequence of the inflammatory response in IBD, or a 
primary defect that prompts mucosal inflammation is still a matter of intense debate. However, 
there is substantial evidence that compromised TJ integrity is an early event in IBD pathogenesis, 
which would support the suggestion that IBD is an impaired barrier disease with increased intestinal 
permeability preceding the onset of mucosal inflammation.169 First, genetic susceptibility to 
increased intestinal permeability is demonstrated by the fact that several of the IBD candidate genes 
identified so far are involved in intestinal epithelial barrier regulation, including TJ assembly and 
regulation, cell adhesion and polarity, mucus and glycoprotein regulation, bacterial sensing, 
membrane transport, epithelial differentiation and restitution.193 Secondly, increased intestinal 
permeability has been documented in a subset of clinically healthy, first-degree relatives of CD 
patients. Also, CD patients with quiescent disease who display increased intestinal permeability have 
an elevated risk of relapse. Interestingly, the observed presence of this permeability defect in 
genetically unrelated relatives of CD patients, e.g. spouses, suggests that this abnormal permeability 
may be secondary to environmental as well as genetic factors.169,194-196 
Microscopically, this increased intestinal permeability is characterised by a reduced number of TJ 
strands as well as increased strand breaks.197 This loss of TJ integrity is the result of inflammation-
induced deregulation of three distinct processes that are responsible for the continuous remodeling 
of TJ structures under physiological conditions; de novo TJ gene expression, proteolytic cleavage of 
transmembrane TJ proteins, and kinase-mediated internalisation of TJ components. 
1.3.4.1 Deregulated tight junction gene expression 
Sustained inflammation in IBD is associated with mucosal overproduction of pro-inflammatory 
cytokines secreted predominantly by various cells of the innate and adaptive immune system, and to 
some extent by the IECs themselves as well. Prominent Th1/Th17 cytokines produced in affected 
mucosa of CD patients are TNF, IFNγ, IL-6, IL-17 and IL-23, while Th2 responses in UC patients induce 
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expression of o.a. IL-5, IL-6, IL-13 and TNF.198 We will only discuss expressional deregulation of ZO-1, 
OCLN and CLDN1, the three TJ proteins that were investigated during this research. 
1.3.4.1.1 Loss of zonula occludens 1 and occludin expression during intestinal inflammation 
Reduced expression of both ZO-1 and OCLN has been described in colonic biopsies from CD and UC 
patients with active disease.199-201 In vitro, a decrease in ZO-1 and OCLN protein levels is induced by 
TNF in IECs, which is associated with an increase in TJ permeability.201,202 Loss of ZO-1 protein 
expression and concomitant increased permeability preceding the development of significant 
intestinal inflammation is also observed in acute DSS-induced colitis.203 
1.3.4.1.2 Ambivalent role of claudin-1 in health and disease 
Claudin expression is also severely disturbed in IBD but the change in expression is dependent on the 
type of claudin. In general, expression of pore-sealing claudins is decreased (e.g. CLDN3, CLDN4, 
CLDN5 and CLDN8), while expression of pore-forming claudins is increased (e.g. CLDN2).187,199 
Remarkably, increased claudin-1 (CLDN1) protein levels have been documented in IBD and in acute 
DSS-induced colitis despite it being a pore-sealing claudin.201,203,204 
Under normal physiological conditions, CLDN1 acts as a key pore-sealing TJ protein crucial to 
epithelial barrier integrity; its genetic deletion results in rapid postnatal death due to severe 
epidermal permeability defects.205 Also, baseline CLDN1 overexpression in vitro results in increased 
barrier tightness while its concomitant knockdown decreases it.145 Under inflammatory conditions 
however, the role of CLDN1 is much less straightforward. For example, in vitro pro-inflammatory 
cytokine-induced upregulation of CLDN1 coincides with a redistribution of the protein away from the 
TJs and a concomitant increase in intestinal permeability.206,207 Apparently, elevating CLDN1 
expression under baseline conditions increases epithelial barrier integrity, whereas under 
inflammatory conditions, its internalisation causes a weakening of the intestinal barrier despite an 
increase in overall expression. The in vivo relevance of CLDN1 overexpression is demonstrated by the 
observation that intestinal epithelial overexpression renders mice more susceptible to colitis and 
impairs their recovery.208 It appears therefore, that the function of CLDN1 is not restricted to its 
traditional role of maintaining intestinal barrier function, and that its elevation during mucosal 
inflammation is detrimental to both epithelial integrity and further downstream pathways 
responsible for colonic homeostasis.  
1.3.4.2 Proteolytic cleavage of transmembrane tight junction proteins 
The extra- and intracellular domains of epithelial transmembrane junction proteins are amenable to 
proteolytic cleavage by extracellular proteases or sheddases (e.g. matrix metalloprotease (MMP), 
serine protease, bacterial protease) and intracellular proteases (e.g. calpain, capsase, γ-secretase), 
respectively. Under physiological circumstances these cleavage products are generated as a result of 
CHAPTER I 
46 
the continuous turnover of transmembrane junctional proteins and seem to exert distinct biological 
effects. For example, extracellular cleavage fragments help control normal homeostatic epithelial 
events like cell proliferation, migration and apoptosis, whereas intracellular cleavage products can 
translocate to the nucleus to regulate transcriptional activity and cell survival. Recent studies have 
revealed that in pathological conditions such as inflammation, increased junctional cleavage products 
are often detected. However, current knowledge on the effect of TJ protein cleavage and their extra- 
and intracellular cleavage products in inflammation as well as their contribution to intestinal 
pathogenesis is limited.209 Most of the results obtained so for concern OCLN and the observation that 
extra- and intracellular cleavage of this TJ protein is associated with a decrease in epithelial barrier 
function. Huet et al. have reported that the induction of MMP9, a protease whose total levels and 
activity are increased in the inflamed IBD mucosa210, results in cleavage of the OCLN extracellular 
domain and disruption of barrier function associated with pathogenesis of dry eye disease.211 A 
perturbation of TJ integrity and decrease in epithelial barrier function can also be induced through 
extracellular OCLN cleavage by several bacterial proteases, including a heamagglutinin/protease from 
Vibrio cholera212 and an aerolysin from Aeromonas hydrophila213, two pathogens that cause clinical 
diarrhea in humans. Occludin is also cleaved intracellularly by a calpain protease activated by the 
Group A Streptococcus virulence factor Streptolysin S, which disrupts barrier function of IECs and 
keratinocytes.214 Calpain protease activity is also induced by TLR2 signalling in response to bacterial 
pathogen recognition in airway epithelial cells, which leads to intracellular cleavage of OCLN in order 
to a accommodate transmigration of the recruited leukocytes.215 Finally, Willemsen et al. have 
demonstrated that IFNγ activates serine proteases in IECs in vitro that cleave both the intra- and 
extracellular domains of CLDN2 .216 Interestingly, serine protease inhibition completely abrogated 
IFNγ-mediated barrier disruption, which was associated with preservation of CLDN2 expression.  
1.3.4.3 Kinase-mediated tight junction internalisation 
Besides altering TJ gene expression, pro-inflammatory cytokines also compromise barrier integrity 
through kinase-mediated internalisation of TJ proteins. A significant body of evidence has 
accumulated in recent years, identifying TJs as targets of multiple kinases that are activated under 
diverse (patho)physiological conditions and which enhance or restrict paracellular permeability as 
well as regulate the formation and disassembly of TJs.185 In this section, we will only elaborate on the 
role of Rho-associated kinases (ROCK) and myosin light chain kinases (MLCK) in cytokine-induced TJ 
internalisation. 
1.3.4.3.1 Rho/ROCK and MLCK signalling regulates actomyosin cytoskeletal TJ dynamics 
Rho-associated kinases (~160 kDa) are serine/threonine kinases consisting of an N-terminal kinase 
domain, followed by a potential coiled-coil-forming region containing a Rho-binding domain, and a C-
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terminal end containing a pleckstrin homology domain with an internal cysteine-rich domain. Two 
ROCK isoforms have been identified; ROCK1 and ROCK2, which are ubiquitously expressed in human 
and mouse tissues. The amino acid sequences of both isoforms show a 65% overall similarity, with 
the kinase domains showing the highest similarity (92%). In the inactive ROCK, the C-terminal 
pleckstrin homology domain and Rho-binding domain bind to the N-terminal kinase domain, forming 
an autoinhibitory loop. The Rho GTPase molecular switch protein binds to the Rho-binding domain of 
ROCK only in its activated form. Activation of the Rho protein, which entails a conversion from a 
GDP-bound (inactive) to a GTP-bound (active) conformation, occurs through guanine nucleotide 
exchange factors, which are themselves activated in response to the binding of extracellular chemical 
(e.g. growth factors, hormones, cytokines) or physical (e.g. adhesion to the extracellular matrix) 
stimuli to their respective transmembrane receptors.217 The interaction between the GTP-bound Rho 
GTPase and the Rho-binding domain of ROCK is believed to disrupt the negative regulatory 
interactions between the kinase domain and the C-terminal autoinhibitory region, which frees the 
ROCK catalytic activity. Activation of MLCK on the other hand, is dependent on a conformational 
change induced by the binding of a Ca2+-Calmodulin complex, which exposes the catalytic site of the 
kinase. The main ROCK phosphorylation substrates pertaining to epithelial cytoskeletal dynamics are 
the non-muscle myosin II light chain (MLC), MLC phosphatase (MLCP) and Lin11, Isl1 and Mec3 
kinase (LIMK) (Figure 6). Both ROCK and MLCK phosphorylate MLC at the same serine residue, which 
enables the binding of myosin to the actin cytoskeletal filaments and allows fiber contraction to 
begin. ROCK action also increases levels of phosphorylated MLC by inhibiting its dephosphorylation 
by MLCP. ROCK phosphorylation of LIMKs at specific threonine residues enhances ability of LIMKs to 
phosphorylate cofilin, an actin-depolymerising protein, which also stabilises actin filaments.218 
Linkage of these actin filaments to the TJs via the cytoplasmatic plaque stabilises the junctional 
complex at the cell border, but also provide the force for TJ disruption upon contraction of the 
perijunctional actomyosin ring following MLC phosphorylation. The Rho/ROCK signalling pathway 
thus participates both in the assembly and disassembly of TJs. 
Of note is that ROCK activity can also affect paracellular permeability by directly phosphorylating TJ 
proteins. For example, phosphorylation of OCLN and CLDN5 by ROCK has been reported in brain 
endothelial cells and correlates with diminished barrier tightness.219 
CHAPTER I 
48 
 
Figure 6. Actin cytoskeletal ROCK targets. Extracellular stimuli induce activation of the guanine exchange 
factor (GEF), which in turn actives the Rho GTPase molecular switch protein by stimulating the release of GDP to 
allow binding of GTP. The Rho protein is cycled back to its inactive form by the GTPase-activating protein (GAP), 
which enhances the intrinsic GTP-hydrolysis activity of Rho. The GTP-bound Rho activates ROCK, which 
phosphorylates several substrates pertaining to actin cytoskeletal dynamics. ROCK activity directly enhances 
contraction of actin fibers by phosphorylating the non-muscle myosin II light chain (MLC). ROCK also indirectly 
increases phosphorylated MLC levels through phosphorylation of the myosin binding subunit of the myosin light 
chain phosphatase (MLCP), thereby inhibiting MLCP-mediated dephosphorylation of MLC. ROCK 
phosphorylation of LIMKs enhances ability of LIMKs to phosphorylate cofilin, an actin-depolymerising protein, 
which also stabilises actin filaments. GEF, guanine exchange factor; GAP, GTPase-activating protein; ROCK, Rho-
associated kinase; MLC, myosin light chain; MLCP, myosin light chain phosphatase; LIMK, Lin11, Isl1 and Mec3 
kinase. Adapted from Wikipedia. 
1.3.4.3.2 Cytokine-induced TJ internalisation is mediated by ROCK/MLCK activation 
The in vitro detrimental effect of pro-inflammatory cytokines like TNF, IFNγ and IL-1β on IEC 
paracellular permeability has been documented extensively, with altered junctional localisation of 
OCLN, ZO-1 and CLDN1 being induced through an NF-κB-mediated, apoptosis-independent 
process.202,206,220-222 Further research revealed a role for both ROCK and MLCK in this inflammation-
induced internalisation process. Utech et al. described how IFNγ selectively upregulates expression 
of ROCK, but not of MLCK, to induce mammalian non-muscle myosin II-dependent endocytosis of 
OCLN and CLDN1 into actin-coated vacuoles at the apical plasma membrane of T84 monolayers.223 
The involvemement of MLCK in TJ internalisation and concomittant barrier disruption was 
demonstrated in vitro in a study by Wang et al..71 They showed that IFNγ and TNF synergise to induce 
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intestinal epithelial barrier dysfunction in Caco-2 monolayers, measured by a drop in TEER, which 
was associated with an upregulated MLCK expression and an increase in MLC phosphorylation. This 
TNF/IFNγ-induced loss of barrier function correlated with a morphological disruption of the TJ 
structure, caused by an evident removal of ZO-1, OCLN and CLDN1 off the TJs into intracellular pools. 
Also in vivo, MLCK activation and subsequent MLC phosphorylation were shown to be essential for 
cytokine-mediated intestinal barrier dysfunction. In mice, systemic T cell activation following the 
administration of anti-CD3 antibodies causes acute immune-mediated diarrheal disease associated 
with barrier dysfunction and induction of IFNγ and TNF, which can be blocked by antagonism of 
either cytokine.224 Phosphorylation of MLC increased abruptly after T cell activation and coincided 
with the development of diarrhea. Genetic knockout of MLCK or treatment of wild-type mice with a 
highly specific peptide MLCK inhibitor prevented epithelial MLC phosphorylation, TJ disruption 
characterised most predominantly by OCLN internalisation into intracellular vesicles, and diarrhea 
following T cell activation. Myosin light chain kinase as also shown to be involved in endotoxemia-
induced increase in intestinal epithelial permeability, as demonstrated in a study by Moriez et al. 
who showed that LPS-induced increase in colonic paracellular permeability was associated with 
changes in TJ morphology and increased MLC phosphorylation.225 Addition of the selective ML-7 
MCLK inhibitor prevented all LPS-induced effects, suggesting that inhibition of MLCK-dependent 
colonocyte cytoskeletal contraction prevents LPS-induced alterations in paracellular permeability and 
its subsequent effects. The aforementioned observation that in vivo TNF-induced MLC 
phosphorylation, OCLN internalisation, paracellular barrier loss, and diarrhea are all prevented by 
genetic or pharmacological MLCK inhibition, suggests that these events are closely linked. The exact 
mechanism of TNF-induced, MLCK-mediated OCLN internalisation and the fact whether this 
endocytotic event is required for in vivo barrier loss, was further elucidated by Marchiando et al.226 In 
an in vivo mouse model in which barrier disruption and subsequent diarrhea is induced by 
intraperitoneal TNF injection, OCLN internalisation was identified as the most obvious change in the 
TJ structure and was shown to precede intestinal fluid secretion. This OCLN removal from the TJs is 
central to both the barrier defect and diarrhea associated with TNF treatment, as evidenced by the 
fact that OCLN overexpression as well as chemical and genetic inhibition of caveolin-1-mediated 
OCLN endocytosis limited barrier loss and prevented diarrhea in this model. Together, these studies 
demonstrate the essential role of MLCK-triggered, caveolin-1-dependent OCLN endocytosis in TNF-
induced loss of barrier integrity. 
1.3.5 Therapeutic potential of Rho-associated kinase inhibition in intestinal inflammation 
The involvement of ROCK activity in inflammation-induced epithelial barrier function has prompted 
research into the use of ROCK inhibitors, such as Y-27632 and fasudil, to ameliorate inflammation in 
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several pathologies. For example, ROCK blockade using Y-27632 in a mouse model of LPS-induced 
renal failure alleviates inflammation by attenuation of NF-κB signalling.227 Y-27632 and fasudil also 
decreased in vitro production of TNF, IL-1β and IL-6 by synoviocytes and PBMCs from patients with 
active rheumatoid arthritis in an NF-κB-dependent manner.228 The first in vivo evidence of a role for 
RhoA-dependent signalling in IBD was provided by Segain et al. who reported an increased activation 
of RhoA and its effector ROCK in the inflamed intestinal mucosa of CD patients and of rats with TNBS-
induced colitis. They showed that blockade of ROCK using Y-27632 inhibited pro-inflammatory 
cytokine production by LPMCs and PBMCs via inhibition of NF-κB activation, and markedly reduced 
colonic inflammation in TNBS-colitis rats.229 An additional barrier-protective effect of ROCK inhibition 
was observed in an LPS-induced endotoxemia model in rats, in which administration of Y-27632 
markedly decreased apoptosis of IECs.230 Collectively, these data illustrate the potential of specific 
ROCK inhibition as a novel therapeutic approach to attenuate intestinal inflammation in IBD. 
However, there are a few reservations concerning the therapeutic use of current ROCK inhibitors like 
Y-27632. First, although Y-27632 is classified as a specific ROCK inhibitor and is commonly used to 
study ROCK functions, it also inhibits other protein kinases, especially at higher concentrations.218,231 
Secondly, important side effects such as cardiovascular hypotension warrant for great caution if 
these compounds reach systemic circulation.232 
This is why Amakem Therapeutics developed AMA0825, a potent and selective ROCK1/2 inhibitor 
specifically designed to have a localised action in the intestine. AMA0825 is structurally related to the 
reference ROCK inhibitor Y-27632 (Figure 7A). However, due to an international patent application233, 
the exact chemical structure of AMA0825 cannot be disclosed. Briefly, the central cyclohexane ring in 
the ROCK inhibitor scaffold of Y-27632 is replaced by an aromatic phenyl ring in the AMA0825 
compound. This phenyl ring is substituted by an aromatic side chain (i.e. an arylamide group), which 
in itself is further substituted by a cyclic ester group. The ester moiety is amenable to hydrolysis by 
esterase enzymes present in the blood, which yields a corresponding carboxylic acid metabolite with 
negligible functional activity compared to the parent compound. This is the so-called soft drug 
approach in which biologically active compounds are designed to undergo metabolic inactivation by 
controlled conversion of the parent molecule into a predictable, non-toxic metabolite with a 
markedly decreased functional activity. As a soft drug, AMA0825 has therefore been optimised as a 
locally acting compound with sufficient stability in its target organ while being rapidly inactivated 
once it enters the systemic circulation.234,235 AMA0825 has been profiled for its in vitro on-target 
potency against ROCK2, revealing an IC50 value of less than 0.05 nM, which is approximately a 1000 
times lower than the IC50 value of Y-27632 in the same assay (Figure 7B). In a second line of testing, 
cellular activity of AMA0825 was evaluated using an MLC phosphorylation assay in the rat smooth 
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muscle cell line A7r5, which endogenously expresses ROCK. In this functional assay, AMA0825 
displayed an EC50 value of 40 nM, which is approximately 25 times lower than the EC50 value of Y-
27632 in the same assay (Figure 7B). Selectivity of AMA0825 was tested on a panel of more than 340 
kinases at a concentration of 100 nM. Kinases whose activity was inhibited by 50% or more are 
shown as yellow and red dots in the selectivity profile (Figure 7C). The AMA0825 IC50 values for some 
of these kinases are listed in Figure 7D. Off-target inhibition of other kinases besides ROCK is limited; 
cross-reactivity with PKC δ, ε and θ was observed but with considerably higher IC50 values of 5, 20 
and 100 nM, respectively. Potent and selective ROCK targeting without the systemic side-effects of 
traditional inhibitors, therefore represents a promising treatment option for in vivo counteraction of 
inflammation-induced epithelial dysfunction. 
 
Figure 7. On-target potency and selectivity of AMA0825. (A) Chemical structure of the traditional ROCK 
inhibitor Y-27632. (B) AMA0825 and Y-27632 activity in on-target and cell-based assays. IC50 values of the 
compounds for inhibition of ROCK2 activity are listed as well as their EC50 values in a cellular assay for ROCK 
activity, assessed by the measurement of MLC-Thr18/Ser19 phosphorylation (MLC-PP). (C) Kinase selectivity 
profile of AMA0825 at 100 nM. Data are shown schematically with the color of the dots representing the 
percentage of inhibition of kinase activity by AMA0825; red: > 90% inhibition, yellow: between 50% and 90% 
inhibition, and green: < 50% inhibition. (D) AMA0825 IC50 values and the percentages of residual kinase activity 
of ROCK1/2 and some of the off-target kinases that were hit in the selectivity profile (> 50% inhibition, yellow 
and red dots). DMPK2, dystrophia myotonica protein kinase 2; LATS2, large tumour suppressor kinase 2; PKC, 
protein kinase C; PRK, protein kinase; ROCK, Rho-associated protein kinase; NT, not tested. 
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1.4 EXPERIMENTAL IBD MODELS OF INTESTINAL EPITHELIAL BARRIER DYSFUNCTION 
In the fourth and final part of this introduction, a short explanatory overview will be given of the 
different in vitro and in vivo models of intestinal epithelial barrier dysfunction that were used during 
this research to investigate the effect of the B. pullicaecorum butyrate-producing bacterium and the 
AMA0825 local ROCK inhibitor on epithelial protection during IBD-like inflammation. 
1.4.1 Mouse models of IBD 
Although they are not representative of the complexity of human disease, mouse models are 
indispensable to both the study of IBD immunology as well as the pre-clinical evaluation of potential 
therapeutic compounds. Multiple models of mucosal inflammation exist, each with their individual 
capacities to provide insight into IBD pathogenesis. The IBD mouse models used during this research 
are all characterised by alterations to the intestinal epithelial barrier, which contribute to disease. 
1.4.1.1 Dextran sulfate sodium-induced model of colitis 
Dextran sulfate sodium (DSS)-colitis is a chemical mouse model of colitis induced by administration of 
DSS - a sulphated polysaccharide - through the drinking water. The onset and severity of colitis are 
controllable by varying the DSS concentration, molecular weight and duration of exposure. 
Additional factors that further influence response to DSS are host genetic susceptibility (strain, 
gender) and microbiological composition of the housing conditions and the intestinal microbiota.107 
Clinically, mice develop bloody diarrhea and lose weight progressively. These parameters of disease 
activity are monitored throughout the course of colitis since they correlate well with the degree of 
histological inflammation. Histopathologically, DSS-colitis is characterised by epithelial erosion, 
goblet cell depletion, crypt loss and mucosal and submucosal edema due to infiltration of acute 
inflammatory cells like neutrophils and macrophages. Other post-mortem analyses that can be 
performed to further assess the degree of inflammation are; measurement of the colon length, 
assessment of colonic myeloperoxidase activity to quantify the infiltration of neutrophils, and 
determination of colonic pro-inflammatory cytokine levels. In this model, epithelial erosion is caused 
by colonocyte apoptosis which, along with the ensuing increased intestinal permeability, is observed 
before the onset of any clinical signs of inflammation.106,236 This would imply that barrier disruption is 
the initiating event, resulting in translocation of luminal antigens and subsequent influx of 
inflammatory cells that secrete both Th1 and Th2 pro-inflammatory cytokines, which further 
propagates the inflammatory response.237 Given the superficial nature and the exclusively colonic 
localisation of the inflammation, DSS-colitis best resembles human UC. 
The exact pathogenic mechanism of DSS remains unknown. A recent hypothesis states that DSS is 
metabolised by the intestinal microbiota of the caecum into sulphate ions and a carbohydrate 
moiety. These sulphate ions are further converted by sulphate reducing bacteria to yield toxic sulfite, 
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which could directly damage the intestinal epithelium.238 This hypothesis would also explain the 
limitation of the inflammation to the most distal part of the colon where the bacterial load is highest. 
Additionally, DSS is detected in the macrophages of the mesenteric lymph nodes and the colon from 
the first day after the start of administration. This accumulation of DSS has been reported to lower 
the bacterial phagocytic ability of the macrophages, which could contribute to inflammation.239 
Exactly how DSS penetrates the mucosal barrier before any microscopic signs of epithelial damage 
are observed, remains uncertain. However, recent in vitro experiments indicated that DSS increases 
paracellular permeability in intestinal epithelial Caco-2 monolayers, which is not caused by cell 
damage.240 Araki et al. also described how nuclear translocation of DSS in Caco-2 cells is associated 
with cell cycle arrest.241 Given the high turnover rate of the intestinal epithelium, this could lead to 
loss of barrier integrity and facilitate luminal influx into the underlying tissue. 
In conclusion, DSS-colitis is a simple, low cost and reproducible model that allows the study of 
epithelial response to injury and other aspects of the acute phase of colitis pathogenesis.242 
Furthermore, several currently used IBD therapeutics have shown efficacy in this model, validating 
DSS-colitis as a relevant model for the translation of mice data to human disease.243,244 
1.4.1.2 2,4,6-trinitrobenzene sulfonic acid-induced model of colitis 
Like the DSS-induced colitis model, 2,4,6-trinitrobenzene sulfonic acid (TNBS)-colitis is chemically 
induced by intrarectally administrating TNBS combined with ethanol. Severity of colitis depends on 
the dose of TNBS, percentage of ethanol, and age and genetic background of the mice. The ethanol 
temporary permeabilises the epithelial barrier, allowing the TNBS to haptenise autologous or 
microbial proteins, rendering them immunogenic to the host immune system.245 The colitis induced 
by a single TNBS application is an acute, local reaction characterised by transmural inflammation with 
ulceration, infiltration of neutrophils and macrophages into the mucosal and submucosal layers, and 
production of Th1 cytokines. A specific Th1-cell mediated autoimmune response to the haptenised 
proteins is only elicited after a second TNBS administration. Several repeated administrations of 
TNBS results in a chronic colitis, characterised by the development of fibrosis.246 Given the 
transmural nature of the inflammation, the presence of epithelial ulcers, the Th1 specific cytokine 
profile, and the fibrotic lesions in the chronic setting, TNBS-colitis best resembles human colonic CD. 
The clinical follow-up of disease activity and post-mortem assessment of inflammation in this model 
are the same as for the DSS-induced colitis model. 
1.4.1.3 TNFΔARE/+ model of ileitis 
This mouse model is the result of a targeted deletion of AU-rich elements in the 3’ untranslated 
region of the TNF gene, which leads to loss of posttranscriptional regulation of the TNF mRNA and 
increased constitutive and inducible levels of the TNF protein.247 This chronic overproduction of TNF 
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leads to two distinct phenotypes in TNFΔARE/+ mice from the age of 4 weeks on; polyarthritis and 
terminal ileitis, which causes reduced weight gain compared to their wild-type littermates. Mucosal 
inflammation in these mice closely resembles human CD and is characterised by architectural 
changes in the villi, transmural inflammation, extended infiltration of both acute and chronic 
inflammatory cells, and granulomata in later stages. The pivotal role of the epithelium in initiating 
pathology in this model was demonstrated by Roulis et al. who showed that IECs as producers, but 
not as targets, of endogenous TNF suffice to cause intestinal disease.248 Endogenous overproduction 
of TNF was shown to be dependent on TLR/Myd88-mediated innate recognition of indigenous 
microbiota. Although TNF is known to promote loss of barrier integrity, TNFΔARE/+ mice do not display 
any major defects in paracellular permeability or mucus layer formation, and IECs remain largely 
intact. However, disease progression in these mice is associated with Paneth cell loss and 
concomitant diminished antimicrobial gene expression. This dampened antimicrobial response 
results in dysbiosis involving increased abundance of epithelial-adhering SFB, which may further 
promote disease.108 The presence of these SFB, which are also abundant colonisers of gut-associated 
issues in humans, in the lamina propria of the murine small intestine has been shown to induce the 
appearance of CD4+ T helper cells that produce IL-17 (Th17 cells). Colonisation with SFB was 
correlated with an increased expression of genes associated with inflammation and antimicrobial 
defenses, and resulted in an enhanced resistance to the intestinal pathogen Citrobacter rodentium. 
At steady state, these SFB thus contribute to Th17-mediated mucosal protection. However, an 
inflammation-induced increase in SFB numbers in the case of TNFΔARE/+ mice, can aggravate intestinal 
disease given the pro-inflammatory potential of Th17 cells.102 
1.4.1.4 Lipopolysaccharide-induced endotoxemia model 
In the intestine, epithelial cells are generated in the crypt and migrate along the villus axis before 
being shed at the villus tip in a highly regulated process of TJ rearrangements, which allow 
detachment and release of IECs while at the same time preventing gap formation within the 
epithelium. The small intestine, with an estimated 1011 cell being shed per day, therefore has one of 
the highest cell turnover rates in the body.249 Under inflammatory conditions however, the rate of 
shedding from the villus tip greatly exceeds the rate of generation of new cells in the crypt, resulting 
in gap formation and villus shortening. Indeed, pathological IEC shedding and the ensuing focal 
permeability defects have been described as an early event in IBD pathogenesis.250 A mouse model of 
pathological LPS-induced small intestinal IEC apoptosis and shedding was developed by Williams et 
al. to study this process, since IEC shedding in mice is morphologically analogous to humans.251 
Intraperitoneal administration of a sublethal dose of LPS was found to be a simple, rapid and 
consistent stimulus for initiating a systemic inflammatory response. Briefly, this model is 
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characterised by increased IEC apoptosis in the apical 50% of the villus, and shedding at the villus tip, 
which peaks 1.5 hours after LPS administration. This coincides with villus shortening, fluid exudation 
into the gut, and the onset of diarrhea. Increased gut-to-circulation permeability, detectable after 
oral gavage with fluorescein isothiocyanate (FITC)-dextran, is observed at 5 hours post-LPS. 
Mechanistically, systemically delivered LPS is first detected by resident mononuclear immune cells, 
which produce TNF in response to TLR4 receptor activation by LPS. TNF subsequently binds to the 
TNF receptor 1 (TNFR1) expressed on IECs, triggering apoptosis and shedding if NF-κB2 signalling 
dominates, or cell survival if NF-κB1 signalling is favoured. 
1.4.2 In vitro models of intestinal barrier dysfunction 
For the in vitro modelling of human intestinal epithelium we used monolayers of either Caco-2 or T84 
IECs. Both cell lines are derived from a colorectal adenocarcinoma and differentiate spontaneously 
upon reaching confluency into a monolayer of polarised, columnar IECs characterised by the 
appearance of TJs between adjacent cells, apical microvilli, and the expression of brush border 
hydrolases.252 Complete functional and morphological differentiation takes two to three weeks on 
average. Both cell lines are utilised interchangeably despite evidence that differentiated Caco-2 cells 
closely resemble small intestinal enterocytes, whereas differentiated T84 cells are less well 
characterised.253,254 
Barrier studies are generally performed on Caco-2 or T84 cells cultured on semi-permeable filter 
supports, since this improves morphological and functional differentiation by allowing free access of 
nutrients to both the apical and basolateral sides of the monolayer.252 This system also facilitates 
measurements of monolayer integrity and permits the separation of apical and basolateral 
stimulation of the cells. The integrity of the monolayer is determined by the TJs, which restrict 
paracellular diffusion of ions and larger molecules in a selective manner, based on both size and 
charge. Ion permeability of the monolayer is generally determined by measuring TEER while 
paracellular permeability based on size can be monitored using non-ionic, fluorescently labelled 
hydrophilic tracers like lucifer yellow or FITC-dextran. 
Barrier disruption in this model is induced by stimulation of the monolayer with pro-inflammatory 
cytokines such as TNF202, INFγ222,223 and IL-1β221, or other compounds such as ethanol255, hydrogen 
peroxide256 or bacterial components like LPS257. In our experiments, a combination of IFNγ and TNF is 
used since these cytokines are known to have a synergistic effect on the induction of intestinal 
epithelial barrier dysfunction.71,258,259 Barrier-disrupting agents are always added basolaterally given 
the polarised expression of their receptors on IECs. This is in accordance with the fact that in the gut, 
activated immune cells such as macrophages, DCs and intraepithelial lymphocytes that secrete these 
pro-inflammatory mediators, are also located in the mucosa underneath the epithelium. Drugs or 
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food compounds with a suspected beneficial effect on barrier function are usually added apically to 
the monolayer. An expansion on this model is the coculture system first described by Satsu et al.260 in 
which a Caco-2 epithelial monolayer is placed on top of activated macrophage-like THP1 cells. THP1 
cells are human, acute monocytic leukemia cells that differentiate into adherent activated 
macrophages after treatment with phorbol myristrate acetate (PMA) for a minimum of 48 hours. 
PMA treatment dramatically increases TNF, IL-1β, IL-6 and IL-8 secretion by THP1 cells, which induces 
a loss of TEER and an increase in lactate dehydrogenase (LDH) release in the Caco-2 monolayer. An 
indirect coculture system can also be used, in which the epithelial monolayer is stimulated 
basolaterally with the conditioned medium of PMA-activated THP1 cells, instead of the cultured 
THP1 cells themselves. Barrier disruption in this coculture model is significantly suppressed by adding 
TNF neutralising agents, suggesting that TNF is the main damaging factor. Affected monolayers show 
both apoptotic and necrotic characteristics in which TNFR1-mediated NF-κB signalling seems to be 
involved. It is well established that pro-inflammatory cytokines like TNF play a key role in IBD 
pathogenesis, in part by inducing excessive epithelial cell death, and that elevated mucosal TNF 
levels as well as increased activation of its transcriptional regulator NF-κB, have been reported in IBD 
patients.198 The similarity between the in vivo inflammation and the nature of the THP1-induced 
damage to Caco-2 monolayers, validates the use of this coculture system as an in vitro model of 
inflammation-induced epithelial barrier dysfunction, and offers a convenient platform for the 
evaluation of anti-inflammatory drugs or food compounds as potential treatment options for 
restoring intestinal epithelial barrier integrity in IBD.  
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RATIONALE 
Intestinal epithelial barrier dysfunction is a major hallmark of IBD caused mainly by TJ deregulation 
and IEC apoptosis, leading to an influx of luminal antigens which sustains inflammation. Whether 
increased intestinal permeability is a pre-existing defect or the consequence of underlying mucosal 
inflammation remains unclear. Either way, restoration of epithelial barrier integrity is crucial to 
mucosal healing, a recently emerged key treatment goal in IBD that predicts sustained clinical 
remission. In current IBD management, mucosal healing is usually achieved as a consequence of 
administering immunosuppressive or immunomodulating drugs. However, not all patients respond to 
the current drugs or lose response over time, and considerable side effects often occur (e.g. allergic 
reactions). 
Therefore, the primary aim of this thesis was the study of two pathways directly involved in 
maintenance and regulation of TJ integrity; butyrate production and ROCK function. In the first part, 
we investigated the butyrate-producing Butyricicoccus pullicaecorum 25-3T strain. Given the butyrate 
deficiency during intestinal inflammation in IBD and the known barrier-protective properties of 
butyrate, B. pullicaecorum 25-3T could potentially be used as a pharmabiotic to promote mucosal 
healing in IBD. Our objective was therefore to specifically analyse the barrier-protective properties of 
B. pullicaecorum 25-3T (chapter III). 
The second part focusses on epithelial ROCK function. These kinases regulate actin-dependent TJ 
dynamics, including cytokine-induced internalisation of TJ proteins. The involvement of ROCK in 
inflammation-induced loss of epithelial barrier integrity and the elevated ROCK activity observed in 
the intestinal mucosa of patients with active IBD, has prompted research into the use of ROCK 
inhibitors to counteract epithelial dysfunction in IBD. Current ROCK inhibitors however, have 
selectivity issues and display considerable side effects upon systemic exposure. This is why Amakem 
Therapeutics developed AMA0825; a local ROCK inhibitor specifically designed to target the gut and 
minimise systemic exposure. In this part of the thesis, we investigated the effect of AMA0825 on 
inflammation-induced intestinal epithelial barrier dysfunction and the associated mucosal 
inflammatory response (chapter IV). 
A secondary aim within this thesis was the comparison between differentiated Caco-2 and T84 cells, 
which were both used frequently as in vitro models of epithelial monolayers. During the experiments 
performed with these cell lines, we observed that they behaved differently in response to various 
stimuli despite their shared colonic origins. In the third part of this thesis, we therefore further 
characterised Caco-2 and T84 monolayers (chapter V). 
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SPECIFIC RESEARCH AIMS 
1. Investigate the barrier-protective potential of Butyricicoccus pullicaecorum 25-3T 
The aims of this study were to: 
 determine the expression of butyrate-responsive TJ genes OCLN, TJP1 and CLDN1 in a 
collection of mucosal biopsies from UC patients and healthy controls and correlate this to the 
abundance of Butyricicoccus in the mucosa of UC patients and healthy controls 
 investigate whether butyrate influences in vitro expression of OCLN, TJP1 and CLDN1 and 
evaluate the effect on repair of IEC monolayer integrity 
 investigate whether expression of OCLN, TJP1 and CLDN1 is influenced ex vivo by B. 
pullicaecorum 25-3T conditioned medium in mucosal biopsies of UC patients with active 
disease 
The results from this study are described in chapter III. 
2. Investigate the effect of the new local ROCK inhibitor AMA0825 on inflammation-induced 
epithelial dysfunction and the associated mucosal response 
The aims of this study were to: 
 evaluate the barrier-protective properties of AMA0825 on repair of IEC monolayers in vitro 
 evaluate the anti-inflammatory properties of AMA0825 on IECs in vitro 
 evaluate the efficacy of AMA0825 in decreasing clinical disease severity, epithelial 
destruction and the associated inflammatory response in two mouse models of acute colitis 
induced by a disturbance of epithelial integrity 
 evaluate the anti-apoptotic potential of AMA0825 during receptor-mediated apoptosis in 
IECs in vitro and during LPS-induced enterocyte apoptosis in vivo 
The results from this study are described in chapter IV. 
3. Compare the differentiation-induced expression profiles of Caco-2 and T84 epithelial cells 
The aims of this study were to: 
 further characterise differentiated Caco-2 and T84 cell lines through expressional analysis of 
selected differentiation markers 
 compare the functional response to butyrate between both cell lines 
The results from this study are described in chapter V. 
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Abstract 
Background and Aims. Butyricicoccus is a butyrate-producing clostridial cluster IV genus whose 
numbers are reduced in stool of ulcerative colitis (UC) patients. Conditioned medium of 
Butyricicoccus (B.) pullicaecorum prevents tumor necrosis factor (TNF)/interferon gamma (IFNγ)-
induced increase in epithelial permeability in vitro. Since butyrate influences intestinal barrier 
integrity, we further investigated the relationship between the abundance of mucosa-associated 
Butyricicoccus and the expression of butyrate-regulated tight junction (TJ) genes. 
Methods. Tight junction protein 1 (TJP1), occludin (OCLN), claudin-1 (CLDN1) and Butyricicoccus 16S 
rRNA expression was analysed in a collection of colonic biopsies of healthy controls and UC patients 
with active disease. The effect of butyrate and B. pullicaecorum conditioned medium on TJ gene 
expression was investigated in TNF/IFNγ-stimulated Caco-2 monolayers and inflamed mucosal 
biopsies of UC patients. 
Results. TJP1 expression was significantly decreased in inflamed UC mucosa, whereas CLDN1 mRNA 
levels were increased. OCLN did not differ significantly between both groups. Mucosa-associated 
Butyricicoccus 16S rRNA transcripts were reduced in active UC patients compared to healthy 
controls. Interestingly, Butyricicoccus activity negatively correlated with CLDN1 expression. Butyrate 
reversed the inflammation-induced increase of CLDN1 protein levels and stimulation of inflamed UC 
biopsies with B. pullicaecorum conditioned medium normalised CLDN1 mRNA levels. 
Conclusions. Butyricicoccus is a mucosa-associated bacterial genus underrepresented in colonic 
mucosa of patients with active UC whose activity inversely correlates with CLDN1 expression. 
Butyrate and B. pullicaecorum conditioned medium reduce CLDN1 expression, supporting its use as a 
pharmabiotic preserving epithelial TJ integrity. 
 
Keywords 
tight junctions, pharmabiotic, butyrate 
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Introduction 
In the healthy gut, a symbiotic relationship exists between the host and commensal bacteria, which is 
paramount to our general wellbeing. Commensals are i.a. crucial to the maintenance of 
immunological gut homeostasis. During adult life, the composition of the intestinal microbiota is 
fairly stable but may fluctuate due to infections or oral antibiotic treatment. This fluctuation 
generally entails a decrease in both bacterial abundance and diversity - a condition termed 
dysbiosis.1 Several chronic diseases, including Inflammatory Bowel Disease (IBD), are associated with 
intestinal dysbiosis. IBD, comprising Crohn’s disease (CD) and ulcerative colitis (UC), is characterised 
by a chronic, relapsing inflammation of the gastrointestinal tract. The etiology of IBD is unknown but 
inflammation most likely results from an abnormal mucosal immune response to antigens derived 
from the commensal microbiota in a genetically susceptible host. One of the most important 
microbial communities affected by intestinal inflammation are specific butyrate-producing members 
of the Firmicutes phylum like the Lachnospiraceae subgroup (which comprises Clostridium XIVa and 
IV groups within the order Clostridiales) which are underrepresented in the mucosal microbiota of 
patients with IBD compared to healthy subjects.2 Butyrate is a short-chain fatty acid (SCFA) produced 
during fermentation of dietary fiber in the colon. Besides being the main energy source for 
colonocytes, butyrate is also responsible for the maintenance of colonic homeostasis by modulating 
a wide variety of cellular functions including proliferation, differentiation, apoptosis and the control 
of intestinal epithelial permeability.3,4 Butyrate is a potent anti-inflammatory mediator given its role 
in promoting epithelial barrier function,5 its inhibitory effect on cytokine expression6 and its ability to 
induce differentiation of colonic regulatory T cells.7 Most of the butyrate-producing bacteria cultured 
so far belong to the clostridial clusters XIVa and IV that include Roseburia8 and Faecalibacterium9 
species respectively, two abundant colonisers of the human gut. A decrease in both Roseburia 
hominis and Faecalibacterium prausnitzii has been documented in stools of UC patients with both 
species showing an inverse correlation with disease activity.10 
Consequently, there is increasing interest in using butyrate to restore homeostasis in IBD. However, 
its routine clinical application has been impeded by practical issues. When administered orally, 
butyrate might not reach the colon in sufficient amounts due to its rapid gastric and duodenal 
absorption. Besides, butyrate has a very unpleasant taste and smell. Rectal butyrate enemas have 
proven to be effective in treating distal UC11,12 but are cumbersome for the patient and exposure of 
the colonic mucosa to the butyrate is brief and discontinuous. The administration of naturally 
occurring butyrate-producing bacteria that would continuously secrete butyrate into the colonic 
lumen is an alternative strategy to locally increase butyrate concentrations. One of these high-level 
butyrate-producing bacteria is Butyricicoccus pullicaecorum (B. pullicaecorum), an anaerobic Gram-
positive clostridial cluster IV species, first isolated from the caecal content of a broiler chicken.13 The 
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average number of Butyricicoccus is decreased in stool samples of IBD patients and a specific B. 
pullicaecorum strain is able to reduce intestinal inflammation in a rat colitis model. Furthermore, its 
conditioned medium prevents cytokine-induced increase in epithelial permeability in vitro.14 
A dysfunctional epithelial barrier is one of the key characteristics of IBD.15 This barrier consists of a 
single layer of epithelial cells linked together by tight junctions (TJs) which seal off the intercellular 
space and regulate selective paracellular ionic solute transport. Tight junctions are composed of four 
different integral membrane proteins: occludin (OCLN), tricellulin, junctional adhesion molecules and 
claudins which are linked to the actin cytoskeleton through scaffolding proteins like tight junction 
protein 1 (TJP1).16 In IBD, expression of most claudins – like other TJ proteins- is reduced.17 
Remarkably, claudin-1 (CLDN1) protein levels are increased in areas of active inflammation.18 Given 
the reduction of Butyricicoccus numbers in IBD and the ability of its conditioned medium to prevent 
cytokine-induced epithelial dysfunction, B. pullicaecorum bacteria therefore seem conceptually 
attractive as pharmabiotics to reduce intestinal inflammation or to prevent disease relapse in IBD 
patients. However, it is currently unknown how Butyricicoccus could affect barrier integrity in human 
IBD. Therefore, the purpose of this study was to detect and quantify Butyricicoccus in human colonic 
mucosa and to further investigate the host response to butyrate and conditioned medium of B. 
pullicaecorum in terms of epithelial barrier function.   
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Materials and Methods 
Ethics statement. The use of patient material was approved by the Ethics Committee of the Ghent 
University Hospital (permit number UZG 2004/242). Written informed consent was obtained from all 
participants. Mice were housed in the laboratory animal facility at Ghent University Hospital 
according to the institutional animal healthcare guidelines. This study was approved by the 
Institutional Review Board of the Faculty of Medicine and Health Sciences of Ghent University 
(ECD2014-25). 
Patient samples. Biopsies from healthy controls (N=36), UC patients with active disease (N=37) and 
UC patients in clinical and endoscopic remission (N=16) were obtained during routine colonoscopy. 
Active disease in UC patients was defined as the presence of endoscopic signs of disease activity 
(Mayo score of 1 or higher) and biopsies were taken from the inflamed site (sigmoid or rectum). UC 
patients in remission had no clinical or endoscopic signs of inflammation (Mayo score of 0). Control 
biopsies were taken from the sigmoid of healthy patients who underwent colonoscopy to screen for 
cancer. Patient characteristics are provided in Table 1. All biopsies were immediately placed in 
RNAlater (Ambion, Cambridgeshire, UK) and stored at -80°C. 
Mice and experimental protocol. Heterozygous C57BL/6 TNFΔARE/WT mice and TNFWT/WT littermates 
were conventionally raised in a temperature-controlled room at 20°C with a light/dark cycle of 12/12 
hrs. Water and a commercial chow (mice maintenance chow, Carfil Labofood, Pavan Service, 
Belgium) were provided ad libitum. At 24 weeks of age, eight TNFΔARE/WT mice and eight TNFWT/WT 
littermate controls were sacrificed by cervical dislocation. The terminal ileum was removed, opened 
longitudinally and washed with phosphate buffered saline (PBS). Tissue samples were cut, snap-
frozen and stored at -80°C until analysis. 
Bacterial strain and growth conditions. B. pullicaecorum 25-3T (LMG 24109T) was grown overnight at 
37°C in an anaerobic (90% N2, 10% CO2) workstation (GP-Campus, Jacomex, TCPS NV, Rotselaar, 
Belgium) in anaerobic modified M2GSC medium at pH 6 prepared as described by Miyazaki et al.19 
but without clarified rumen fluid. The bacterial cells were collected by centrifugation (10 min, 5000 g, 
37°C) and discarded. The resulting supernatant was sterile-filtered (0.22 µm) and the concentration 
of short-chain fatty acids (acetate, propionate, butyrate, isobutyrate, valerate, isovalerate, caproate 
and isocaproate) was determined using a gas chromatograph as described previously.20 Only butyrate 
was detected in supernatant of B. pullicaecorum 25-3T at a concentration of 4 mM. 
Stimulation of colonic mucosal biopsies with B. pullicaecorum conditioned medium. Colonic 
biopsies from patients with active UC (N=25) were obtained as described above and harvested in 
RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, 100 
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µg/ml streptomycin, 200 µg/ml gentamycin and 250 ng/ml Fungizone® antimycotic (all Life 
Technologies, Gent, Belgium). Patient characteristics are provided in Table 1. Biopsies were cultured 
for 24 hrs with B. pullicaecorum conditioned medium diluted to contain 2 mM of butyrate or M2GSC 
anaerobic medium as control. Biopsies were recovered in RNAlater and stored at -80°C. 
Cell culture and induction of barrier dysfunction in vitro. Caco-2 cells (HTB-37, ATCC Cell Biology 
Collection, Manassas, VA, USA) were seeded on 24-well semipermeable inserts (0.4 µm, translucent 
ThinCerts™, Greiner Bio-One, Vilvoorde, Belgium) at a density of 105 cells per well and cultured for a 
minimum of two weeks in Dulbecco’s modified Eagle medium supplemented with 10% FBS (both Life 
Technologies). After this period, the integrity of the monolayer was evaluated by measuring the 
transepithelial electrical resistance (TEER) using a Millicell ERS-2 Voltohmmeter (Merck Millipore, 
Billerica, MA, USA) to ensure that functional polarised epithelial monolayers with absolute TEER-
values of more than 3000 Ohm were obtained. The Caco-2 differentiated monolayer was then 
incubated apically with 8 mM sodium butyrate (NaB) (Sigma-Aldrich, Diegem, Belgium) and 
basolaterally with recombinant human 100 ng/ml tumor necrosis factor (TNF) and 300 ng/ml 
interferon gamma (IFNγ) (both Life Technologies) to induce barrier dysfunction measured as a drop 
in TEER. After 48 hrs, absolute TEER values were normalised to their pre-treatment values and 
expressed as a percentage of the initial TEER values. After the TEER measurements, Caco-2 inserts 
were used for CLDN1 detection by either western blotting or immunofluorescence. Medium from the 
basolateral compartments was used for interleukin-8 (IL-8) detection. 
IL-8 measurements. IL-8 secretion into the basolateral medium was measured using an enzyme-
linked immunosorbent assay (ELISA) (R&D Systems, Abingdon, UK) according to the manufacturer’s 
instructions. IL-8 concentration was expressed as picograms of cytokine per milliliter of medium. 
Western blot analysis. Caco-2 monolayers were lysed using sonication on ice for 1 min in 200 µl of 
Radio Immunoprecipitation Assay buffer supplemented with a phosphatase and protease inhibitor 
cocktail (Sigma-Aldrich). The concentration of protein lysates were determined using the Bio-Rad 
Protein Assay (Bio-Rad, Temse, Belgium) according to the manufacturer’s instructions with bovine 
serum albumin (BSA) as a protein standard. Thirty µg of each sample was mixed with 1:4 loading 
buffer (Life Technologies) and 1 mM dithiothreitol (Roche, Vilvoorde, Belgium). Samples were 
denatured by boiling for 10 min at 95°C, separated on a 4–12% gradient Bis-Tris SDS-PAGE gel and 
transferred to a nitrocellulose membrane using a wet transfer (all Life Technologies). Afterwards, 
membranes were blocked with 5% BSA in Tris buffered saline with 0.1% Tween-20 (TBST) (Sigma-
Aldrich) and incubated overnight at 4°C with 1:1000 rabbit anti-CLDN1 antibody (Cell Signalling, 
Leiden, The Netherlands) in 5% BSA in TBST. Next, blots were incubated for 1 h at room temperature 
with 1:2000 secondary goat anti-rabbit IgG, HRP-conjugated secondary antibody (Cell Signalling). 
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Bound antibodies were visualised using the BM Chemiluminescence Western Blotting Substrate POD 
(Roche) according to manufacturer’s instructions and membranes were exposed to X-ray films. Equal 
loading of proteins was confirmed by immunoblotting with 1:5000 anti-tubulin (Abcam, Cambridge, 
UK) antibody in 5% BSA in TBST. 
Immunofluorescence staining. Caco-2 inserts were fixed in cold methanol: acetone (50%: 50%) for 1 
min. Blocking step was performed using 10% (v/v) normal goat serum (Sigma-Aldrich) in PBS. Then 
cells were incubated for 1 h with 1:200 rabbit anti-CLDN1 antibody (Life Technologies) in 2% normal 
goat serum in PBS. After washing, the cells were stained with 1:200 Alexa Fluor 488 anti-rabbit 
secondary antibody (Life Technologies) in 2% normal goat serum in PBS for 30 min in the dark at 
room temperature. Cells were incubated with DAPI (Life Technologies) for 5 minutes to allow nuclear 
staining. Inserts were mounted using mounting medium containing an anti-fading agent (Dako, 
Heverlee, Belgium). Cells were examined under a BD Pathway 435 confocal laser microscope (BD 
Biosciences, San Diego, CA, USA) and images were processed using Adobe Photoshop software 5.5 
(Adobe systems, Dublin, Ireland). 
RNA extraction. Total RNA from Caco-2, human mucosal biopsies and mice terminal ileum tissue 
samples was extracted using the Qiagen RNeasy Mini Kit (Qiagen, Venlo, The Netherlands) with on-
column DNase treatment. Concentration and purity was determined using nanodrop technology 
(BioPhotometer Plus, Eppendorf, Rotselaar, Belgium). All samples exhibited an OD260/OD280 ratio 
between 1.8 and 2.1. 
Quantitative Real-Time PCR. One microgram of total RNA was converted to single stranded cDNA by 
reverse transcription using the iScript™ cDNA synthesis kit (Bio-Rad) according to the manufacturer’s 
instructions. The cDNA was diluted to a concentration of 5 ng/µl and 15 nanogram was used in 
quantitative real-time PCR (qRT-PCR) with SYBR Green (SensiMix™ SYBR No-ROX kit, GC biotech, 
Alphen a/d Rijn, The Netherlands) and 250 nM of each primer. A two-step program was performed 
on the LightCycler 480 (Roche). Cycling conditions were 95°C for 10 min, 45 cycles of 95°C for 10 s 
and 60°C for 1 min. Melting curve analysis confirmed primer specificities. All reactions were 
performed in duplicate. Expression of all eukaryotic genes was normalised to the stably-expressed 
reference gene levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and succinate 
dehydrogenase complex A subunit (SDHA) for the Caco-2 cDNA, to GAPDH, tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein (YWHAZ) and hydroxymethyl-
bilane synthase (HMBS) for B. pullicaecorum-stimulated active UC biopsy cDNA, to GAPDH, YWHAZ 
and HMBS for all other human biopsy cDNA and to Hmbs and Gapdh for mice terminal ileum tissue 
samples. To enable normalisation to biopsy size, the number of cDNA copies corresponding to the 
Butyricicoccus 16S rRNA gene were normalised to the expression of human GAPDH, HMBS and 
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YWHAZ as described previously.21 The PCR efficiency of each primer pair was calculated using a 
standard curve of reference cDNA. Amplification efficiency was determined using the formula 10-
1/slope. Sequences of the primer sets are listed in Table 2. 
Statistical analysis. Statistical analysis was performed using GraphPad Prism software (GraphPad, La 
Jolla, CA, USA) and SPSS Statistics version 22.0 (IBM SPSS Statistics, Armonk, NY, USA). Values are 
presented as the mean ± standard error of the mean (SEM). Normality of the data was checked using 
the Kolmogorov-Smirnoff test. Differences between groups were analysed using an unpaired 
Student’s t-test for independent samples in case of normally distributed data (applying the Welch’s 
correction in case of unequal variances) or the Mann-Whitney statistic if the data were not normally 
distributed. Two-tailed probabilities were calculated and p-values less than 0.05 were considered 
statistically significant. Prevalence of the genus Butyricicoccus in healthy controls versus active UC 
patients was calculated using a Fisher’s exact test. The Kolmogorov-Smirnoff test also determined 
the use of either a parametric (Pearson) or a non-parametric (Spearman) correlation test. 
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Results 
Tight junction gene expression is deregulated during intestinal inflammation 
In order to link the presence of Butyricicoccus with barrier integrity in vivo, mRNA expression levels 
of three major TJ genes - CLDN1, TJP1 and OCLN - were measured in a collection of colonic mucosal 
biopsies from healthy controls (N=36) and patients with active UC (N=37) using qRT-PCR. Expression 
of TJP1 was significantly decreased (p < 0.001, Figure 1A) in UC biopsies, whereas CLDN1 expression 
was significantly increased (p < 0.0001, Figure 1B). Expression of OCLN did not differ significantly 
between active UC patients and healthy controls (p = 0.091, Figure 1C). In remission, no significant 
differences were observed (Figure 1A-C). The inflammation-associated upregulation of CLDN1 
observed in active UC seems counter-intuitive, however increased CLDN1 levels have been reported 
in experimental models for colitis.22 Also inflammation of the ileum in TNFΔARE/WT mice23 exhibits an 
increased expression of Cldn1 (p = 0.0002, Figure 1D). 
 
Figure 1. Tight junction gene expression in biopsies of UC patients vs. healthy controls and in TNF
ΔARE/WT
 mice 
vs. TNF
WT/WT
 littermate controls. (A-C) TJP1, OCLN and CLDN1 mRNA levels in colonic mucosal biopsies of 
healthy controls (N=36), UC patients with active disease (N=37) and UC patients in remission (N=16). (D) Cldn1 
expression in terminal ileum samples of 24-week old TNF
ΔARE/WT
 mice (N=8) vs. TNF
WT/WT
 littermate controls 
(N=8). **p < 0.01, ***p < 0.001. NS, not significant. 
Butyricicoccus activity is decreased in mucosal samples of patients with active UC 
Next, we used this biopsy cohort to determine whether Butyricicoccus bacteria were present using 
genus specific 16S rRNA primers. Butyricicoccus 16S rRNA levels could be measured adequately, 
ranging from 0 to 100.000 copies. Functionally active Butyricicoccus bacteria were detectable in all 
healthy control samples but below detection in eight out of 37 active UC samples (Fisher’s exact p = 
0.0052). In UC samples with detectable 16S rRNA transcripts, the absolute numbers were reduced 
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compared to those of healthy controls (p = 0.046, Figure 2A). Interestingly, the amount of 
Butyricicoccus inversely correlated with CLDN1 mRNA levels (Pearson R = -0.239, p = 0.024, Figure 
2B). 
 
Figure 2. Quantification of Butyricicoccus activity in colonic mucosal biopsies of healthy controls and UC 
patients. (A) Butyricicoccus activity in colonic mucosal biopsies of healthy controls (N=36), UC patients with 
active disease (N=37) and UC patients in remission (N=16). Bacterial activity is expressed as log10 copy number 
of normalised 16S rRNA genes for Butyricicoccus. (B) Correlation plot between CLDN1 levels and Butyricicoccus 
activity in biopsies of healthy controls (grey), patients with active UC (black) and UC patients in remission (grey 
with black borders). *p < 0.05. NS, not significant. 
Butyrate counteracts TNF/IFNγ-induced barrier disruption and TJ deregulation 
Next, we questioned whether the in vitro model for barrier disruption using TNF/IFNγ-stimulated 
Caco-2 monolayers mimics deregulated TJ gene expression observed in UC biopsies. Forty-eight hrs 
following the addition of TNF/IFNγ, a significant drop in TEER was observed (p < 0.0001, Figure 3A), 
which coincided with increased IL-8 production (p = 0.0043, Figure 3B) and a significant reduction of 
TJP1 and OCLN mRNA levels (p = 0.0065 and 0.0014, respectively, Figure 3C-D), while CLDN1 mRNA (p 
= 0.012, Figure 3E) and CLDN1 protein expression were increased (Figure 3F). In addition, CLDN1, 
which localises to the plasma membrane in functionally intact Caco-2 monolayers, internalised 
following TNF/IFNγ-stimulation (Figure 3G). The addition of 8 mM butyrate to the transwell culture 
inhibited the TNF/IFNγ-induced TEER drop (p = 0.001), diminished IL-8 secretion (p > 0.05), and 
increased the expression of TJ genes TJP1 (p = 0.0223) and OCLN (p = 0.0012) (Figure 3A-D). Although 
the TNF/IFNγ-induced increase in mRNA expression of CLDN1 was not influenced by butyrate (Figure 
3E), total protein levels of CLDN1 (Figure 3F) were markedly decreased. However, cytoplasmic 
expression of CLDN1 was still observed (Figure 3G). 
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Figure 3. Effect of butyrate on TNF/IFNγ-induced barrier disruption and TJ deregulation in Caco-2 
monolayers. Caco-2 differentiated monolayers were stimulated basolaterally with a combination of TNF and 
IFNγ and treated apically with 8 mM NaB. After 48 hrs, TEER (A), basolateral IL-8 secretion (B), TJP1 (C), OCLN 
(D) and CLDN1 (E) mRNA levels and CLDN1 protein expression (F) were determined. (G) Immunofluorescent 
microscopic images (63x) of CLDN1 internalisation in a Caco-2 monolayer stimulated with TNF/IFNγ and 8 mM 
NaB. Data in Figures 3A-E represent the mean ± SEM of 3 replicates/group. *p < 0.05, **p < 0.01, ***p < 0.001. 
NS, not significant. 
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B. pullicaecorum conditioned medium reduces CLDN1 expression in mucosa of patients with active 
UC 
Finally, to investigate whether B. pullicaecorum affects TJ expression ex vivo, mucosal biopsies of UC 
patients with active disease (N=25) were stimulated with B. pullicaecorum conditioned medium 
diluted to contain 2 mM of butyrate or an equal dilution of the growth medium control. After 24 hrs, 
a decrease in CLDN1 mRNA levels compared to medium control (p = 0.001, Figure 4A) was observed, 
while TJP1 and OCLN expression were not significantly affected by the conditioned medium (Figure 
4B-C). 
 
Figure 4. Effect of B. pullicaecorum conditioned medium on TJ expression in colonic mucosal biopsies of active 
UC patients. CLDN1 (A), TJP1 (B) and OCLN (C) expression in paired colonic biopsies from the same UC patients 
(N=25) treated with B. pullicaecorum conditioned medium diluted to contain 2 mM of butyrate or M2GSC 
anaerobic medium as control for 24 hrs. **p < 0.01. BP, B. pullicaecorum; NS, not significant. 
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Discussion 
Intestinal epithelial TJ integrity is compromised in IBD. The observed abnormalities include reduced 
strand numbers, strand discontinuities and reduced depth of the TJ complex. Changes in expression 
and localisation of specific TJ molecules have also been described.24,25 In our collection of colonic 
mucosal biopsies we also observed a severely deregulated expression of two major TJ genes – TJP1 
and CLDN1 – in samples of patients with active UC compared to healthy controls; TJP1 is 
underrepresented in inflamed tissue, whereas CLDN1 is highly upregulated. A similar increase in 
Cldn1 was observed in a model for Crohn’s-like ileitis due to constitutive overexpression of TNF; a key 
pro-inflammatory cytokine in IBD. Likewise, compromised TJ integrity mimicked in vitro by 
stimulating differentiated Caco-2 monolayers with TNF/IFNγ leads to loss of TJP1 and OCLN and an 
increase in CLDN1. In addition, CLDN1, which is localised solely at the plasma membrane in 
functionally intact Caco-2 monolayers, internalises following TNF/IFNγ-stimulation. Under normal 
physiological conditions, CLDN1 is a key pore-sealing TJ protein crucial to epithelial barrier integrity; 
its genetic deletion results in rapid postnatal death due to severe epidermal permeability defects.26 
Also, baseline CLDN1 overexpression in vitro results in increased barrier tightness while its 
concomitant knockdown decreases it.5 Under inflammatory conditions however, the role of CLDN1 is 
much less straightforward. In agreement with upregulated CLDN1 mRNA levels in our cohort, 
increased CLDN1 protein levels have been documented in IBD and in acute DSS-induced colitis.22,27 
Also, its intestinal epithelial overexpression renders mice more susceptible to colitis and impairs their 
recovery.28 Interestingly, in vitro pro-inflammatory cytokine-induced upregulation of CLDN1 coincides 
with a redistribution of the protein away from the TJs29,30 and a concomitant increase in intestinal 
permeability. So it appears that elevating CLDN1 expression under baseline conditions increases 
epithelial barrier integrity, whereas under inflammatory conditions its internalisation causes a 
weakening of the intestinal barrier despite an increase in overall expression. Next, we found that this 
aberrant CLDN1 expression in colonic mucosa of active UC patients negatively correlates with 
reduced Butyricicoccus activity. The detection of the genus Butyricicoccus in mucosal tissue is in 
agreement with a study published by Nava and Stappenbeck who identified Butyricicoccus as an 
autochthonous microbe predominantly colonising the mucosa-associated surface of the colon.31 This 
close proximity of Butyricicoccus bacteria to the apical surface of the colonic epithelium facilitates 
host access to its metabolites, like butyrate, which are essential to cellular homeostasis. Since 
butyrate is known to promote intestinal epithelial barrier function, we analysed its effect on 
TNF/IFNγ-induced deregulation of TJ gene expression in vitro. Butyrate completely prevented loss of 
TEER in TNF/IFNγ-stimulated Caco-2 monolayers while increasing TJP1 and OCLN expression. Neither 
increased CLDN1 mRNA levels nor CLDN1 internalisation was reduced by butyrate, however a drop in 
total CLDN1 protein levels was observed. Finally, ex vivo stimulation of inflamed UC biopsies showed 
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that the observed in vitro effects of butyrate could be mimicked by B. pullicaecorum conditioned 
medium; i.e. a marked reduction in CLDN1 levels. 
In conclusion, this study demonstrates that the functions of CLDN1 are not restricted to its traditional 
role of maintaining intestinal barrier function and that its elevation during mucosal inflammation is 
detrimental to both epithelial integrity and further downstream pathways responsible for colonic 
homeostasis. Given the effect of both butyrate and B. pullicaecorum conditioned medium on CLDN1 
expression, these results further substantiate the use of Butyricicoccus as a pharmabiotic in order to 
preserve epithelial TJ integrity. 
 
Funding 
This work was funded by the Flemish Agency for Innovation by Science and Technology (IWT) under 
the project number SBO-100016. LVDB and DL are paid by grants from the Research Foundation 
Flanders (FWO 11J9915N and 1298213N). 
 
Conflicts of Interest 
VE, RD and FVI are listed as co-inventors on a patent application for use of butyrate-producing 
bacterial strains related to B. pullicaecorum in the prevention and/or treatment of intestinal health 
problems (International Application Number PCT/EP2010/052184 and International Application 
Number WO2010/094789 A1). For the remaining authors no conflicts of interest were declared.  
 
Acknowledgements 
The authors are particularly grateful to Dr. George Kollias at the Biomedical Sciences Research Center 
‘‘Alexander Fleming’’ (Vari, Greece) for providing the TNFΔARE/WT mice. We would also like to thank ir. 
Elien Glorieus for the excellent assistance in obtaining patient samples, and Drs. Elke Decrock and 
Marijke De Bock for assisting with immunofluorescent staining and confocal microscopy. 
  
CHAPTER III 
91 
Tables 
Table 1. Patient characteristics. 
 healthy controls UC inflamed UC remission 
For baseline expression of Butyricicoccus and tight junction complex genes in colonic mucosa 
N (patients) 36 37 16 
Gender (male/female) 16/20 25/12 12/4 
Age (years, mean) 52 36 42 
Age (years, range) 18-80 6-68 16-74 
Disease location (E1/E2/E3) N/A 8/17/12 N/A 
Medication    
 None 36 11 1 
 5-Aminosalicylates 0 15 10 
 Corticosteroids 0 11 1 
 Immunomodulators 0 7 6 
 Biologicals 0 7 4 
For stimulation of inflamed UC biopsies with B. pullicaecorum conditioned medium 
N (patients) N/A 25 N/A 
Gender (male/female) N/A 15/10 N/A 
Age (years, mean) N/A 40 N/A 
Age (years, range) N/A 20-68 N/A 
Disease location (E1/E2/E3) N/A 13/10/2 N/A 
Medication    
 None N/A 2 N/A 
 5-Aminosalicylates N/A 16 N/A 
 Corticosteroids N/A 7 N/A 
 Immunomodulators N/A 9 N/A 
 Biologicals N/A 10 N/A 
E1, proctitis; E2, distal colitis; E3, pancolitis; N/A, not applicable. 
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Table 2. Primers for qRT-PCR analysis. 
Gene symbol Species Forward (5’-3’) Reverse (3’-5’) E (%) 
N/A Butyricicoccus ACCTGAAGAATAAGCTCC GATAACGTTGCTCCCTACGT 74 
Gapdh mouse CATGGCCTTCCGTGTTCCTA GCGGCACGTCAGATCCA 88 
Hmbs mouse AAGGGCTTTTCTGAGGCACC AGTTGCCCATCTTTCATCACTG 95 
Cldn1 mouse TGCCCCAGTGGAAGATTTACT CTTTGCGAAACGCAGGACAT 97 
CLDN1 human GGGATGGATCGGCGCCATCG CGTACATGGCCTGGGCGGTC 104 
TJP1 human CTCACCACAAGCGCAGCCACAA ACAGCAGAGGTTGATGATGCTGGG 98 
OCLN human AGACGTCCCCAGCCCAGTCC CGTACATGGCCTGGGCGGTC 111 
GAPDH human TGCACCACCAACTGCTTAGC GGCATGGACTGTGGTCATGAG 91 
SDHA human TGGGAACAAGAGGGCATCTG CCACCACTGCATCAAATTCATG 92 
YWHAZ human ACTTTTGGTACATTGTGGCTTCAA CCGCCAGGACAAACCAGTAT 93 
HMBS human GGCAATGCGGCTGCAA GGGTACCCACGCGAATCAC 101 
N/A, not applicable; E, efficiency. 
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Abstract 
Background and Aims. Intestinal epithelial barrier dysfunction is a major hallmark of inflammatory 
bowel disease, and is caused by enterocyte apoptosis and tight junction (TJ) destabilisation. Both 
processes are supposed to be mediated in part by Rho-associated kinases (ROCK), and elevated ROCK 
activity is present in the intestinal mucosa of patients with Crohn’s disease. The aim of this study was 
to evaluate the efficacy of a locally acting ROCK inhibitor, AMA0825, in counteracting inflammation-
induced loss of epithelial barrier integrity. 
Methods. Barrier-protective effects of AMA0825 were investigated in tumor necrosis factor 
(TNF)/interferon gamma (IFNγ)-stimulated Caco-2 monolayers. AMA0825 anti-inflammatory 
potential was evaluated in vitro in TNF/IFNγ-stimulated HT-29 epithelial cells through assessment of 
nuclear factor κB (NF-κB) activation, and in two mouse models of acute colitis induced by the 
disturbance of epithelial integrity. The effect of AMA0825 on receptor-mediated epithelial apoptosis 
was examined in vitro in HT-29 cells, and in vivo in an endotoxemia-induced mouse model of 
enterocyte apoptosis. 
Results. AMA0825 efficiently reduced myosin light chain phosphorylation in intestinal epithelial cells 
in vitro, but did not prevent cytokine-induced intestinal epithelial loss of barrier integrity or NF-κB 
activation. During dextran sulfate sodium- and 2,4,6-trinitrobenzene sulfonic acid- induced colitis, 
AMA0825 did not influence disease activity or prevent the development of erosions, and did not 
alter the ensuing inflammatory response. Finally, AMA0825 was not able to prevent TNF/IFNγ-
mediated apoptosis of HT-29 colonocytes, or inhibit in vivo lipopolysaccharide-induced enterocyte 
apoptosis and intestinal permeability. 
Conclusions. Despite the previously documented involvement of ROCK in inflammation-induced 
intestinal epithelial barrier dysfunction, no amelioration was observed using our newly developed 
selective, local ROCK inhibitor AMA0825. 
Comment. Other research from our lab demonstrated a role for ROCK inhibition using AMA0825 in 
preventing and reversing intestinal fibrosis in two different mouse models. On a cellular level, 
AMA0825 prevented the transforming growth factor β-induced transition of fibroblasts to 
myofibroblasts by reducing the activation of the myocardin-related transcription factor and p38 
mitogen-activated protein kinase signalling pathways. In addition, AMA0825 potentiated autophagy 
in these cells. 
 
Keywords 
rho kinase inhibitor, intestinal inflammation, apoptosis  
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Introduction 
The intestinal epithelium forms a protective barrier that physically separates the gut lumen from the 
host’s mucosa. This barrier is made up of a single layer of intestinal epithelial cells (IEC) tightly held 
together through junctional complexes, which restrict the translocation of luminal antigens and other 
macromolecules into the underlying interstitium while still allowing the selective passage of water, 
electrolytes and nutrients.1 Of the three types of junctional complexes that link IECs together, the 
most apically located tight junctions (TJ) are the ones that actually seal off the intercellular space and 
regulate selective paracellular ionic solute transport.2 Transmembrane TJ proteins are anchored to 
the perijunctional cytoskeletal actomyosin ring through peripheral adaptor proteins that form a so-
called cytosolic plaque.3 This plaque also serves as a docking site for a number of signalling proteins 
involved in TJ dynamics and barrier regulation.2,4 One of these is the RhoA GTPase and its associated 
kinase, the Rho-associated kinase (ROCK), a serine/threonine kinase of which two isoforms, ROCK1 
and ROCK2, have been identified. ROCK activity regulates both the assembly and disassembly of TJs, 
as well as paracellular permeability through phosphorylation of targets like the non-muscle myosin II 
light chain (MLC), which enables the contraction of the perijunctional actomyosin ring and 
subsequent disruption of the intercellular junctions, and LIM kinase, which inactivates the actin-
depolymerisation factor cofilin and thereby stabilises the junctional actin cytoskeleton. In addition to 
the regulation of actomyosin contraction and actin polymerisation, ROCK activity can also affect 
paracellular permeability by directly phosphorylating TJ proteins.5-7 
One of the hallmarks of inflammatory bowel disease (IBD) - a chronic and relapsing inflammatory 
condition of the gastro-intestinal tract, comprising Crohn’s disease (CD) and ulcerative colitis (UC) - is 
an impaired intestinal epithelial barrier function1,8,9, which is caused by deregulated TJ protein 
expression and their redistribution off the junctional complex, and by increased IEC apoptosis.10-12 
The activity of RhoA and its effector kinase is elevated in the inflamed intestinal mucosa of CD 
patients, as well as in experimental colitis.13 Pro-inflammatory cytokines like tumor necrosis factor 
(TNF) and interferon gamma (IFNγ) are known to increase intestinal epithelial paracellular 
permeability in IEC monolayers.14-17 Existing evidence for a protective effect of the Y-27632 ROCK 
inhibitor against IFNγ-induced, RhoA/ROCK-mediated endocytosis of epithelial TJ proteins18 and 
against ethanol-induced increase in Caco-2 barrier permeability19,20, suggests a rationale for the use 
of ROCK inhibitors in preventing inflammation-induced loss of TJ integrity. Also membrane blebbing 
of apoptotic cells has been shown to involve RhoA/ROCK signalling.21 Evidence for an effect of ROCK 
inhibition on IEC apoptosis in vivo was demonstrated in a study by Ozdemir et al., who showed that 
Y-27632 reduced endotoxemia-induced enterocyte apoptosis in rats.22 
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Collectively, these data illustrate the potential of ROCK inhibition as a novel therapeutic approach to 
ameliorate the loss of intestinal epithelial barrier integrity in IBD. However, there are a few 
reservations concerning the therapeutic use of current ROCK inhibitors like Y-27632. First, although 
Y-27632 is classified as a selective ROCK inhibitor and is commonly used to study ROCK functions, it 
also inhibits other protein kinases, depending on the concentration used.5,23 Secondly, important side 
effects such as cardiovascular hypotension warrant for great caution if these compounds reach the 
systemic circulation.24 To circumvent this problem, we developed AMA0825; a potent and selective 
ROCK1/2 inhibitor optimised to have a localised action in the intestine due to its degradation upon 
contact with esterase activity in the blood, which minimises systemic exposure. In the present study, 
we evaluated the in vitro and in vivo efficacy of this compound in counteracting inflammation-
induced loss of epithelial barrier integrity and the associated inflammatory response. 
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Materials and Methods 
Ethics statements. Mice were housed in the laboratory animal facility at Ghent University Hospital 
according to the institutional animal healthcare guidelines. This study was approved by the 
Institutional Review Board of the Faculty of Medicine and Health Sciences of Ghent University 
(ECD2013-02). 
Compounds and reagents. AMA0825 was developed by Amakem Therapeutics (Diepenbeek, 
Belgium). For the in vitro experiments, AMA0825 was dissolved in dimethylsulfoxide (DMSO, Sigma-
Aldrich, Diegem, Belgium). Vehicles used for AMA0825 suspension in in vivo experiments; propylene 
glycol (PG), Labrafil® M1944CS and KLEPTOSE® were bought from Sigma-Aldrich, Mosselman SA 
(Ghlin, Belgium) and Roquette Pharma (Brussels, Belgium), respectively. Dextran sulfate sodium (DSS, 
molecular weight 36,000 - 50,000) was bought from MP Biomedicals (Illkirch, France) and 2,4,6-
trinitrobenzene sulfonic acid (TNBS, 5% (w/v) in H2O) from Sigma-Aldrich. Recombinant human IFNγ 
and TNF were purchased from Life Technologies (Gent, Belgium), butyric acid (sodium butyrate) and 
lipopolysaccharide (LPS) from Sigma-Aldrich, and ACHP (2-amino-6-[2-(cyclopropylmethoxy)-6-
hydroxyphenyl]-4-(4-piperidinyl)-3-pyridinecarbonitrile) from Tocris Bioscience (Abington, UK). ACHP 
was dissolved in DMSO. The Y-27632 ROCK inhibitor was bought from Cayman Chemical (Anne Arbor, 
MI, USA) and dissolved in phosphate buffered saline (PBS). 
Cell culture. HT-29 (HTB-38) and Caco-2 (HTB-37) intestinal epithelial adherent cell lines were 
purchased from the American Type Culture Collection (Manassas, VA, USA). HT-29 growth medium 
consists of McCoy’s medium supplemented with 10% fetal bovine serum (FBS), Caco-2 cells were 
cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% FBS. All media and 
supplements were purchased from Life Technologies. Cells were maintained at 37°C in a humidified 
atmosphere of air/CO2 (95:5, v/v) with two medium changes per week. 
Induction of epithelial barrier disruption and determination of monolayer integrity. Caco-2 cells 
were seeded on 24-well semipermeable inserts (0.4 µm, translucent ThinCerts™, Greiner Bio-One, 
Vilvoorde, Belgium) at a density of 100.000 cells/well. Cells were left to differentiate over the course 
of 2 to 3 weeks until functional monolayers with absolute transepithelial electrical resistance (TEER) 
values of more than 6000 Ohm/cm2 were obtained. Next, monolayers were stimulated apically with 
AMA0825 (0.1 µM to 10 µM, 10-fold dilution) or butyric acid (5 mM), and basolaterally with a 
combination of TNF (100 ng/ml) and IFNγ (300 ng/ml) to induce barrier disruption, measured as a 
drop in TEER. After 48 hrs, absolute TEER values were normalised to their pre-treatment values and 
expressed as a percentage of the initial TEER values. Each condition was performed in triplicate. 
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In vitro cytotoxicity assays. HT-29 cells were seeded in 96-well plates (Greiner Bio-One) with each 
well containing 50.000 cells. The next day, cells were stimulated with a dose range of AMA0825 (1 
nM to 10 µM, 10-fold dilution) or an equal concentration of DMSO for 24 hrs. Each condition was 
performed in triplicate and a positive control of 1% Triton X-100 (Sigma-Aldrich) in PBS was included. 
Supernatant was collected for lactate dehydrogenase (LDH) quantification according to the 
manufacturer’s instructions (Roche, Vilvoorde, Belgium) and cells were incubated for an additional 3 
hrs with 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT, Sigma-Aldrich). The 
MTT precipitate was dissolved in DMSO and measured spectrophotometrically at 570 nm (MultiSkan 
Ascent, VWR International, Leuven, Belgium). 
Western blot analysis. HT-29 cells were seeded in 6-well plates (Greiner Bio-One) at a density of 106 
cells/well. The next day, cells were co-incubated for 24 hrs with a combination of TNF (100 ng/ml) 
and IFNγ (300 ng/ml), and a dilution series of AMA0825 (0.1, 0.5, 1, 5, 10 µM), a volume of DMSO 
corresponding to that of the highest AMA0825 concentration or Y-27632 (10 µM). After 24 hrs, cells 
were lysed using sonication on ice for 1 min in 200 µl of Radio Immunoprecipitation Assay buffer 
supplemented with phosphatase and protease inhibitors (Sigma-Aldrich). Lysate protein 
concentrations were determined using the Bio-Rad Protein Assay (Bio-Rad, Temse, Belgium) 
according to the manufacturer’s instructions with bovine serum albumin (BSA) as a protein standard. 
Thirty µg of each sample was mixed with 1:4 loading buffer (Life Technologies) and 1 mM 
dithiothreitol (Roche). Samples were denatured by boiling for 10 min at 95°C, separated on a 4–12% 
gradient Bis-Tris SDS-PAGE gel and transferred to a nitrocellulose membrane using a wet transfer (all 
Life Technologies). Afterwards, membranes were blocked with 5% milk powder in Tris buffered saline 
with 0.1% Tween-20 (TBST) (Sigma-Aldrich) and incubated overnight at 4°C with 1:1000 rabbit anti-
phospho-myosin light chain 2 (Ser19) antibody (Cell Signalling, Leiden, The Netherlands) in 5% BSA in 
TBST. Next, blots were incubated for 1 h at room temperature with 1:2000 secondary goat anti-
rabbit IgG, HRP-conjugated secondary antibody (Cell Signalling). Bound antibodies were visualised 
using the BM Chemiluminescence Western Blotting Substrate POD (Roche) according to 
manufacturer’s instructions and membranes were exposed to X-ray films. Equal loading of proteins 
was confirmed by immunoblotting with 1:5000 anti-tubulin (Abcam, Cambridge, UK) antibody in 5% 
BSA in TBST. Tubulin and phosphorylated MLC protein band intensities were measured using the 
ImageJ program (Java). Intensity values of the phosphorylated MLC bands were normalised to those 
of the corresponding tubulin bands. 
Measurement of NF-κB p65 phosphorylation. HT-29 cells were seeded in 96-well plates at a density 
of 25.000 cells/well. The next day, cells were incubated for 24 hrs with a dilution series (0.1 µM to 10 
µM, 10-fold dilution) of AMA0825, ACHP (10 µM) or a volume of DMSO corresponding to that of the 
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highest AMA0825 concentration. After 24 hrs, the supernatant was removed and cells were briefly 
stimulated with a combination of TNF (100 ng/ml) and IFNγ (300 ng/ml). After 30 minutes, the level 
of p65 phosphorylation was determined using an enzyme-linked immunosorbent assay (ELISA)-based 
detection method (NF-κB p65 (pS536) PhospoTracer, Abcam, Cambridge, UK) with a fluorescent 
read-out signal (λex/λem = 544/590 nm; FLUOstar Omega, BMG Labtech, Germany) according to the 
manufacturer’s instructions. Each condition was performed in triplicate. 
Measurement of IL-8 secretion. HT-29 cells were seeded in 96-well plates at a density of 80.000 
cells/well. The next day, cells were pre-incubated for 1 hour with an dilution series (0.1 µM to 10 µM, 
10-fold dilution) of AMA0825, ACHP (10 µM) or a volume of DMSO corresponding to that of the 
highest AMA0825 concentration. Following the pre-incubation, a combination of TNF (100 ng/ml) 
and IFNγ (300 ng/ml) was added and the cells were incubated with TNF/IFNγ and AMA0825, ACHP or 
DMSO for another 24 hrs. After 24 hrs, IL-8 concentration in the supernatant was determined using 
an ELISA (R&D Systems, Abington, UK) according to the manufacturer’s instructions. Each condition 
was performed in triplicate. 
Induction of apoptosis. HT-29 cells were seeded in 96-well plates at a density of 50.000 cells/well. 
The next day, cells were co-incubated for 24 hrs with a combination of TNF (100 ng/ml) and IFNγ (300 
ng/ml), and a dilution series of AMA0825 (0.1 nM to 10 µM, 10-fold dilution) or an equal volume of 
DMSO. Each condition was performed in triplicate. After 24 hrs, supernatant was discarded and cells 
were lysed for quantification of caspase-3/7 activity. 
Caspase-3/7 activity assay. Enzymatic activity of effector caspases 3 and 7 was assayed in HT-29 
lysates and mouse ileal tissue homogenates using the Caspase-Glo® 3/7 Assay (Promega, Madison, 
WI, USA) according to the manufacturer’s instructions. After 1 hour, the release of light following 
caspase-mediated cleavage of a luminogenic substrate was measured using a luminometer (FLUOstar 
Omega). 
Pharmacokinetic profiling of AMA0825 in C57BL6/J mice. Ten-week old male C57BL/6J mice 
received a single dose of AMA0825 suspended in PG (20% (v/v) in H2O) that was administered 
intragastrically (i.g.). Plasma and colon samples were collected 1, 2, 4, 8 and 24 hrs after AMA0825 
administration. Blood was sampled retro-orbitally under anesthesia (100 mg/kg ketamine and 10 
mg/kg xylazine) and collected in tubes containing EDTA (5 mM final concentration). Plasma was 
extracted and samples were stored at -80°C until analysis. Mice were sacrificed by cervical 
dislocation and their colons were excised, rinsed with ice cold saline, blotted dry, weighed, snap 
frozen, and stored at -80°C. The colon samples were subsequently homogenised, and the 
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concentration of AMA0825 in plasma and colon homogenates was determined by liquid 
chromatography-tandem mass spectrometry (LC/MS-MS) analysis. 
Determination of cardiovascular side-effects of AMA0825. Sixteen-week old Spontaneously 
Hypertensive rats (Charles River Laboratories, Leiden, The Netherlands) were anesthetised using 
isoflurane and were subcutaneously administered with 7.5 mg/kg carprofen (Rimadyl®). Following a 
midline incision in the abdomen, a DSI TA11PA-C40 (Data Sciences International, s'Hertogenbosch, 
The Netherlands) implantable telemetric device was introduced into the peritoneal cavity, and the 
catheter of the device was inserted facing upstream into the descending aorta at a point below the 
renal arteries. The abdominal and skin incisions were then closed. The animals were given 100 mg/kg 
amoxicillin intramuscularly and returned individually to their cages. After 24 hrs, they were given 100 
mg/kg amoxicillin subcutaneously. One week later, the animals were placed individually within their 
home cage on a telemetry receiver (Data Sciences International) to record mean, systolic and 
diastolic arterial blood pressures (mmHg) as well as heart rate (beats/min, derived from pulse blood 
pressure). All generated data were acquired and analysed using EMKA Technologies software. 
AMA0825 was administered i.g., and data were recorded continuously from 30 min before to 4 hrs 
after the administration of AMA0825. Effects were reported at the following time points: 0, 15, 30, 
45, 60, 120, 180 and 240 min after each application. Each animal received both vehicle and the test 
substance, with a wash-out period of at least 48 hrs between each treatment. 
Induction and assessment of colitis. For both the DSS- and TNBS-induced colitis experiments, 8- to 
10-week old male C57BL/6 mice were purchased from Harlan Laboratories (Horst, The Netherlands) 
and conventionally housed in a temperature-controlled room at 20°C with a light/dark cycle of 12/12 
h. Mice had free access to water and a commercial chow (mice maintenance chow, Carfil Labofood, 
Pavan Service, Belgium). In the DSS-induced colitis, mice received 2.5% DSS in their drinking water for 
7 days, followed by another 2 days of tap water. Non-DSS control mice were allowed to drink only 
water. Prior to the start of the experiment, mice were matched for initial body weight. The number 
of mice used for each treatment group was 8 and 6 healthy control mice were also included. Body 
weight was recorded daily. Mice were sacrificed by cervical dislocation 2 days after DSS withdrawal. 
TNBS-colitis was induced by rectally administering 2 mg TNBS in 50% ethanol. The non-TNBS controls 
received PBS in 50% ethanol. Prior to the start of the experiment, mice were matched for initial body 
weight. The number of mice used for each treatment group was 7 and 5 healthy control mice were 
also included. Body weight was recorded daily. Mice were sacrificed by cervical dislocation 4 days 
after TNBS instillation. 
Treatment of colitis. In the DSS-induced colitis, mice were treated prophylactically with AMA0825 (3 
and 10 mg/kg) starting 2 days before induction of colitis. AMA0825 was suspended in PG (20% (v/v) 
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in H2O) and administered i.g. on a daily basis. Suspensions were prepared fresh every day just before 
administration and the dose was adjusted to the measured individual body weight on the respective 
day. Untreated DSS controls and non-DSS controls also received a weight-matched volume of the PG 
vehicle. In the TNBS-induced colitis, mice were treated prophylactically with AMA0825 (0.3 and 3 
mg/kg) starting 2 days before induction of colitis. AMA0825 was suspended in kleptose (5% (w/v) in 
H2O) and administered i.g. on a daily basis. Suspensions were prepared fresh every day just before 
administration and the dose was adjusted to the measured individual body weight on the respective 
day. Untreated TNBS controls and non-TNBS controls also received a weight-matched volume of the 
kleptose vehicle. 
Tissue sampling of colitis. The colon was excised and its length was measured. The colon was opened 
longitudinally and feces were removed by flushing with PBS. Distal colon tissue fragments of 5 mm 
were cut and immersed in formaldehyde (Klinipath, Olen, Belgium), RNAlater (Ambion, 
Cambridgeshire, UK) or snap-frozen, and stored at -80°C until analysis. 
LPS challenge, tissue sampling and determination of intestinal permeability. Thirty-two female, 9-
week-old C57BL6/J mice (Janvier Labs, Le Genest-Saint-Isle, France) were i.p. injected with 7.5 mg/kg 
LPS from Salmonella enterica serotype abortus equi or with PBS. LPS-challenged mice were 
randomised into 3 groups (N=8/group), receiving either 0.3 mg/kg or 3 mg/kg AMA0825 or PG 
vehicle i.g. 48, 24 and 1 hour prior to LPS administration. One hour after LPS challenge, fluorescein 
isothiocyanate (FITC)-labelled dextran (4 kDa, Sigma-Aldrich) was administered i.g. to mice at 125 
mg/kg. Five hrs later, blood obtained by heart puncture was collected in EDTA-coated tubes 
(Sarstedt, Essen, Belgium) and plasma was prepared. Ileal tissue fragments were collected in 
formaldehyde or snap-frozen, and stored at -80°C until analysis. Leakage of FITC-labelled dextran into 
the circulation was determined by measuring the plasma fluorescence (λex/λem = 488/520 nm; 
FLUOstar Omega). 
Histopathology. Formaldehyde-fixed distal colonic tissue sections of 4 µm were stained with 
hematoxylin and eosin and scored in a blinded fashion for intestinal inflammation using a validated 
scoring system.25 Histological sections were evaluated for epithelial erosions, mucosal and 
submucosal influx of inflammatory cells, and mucosal and submucosal thickening. 
Myeloperoxidase assay. Distal colonic and ileal myeloperoxidase (MPO) activity was determined as 
described previously.26 Mucosal MPO values were normalised to the total protein concentration 
measured using the Bio-Rad Protein Assay according to the manufacturer’s instructions. 
Luminex. Mouse distal colonic and ileal tissue homogenates were prepared in PBS containing 
protease and phosphatase inhibitors (Sigma-Aldrich). Total protein concentration was measured 
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using the Bio-Rad Protein Assay. Pro-inflammatory cytokine levels were determined using the bead-
based Bio-Plex ProTM mouse cytokine platform according to the manufacturer’s instructions (Bio-
Rad). Measurements were performed using the Bio-Plex MAGPIX Multiplex Reader and data were 
analysed with the Bio-Plex Manager 6.1 software (Bio-Rad). 
TUNEL staining. Apoptotic cells were detected in paraffin-embedded ileal tissue by terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) according to the manufacturer’s 
protocol (Promega) and nuclei were counterstained by DAPI (Sigma-Aldrich). The mean number of 
TUNEL-positive epithelial nuclei were counted from three fields per mouse (×400). 
RNA extraction. Total RNA from mouse distal colonic tissue fragments was extracted using the 
Qiagen RNeasy Mini Kit (Qiagen, Venlo, The Netherlands) with on-column DNase treatment. 
Concentration and purity was determined using nanodrop technology (BioPhotometer Plus, 
Eppendorf, Rotselaar, Belgium). All samples exhibited an OD260/OD280 ratio between 1.8 and 2.1. 
Quantitative Real-Time PCR (qRT-PCR). One microgram of total RNA was converted to single 
stranded cDNA by reverse transcription using the iScript™ cDNA synthesis kit (Bio-Rad) according to 
the manufacturer’s instructions. The cDNA was diluted to a concentration of 5 ng/µl and 15 
nanogram was used in qRT-PCR with SYBR Green (SensiMix™ SYBR No-ROX kit, GC biotech, Alphen 
a/d Rijn, The Netherlands) and 250 nM of each primer. A two-step program was performed on the 
LightCycler 480 (Roche). Cycling conditions were 95°C for 10 min, 45 cycles of 95°C for 10 s and 60°C 
for 1 min. Melting curve analysis confirmed primer specificities. All reactions were performed in 
duplicate. Expression of mouse cytokine genes was normalised to the stably-expressed reference 
gene levels of glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and succinate dehydrogenase 
complex A subunit (Sdha). The PCR efficiency of each primer pair was calculated using a standard 
curve of reference cDNA. Amplification efficiency was determined using the formula 10-1/slope. 
Sequences of the primer sets are listed in Table 1. 
Statistical analysis. Statistical analysis was performed using GraphPad Prism software (GraphPad, La 
Jolla, CA, USA). Values are presented as the mean ± standard error of the mean (SEM). Normality of 
the data was checked using the Kolmogorov-Smirnoff test. Differences between groups were 
analysed using an unpaired Student’s t-test for independent samples in case of normally distributed 
data (applying the Welch’s correction in case of unequal variances) or the Mann-Whitney statistic if 
the data were not normally distributed. A two-way analysis of variance was performed to determine 
significances in overall body weight variation between treatment groups throughout the duration of 
the DSS- and TNBS-induced colitis experiments. Two-tailed probabilities were calculated and p-values 
less than 0.05 were considered statistically significant.  
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Results 
AMA0825 does not prevent TNF/IFNγ-induced in vitro intestinal epithelial barrier disruption 
We evaluated whether AMA0825 was able to prevent inflammation-induced loss of barrier integrity. 
Previous work demonstrated that AMA0825 dose-dependently inhibits MLC phosphorylation 
(quantified via ELISA) within a concentration range of 1 nM to 10 µM in the rat smooth muscle cell 
line A7r5, which endogenously expresses ROCK (data not shown). TNF/IFNγ-stimulated Caco-2 
monolayers were treated apically with a dose range of AMA0825 (0.1 to 10 µM, 10-fold dilution) or 
butyric acid (5 mM) as a positive control.27 Forty-eight hrs after stimulation with TNF/IFNγ, a 
significant drop in TEER was observed (p = 0.0143, Figure 1). The TNF/IFNγ-induced loss of TEER was 
not counteracted by stimulation with AMA0825 and even significantly increased at a concentration 
of 10 µM (p = 0.0037, Figure 1).  
 
Figure 1. Effect of AMA0825 on TNF/IFNγ-induced barrier disruption in Caco-2 monolayers. Caco-2 
monolayers were stimulated basolaterally with a combination of TNF and IFNγ, and treated apically with a dose 
range of AMA0825 (0.1 to 10 µM, 10-fold dilution) or butyric acid (5 mM). TEER was measured 48 hrs post-
stimulation and expressed as a percentage of the initial resistance prior to stimulation. Data represent the 
mean ± SEM of 3 replicates/group. *p < 0.05, **p < 0.01. AMA, AMA0825; NS, not significant. 
AMA0825 does not ameliorate in vitro TNF/IFNγ-induced NF-κB activation in HT-29 colonocytes 
In a preliminary experiment, cytotoxicity of a dose range of AMA0825 (1 nM to 10 µM, 10-fold 
dilution) on intestinal epithelium were evaluated in HT-29 colonic epithelial cells. AMA0825 was not 
toxic to HT-29 cells up to 10 µM, i.e. no increased LDH release was observed after 24 hrs (Figure 2A). 
Cell viability was reduced at 10 µM (p = 0.0023, Figure 2B) but this was not associated with an 
increased LDH release. Cellular uptake and effectiveness of AMA0825 in HT-29 cells was confirmed 
by detection of decreased protein levels of phosphorylated MLC after stimulation with TNF/IFNγ, 
which was added to induce MLC phosphorylation, and AMA0825 at 10, 5, 1, 0.5 and 0.1 µM for 24 
hrs (Figure 2C). 
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Figure 2. Evaluation of AMA0825 toxicity and effectiveness in HT-29 colonic epithelial cells. (A) Cytotoxicity 
and (B) cell viability after stimulation with AMA0825 or DMSO control for 24 hrs. Cytotoxicity is expressed as a 
percentage of maximal LDH release (i.e. Triton condition), cell viability is expressed as a percentage of control 
(i.e. unstimulated cells). (C) protein expression of phosphorylated MLC after stimulation with TNF/IFNγ and 
AMA0825 or Y-27632 for 24 hrs. A condition stimulated with a volume of DMSO corresponding to that of the 
highest AMA0825 concentration was included to determine if DMSO had any effect on MLC phosphorylation. 
Levels of phosphorylated MLC were normalised to the corresponding levels of the tubulin loading control. Data 
in A and B represent the mean ± SEM of 3 replicates/group. **p < 0.01 compared to DMSO control. AMA, 
AMA0825. 
In the next set of experiments, the anti-inflammatory potential of AMA0825 was evaluated in HT-29 
epithelial cells using a combination of TNF and IFNγ to trigger NF-κB activation, which was measured 
via p65 phosphorylation and the secretion of IL-8. HT-29 cells were treated for 24 hrs with a dose 
range of AMA0825 (0.1 to 10 µM, 10-fold dilution) or ACHP (10 µM) as a positive control28, and then 
stimulated with TNF/IFNγ for 30 min to induce p65 phosphorylation. Phosphorylated p65 levels were 
significantly increased by TNF/IFNγ (p = 0.0001, Figure 3A) but no reduction was observed in any of 
the AMA0825-treated conditions. Also in a second set-up, in which HT-29 cells were co-incubated for 
24 hrs with TNF/IFNγ and a dose range of AMA0825 (0.1 to 10 µM, 10-fold dilution) or ACHP at 10 
µM following a 1 hour pre-incubation with AMA0825 or ACHP alone, TNF/IFNγ-induced IL-8 secretion 
(p = 0.0258, Figure 3B) was not counteracted by stimulation with AMA0825. Significant results for 
AMA0825 at 0.1 µM (p = 0.0008, Figure 3B) are apparently due to a DMSO-related effect on 
inhibition of IL-8 secretion. 
A 
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Figure 3. Effect of AMA0825 on TNF/IFNγ-induced NF-κB activation in HT-29 colonocytes. HT-29 cells were 
stimulated with a dose range of AMA0825 (0.1 to 10 µM, 10-fold dilution) or ACHP (10 µM) for 24 hrs. A 
combination of TNF and IFNγ was added (A) for 30 minutes after the 24 hrs stimulation with the compounds, or 
(B) for 24 hrs together with the compounds following a 1 hour pre-incubation with the compounds alone. Two 
TNF/IFNγ-conditions were included; one with a volume of DMSO corresponding to that of the highest AMA0825 
concentration (black) and one without (white) to determine if DMSO had an effect on NF-κB activation. 
Phosphorylated p65 levels and secretion of IL-8 in each of the AMA0825-treated conditions are compared to 
those in the TNF/IFNγ condition treated with DMSO. The amount of phosphorylated p65 is expressed in relative 
light units (RLU). Data represent the mean ± SEM of 3 replicates/group. *p < 0.05, **p < 0.01, ***p < 0.001. 
AMA, AMA0825; NS, not significant. 
AMA0825 does not ameliorate intestinal inflammation during acute experimental colitis 
In order to further investigate the in vivo potential of ROCK inhibition on the development of 
epithelial erosions, we evaluated the efficacy of AMA0825 in two models of acute intestinal 
inflammation. In a set of preliminary studies, the pharmacokinetic profile of AMA0825 (3 mg/kg, i.g.) 
was evaluated in healthy C57BL/6J mice. At each time point (1, 2, 4, 8 and 24 hrs), the plasma 
concentrations were undetectable (below 1 ng/ml) while the concentration in the colonic tissue was 
above 150 nM, corresponding to approximately three times the EC50 value of AMA0825 in an MLC 
phosphorylation assay (Figure 4A). This profile supports daily dosing of the compound for in vivo 
application in mice. In line with the pharmacokinetics data in mice, AMA0825 (3 and 10 mg/kg i.g.) 
did not significantly modify arterial blood pressure and heart rate compared with placebo in 
spontaneously hypertensive rats (Figure 4B). In conclusion, AMA0825 was shown to be an effective 
ROCK inhibitor with localised action in the colon that is safe for in vivo use. 
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Figure 4. In vivo pharmacokinetic profile and cardiovascular safety assessment of AMA0825 in C57BL6/J 
mice. (A) Determination of the AMA0825 concentration by LC-MS/MS analysis in colon homogenates (full blue 
line, AMA0825 concentration expressed in pmol/ g tissue) and plasma (dotted green line, AMA0825 
concentration expressed in ng/ml) collected 0, 1, 2, 4, 8 and 24 hrs after oral dosing at 3 mg/kg. The red dotted 
line represents the AMA0825 EC50 value in the MLC phosphorylation assay. (B) Cardiovascular safety assessment 
of AMA0825 administered i.g. at 3 and 10 mg/kg in telemetrised Spontaneously Hypertensive rats. Heart rate 
(HR, beats/min) and mean arterial blood pressure (MABP, mmHg) were recorded up to 4 hrs after dosing. BLOQ, 
below level of quantification; LC-MS/MS, liquid chromatography-tandem mass spectrometry. 
AMA0825 was first evaluated in acute DSS-induced colitis, a mouse model in which the integrity of 
the mucosal barrier is directly affected through the toxic effect of DSS on the gut epithelial cells.29 
Prophylactic treatment with AMA0825 at 3 mg/kg decreased overall weight loss compared to the DSS 
controls (p = 0.0256, Figure 5A). Colon length differed significantly between non-DSS and DSS control 
mice (p < 0.0001, Figure 5B), however, AMA0825-treated mice did not show an increase in colon 
length compared to untreated DSS controls. On histological sections, DSS-induced epithelial erosions 
and mucosal inflammatory infiltrate (p = 0.0002 and p < 0.0001, respectively, Figure 5C-D) were not 
attenuated by treatment with AMA0825. The DSS-induced increase in colonic neutrophil infiltration 
(p = 0.0055, Figure 5E) was not affected by treatment with AMA0825. Levels of the pro-inflammatory 
cytokines chemokine (C-X-C motif) ligand 1 (KC) and monocyte chemoattractant protein 1 (MCP1) in 
full-thickness distal colonic lysates were increased upon DSS-administration (p = 0.0002 and 0.0055, 
respectively, Figure 5F) but reduced by treatment with AMA0825. 
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Figure 5. Disease activity parameters and histology following DSS-administration in AMA0825- and control-
treated mice. (A) Weight loss, (B) colon length, (C) representative pictures (200×) of hematoxylin and eosin 
stained sections of the distal colon of non-DSS control mice and mice treated with DSS and vehicle or AMA0825 
at 3 or 10 mg/kg (scale bar represents 100 µm), (D) scores for epithelial erosions and mucosal influx of 
inflammatory cells in distal colonic histological sections, (E) MPO activity in full-thickness distal colonic lysates, 
and (F) KC and MCP1 protein levels in full-thickness distal colonic lysates. Cytokine levels are expressed in pg 
cytokine per ml of lysate and an equal total protein concentration was loaded for each sample. Data represent 
the mean ± SEM of 8 or 6 mice/group. *p < 0.05, **p < 0.01, ***p < 0.001. AMA, AMA0825; NS, not significant. 
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AMA0825 efficacy was evaluated in a second model of mucosal inflammation; the TNBS-induced 
colitis model in which an initial ethanol-mediated disruption of the mucosal barrier elicits a hapten-
induced local colitis.29,30 In this model, prophylactic treatment with AMA0825 at 3 mg/kg decreased 
overall weight loss compared to the TNBS controls (p = 0.0237, Figure 6A). However, colon length did 
not differ significantly between non-TNBS and TNBS controls (Figure 6B), which prevented a fully 
comprehensive analysis of the effect of AMA0825-treatment on amelioration of this disease 
parameter compared to placebo. On histological sections, the degree of erosions and mucosal 
inflammatory infiltration was not significantly different between non-TNBS and TNBS controls (Figure 
6C-D). The lack of any significant histological signs of inflammation do not allow for an analysis of the 
effect of AMA0825 on histological inflammation. Colonic neutrophil infiltration was significantly 
elevated during TNBS-colitis (p = 0.0145, Figure 6E) but was not reduced by treatment with AMA0825 
at 0.3 or 3 mg/kg. Colonic mRNA levels of innate inflammatory (Tnf, Cxcl2) and Th1 (Il-12, Il-1β) 
cytokines were quantified in full-thickness distal colonic lysates but they did not differ significantly 
between non-TNSB and TNBS controls (data not shown), which prevented a fully comprehensive 
analysis of the effect of treatment compared to placebo. 
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Figure 6. Disease activity parameters and histology following TNBS-administration in AMA0825- and control-
treated mice. (A) Weight loss, (B) colon length, (C) representative pictures (200×) of hematoxylin and eosin 
stained sections of the distal colon of non-TNBS control mice and mice treated with TNBS and vehicle or 
AMA0825 at 0.3 or 3 mg/kg (scale bar represents 100 µm), (D) scores for epithelial erosions and mucosal influx 
of inflammatory cells in distal colonic histological sections, and (E) MPO activity in full-thickness distal colonic 
lysates. Data represent the mean ± SEM of 7 or 5 mice/group. *p < 0.05. AMA, AMA0825; NS, not significant. 
AMA0825 does not inhibit in vitro receptor-mediated caspase activation in HT-29 colonocytes 
To evaluate whether AMA0825 exhibits anti-apoptotic properties, HT-29 cells were co-stimulated for 
24 hrs with a combination of TNF and IFNγ, two multifunctional cytokines that are highly produced in 
IBD tissues and which have been implicated in the induction of receptor-mediated IEC apoptosis in 
IBD31-33, and a dose range of AMA0825 (0.1 nM to 10 µM, 10-fold dilution). After 24 hrs, TNF/IFNγ 
significantly induced caspase-3/7 activity (p = 0.0001, Figure 7). However, AMA0825 did not reduce 
TNF/IFNγ-induced effector caspase-3/7 activation in a dose range of 0.1 nM to 10 µM. 
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Figure 7. Effect of AMA0825 on TNF/IFNγ-induced effector caspase activation. Caspase-3/7 activity is 
expressed in relative light units (RLU). Caspase activity levels in each of the AMA0825-treated conditions are 
compared to those of their respective DMSO controls. Data represent the mean ± SEM of 3 replicates/group. 
***p < 0.001. 
AMA0825 does not prevent in vivo LPS-induced intestinal permeability and enterocyte apoptosis 
The effect of AMA0825 on in vivo intestinal epithelial apoptosis was evaluated in a mouse model of 
LPS-induced enterocyte apoptosis. In this model, ileal TNF levels peak after one hour and are 
responsible for increased intestinal permeability, enterocyte apoptosis and luminal shedding, and an 
inflammatory response.34,35 The LPS-induced increase in intestinal permeability was measured 
through detection of FITC-dextran leakage in plasma (p = 0.0047, Figure 8A). Administration of 
AMA0825 48, 24 and 1 hrs prior to LPS challenge at 3 mg/kg did not reduce plasma levels of FITC-
dextran, and even increased it at 0.3 mg/kg (p = 0.0268, Figure 8A). Enterocyte apoptosis was 
evaluated through determination of effector caspase-3/7 activity and microscopic counting of the 
number of apoptotic nuclei in the mucosa and intestinal lumen. Both were increased upon exposure 
to LPS (p = 0.0121, Figure 8B and p = 0.0004, Figure 8C-D, respectively). Treatment with AMA0825 at 
3 mg/kg resulted in a significant reduction of caspase-3/7 activity (p = 0.0224, Figure 8B) but this was 
not associated with an actual decrease in the number of apoptotic enterocytes (Figure 8C-D). 
Treatment with AMA0825 at 0.3 mg/kg, although displaying increased FITC-dextran leakage, was not 
associated with elevated caspase-3/7 activity (Figure 8B). For this reason, the effect of this dose on 
enterocyte apoptosis and luminal shedding was not investigated. 
Also the ensuing local inflammation in this model was not attenuated by AMA0825. LPS-induced ileal 
neutrophil infiltration and production of characteristic pro-inflammatory cytokines (IL-17, IL-1β, IL-6 
and MCP1)36 were not decreased by treatment with AMA0825 at 0.3 or 3 mg/kg (Figure 8D-E). 
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Figure 8. Effect of AMA0825 on LPS-induced intestinal permeability and enterocyte apoptosis. (A) FITC-
dextran fluorescence in plasma, (B) caspase-3/7 activity in full-thickness ileal lysates, (C) representative pictures 
(400×) of TUNEL-stained sections of the terminal ileum of non-LPS control mice and mice treated with LPS and 
AMA0825 at 0.3 and 3 mg/kg, (D) TUNEL-positive ileal enterocytes quantified in six fields per mouse (×400), (E) 
MPO activity in full-thickness ileal lysates, and (F) IL-17, IL-1β, IL-6, and MCP1 protein levels in full-thickness ileal 
lysates. Cytokine levels are expressed in pg cytokine per ml of lysate and an equal total protein concentration 
was loaded for each sample. Data represent the mean ± SEM of 8 mice/group. *p < 0.05, **p < 0.01, ***p < 
0.001. AMA, AMA0825; RLU, relative light units.  
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Discussion 
Intestinal epithelial barrier dysfunction in IBD is caused predominantly by disruption of TJ integrity 
and IEC apoptosis.37 Both of these processes are partially mediated by the RhoA/ROCK signalling 
pathway18,21, whose activity is elevated in mucosa of CD patients.13 Inhibition of ROCK activity using 
Y-27632 has proven to be effective at attenuating in vitro loss of IEC monolayer integrity19,20, 
experimental colitis and mucosal NF-κB signalling13, and in vivo IEC apoptosis.22 However, the 
currently available ROCK inhibitors display severe adverse effects upon systemic exposure and 
harbour selectivity issues.5,23,24 To circumvent this problem, we developed a very selective, local 
ROCK1/2 inhibitor - AMA0825 - which is inactivated upon contact with blood esterases. The aim of 
this study was to evaluate the efficacy of this compound in counteracting inflammation-induced loss 
of intestinal epithelial barrier integrity and the ensuing inflammatory response. 
Although the ROCK-inhibitory capacity of AMA0825 was demonstrated in IECs in vitro by means of a 
reduction in phosphorylated MLC levels, the compound was not able to ameliorate in vitro TNF/IFNγ-
induced epithelial barrier disruption or NF-κB activation. During acute experimental colitis, 
prophylactic AMA0825 treatment did not inhibit the development of erosions nor attenuate the 
downstream mucosal inflammatory response, despite documented local inhibition of ROCK activity.38 
Interestingly, AMA0825 therapy at 3 mg/kg/day resulted in a significant weight loss reduction. The 
reason for this remains unclear but could not be attributed to an improvement of local inflammation 
since no effects were observed on infiltration of acute inflammatory cells, the presence of 
neutrophils, or the secretion of pro-inflammatory cytokines, even though this is the proposed 
mechanism for the anti-inflammatory effects observed for Y-27632 during TNBS-induced colitis.13 
AMA0825 also did not prevent TNF/IFNγ-induced effector caspase activation in HT-29 IECs. However, 
mucosal caspase-3/7 activation was reduced in AMA0825-treated mice in a model of LPS-induced 
intestinal apoptosis, but this was not associated with an actual reduction in the number of apoptotic 
enterocytes or the ensuing intestinal permeability and mucosal pro-inflammatory response. In 
conclusion, inhibiting ROCK activity is not an appropriate target for attenuating intestinal epithelial 
dysfunction and the associated inflammation. 
The absence of any effect of the selective AMA0825 ROCK inhibitor on inflammation-induced 
epithelial dysfunction, suggests that the anti-inflammatory and barrier-protective effects observed 
for Y-27632 in previous studies are most likely due to the off-target inhibition of other cellular 
kinases besides ROCK. Davies et al. describe how Y-27632 not only inhibits the two ROCK isoforms 
(IC50= 800 nM) but also several other kinases; i.e. PKC-related protein kinase 2 with a potency similar 
to that for ROCK2 (IC50= 600 nM), as well as three other protein kinases (mitogen-and stress-
activated protein kinase 1, MAPK-activated protein kinase 1b and phosphorylase kinase) with IC50 
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values 10- to 50-fold higher than those for ROCK2 (IC50= 8.3, 19 and 44 µM, respectively).
23 Other 
protein kinases like PKCα, PKA and MLCK are also inhibited by Y-27632, albeit at even higher 
inhibitory concentrations.39 Like ROCK, all of these protein kinases are known to be involved in TJ 
regulation and are triggered by diverse pathological conditions.6 For AMA0825, limited cross-
reactivity with PKC δ, ε and θ was observed (data not shown). IC50 values for these kinases were 
respectively 5, 20 and 100 nM, which is substantially higher than the AMA0825 IC50 value of less than 
0.05 nM for ROCK2. The ROCK-selectivity of AMA0825 compared to Y-27632 therefore lies in its 
limited cross-reactivity and its extremely low inhibitory concentrations.  
Other research performed in our lab focussed on investigating the effects of AMA0825-mediated 
ROCK inhibition on intestinal fibrosis. Anti-fibrotic effects of ROCK inhibitors have already been 
described in several non-intestinal pathologies involving pro-fibrotic processes; Y-27632 was shown 
to prevent interstitial fibrosis in mouse kidneys with unilateral ureteral obstruction, and suppress 
dimethylnitrosamine-induced hepatic fibrosis in rats, whereas long-term treatment with fasudil 
improved bleomycin-induced pulmonary fibrosis.40-42 Structural fibrosis is a common complication in 
IBD, particularly in patients with ileal CD. Ultimately, up to one-third of CD patients develop an end-
stage fibrotic disease, characterised by intestinal strictures, luminal stenosis and organ failure.43 
Although anti-fibrotic agents were recently FDA-approved for idiopathic pulmonary fibrosis, there is 
currently no treatment available to halt intestinal fibrosis in IBD.44 We demonstrated that AMA0825 
prevents and resolves intestinal fibrosis via effects that combine a reduction in fibroblast activation 
with an increase in the autophagic response in these cells. These results show that local ROCK 
inhibition using AMA0825 represents a promising strategy to counteract intestinal fibrosis in CD. 
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Tables 
Table 1. Primers for qRT-PCR analysis. 
Gene symbol Species Forward (5’-3’) Reverse (3’-5’) E (%) 
Gapdh mouse CATGGCCTTCCGTGTTCCTA GCGGCACGTCAGATCCA 88 
Sdha mouse CTTGAATGAGGCTGACTGTG ATCACATAAGCTGGTCCTGT 102 
Il-1β mouse CAACCAACAAGTGATATTCTCCATG GATCCACACTCTCCAGCTGCA 105 
Il-12 mouse GGAAGCACGGCAGCAGAATA AACTTGAGGGAGAAGTAGGAATGG 94 
Tnf mouse CATCTTCTCAAAATTCGAGTGACAA TGGGAGTAGACAAGGTACAACCC 93 
Cxcl2 mouse GCGCCCAGACAGAAGTCATAG AGCCTTGCCTTTGTTCAGTATC 89 
E, efficiency. 
  
CHAPTER IV 
120 
References 
1. Laukoetter, M.G., Nava, P. & Nusrat, A. Role of the intestinal barrier in inflammatory bowel 
disease. World journal of gastroenterology 14, 401-407 (2008). 
2. Groschwitz, K.R. & Hogan, S.P. Intestinal barrier function: molecular regulation and disease 
pathogenesis. The Journal of allergy and clinical immunology 124, 3-20; quiz 21-22 (2009). 
3. Ivanov, A.I., Parkos, C.A. & Nusrat, A. Cytoskeletal regulation of epithelial barrier function 
during inflammation. The American journal of pathology 177, 512-524 (2010). 
4. Forster, C. Tight junctions and the modulation of barrier function in disease. Histochemistry 
and cell biology 130, 55-70 (2008). 
5. Riento, K. & Ridley, A.J. Rocks: multifunctional kinases in cell behaviour. Nature reviews. 
Molecular cell biology 4, 446-456 (2003). 
6. Gonzalez-Mariscal, L., Tapia, R. & Chamorro, D. Crosstalk of tight junction components with 
signaling pathways. Biochimica et biophysica acta 1778, 729-756 (2008). 
7. Terry, S., Nie, M., Matter, K. & Balda, M.S. Rho signaling and tight junction functions. 
Physiology 25, 16-26 (2010). 
8. Clayburgh, D.R., Shen, L. & Turner, J.R. A porous defense: the leaky epithelial barrier in 
intestinal disease. Laboratory investigation; a journal of technical methods and pathology 84, 
282-291 (2004). 
9. Michielan, A. & D'Inca, R. Intestinal Permeability in Inflammatory Bowel Disease: 
Pathogenesis, Clinical Evaluation, and Therapy of Leaky Gut. Mediators of inflammation 
2015, 628157 (2015). 
10. Hering, N.A., Fromm, M. & Schulzke, J.D. Determinants of colonic barrier function in 
inflammatory bowel disease and potential therapeutics. The Journal of physiology 590, 1035-
1044 (2012). 
11. Di Sabatino, A., et al. Increased enterocyte apoptosis in inflamed areas of Crohn's disease. Dis 
Colon Rectum 46, 1498-1507 (2003). 
12. Iwamoto, M., Koji, T., Makiyama, K., Kobayashi, N. & Nakane, P.K. Apoptosis of crypt 
epithelial cells in ulcerative colitis. J Pathol 180, 152-159 (1996). 
13. Segain, J.P., et al. Rho kinase blockade prevents inflammation via nuclear factor kappa B 
inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology 124, 1180-
1187 (2003). 
14. Ma, T.Y., et al. TNF-alpha-induced increase in intestinal epithelial tight junction permeability 
requires NF-kappa B activation. American journal of physiology. Gastrointestinal and liver 
physiology 286, G367-376 (2004). 
15. Wang, F., et al. IFN-gamma-induced TNFR2 expression is required for TNF-dependent 
intestinal epithelial barrier dysfunction. Gastroenterology 131, 1153-1163 (2006). 
16. Fish, S.M., Proujansky, R. & Reenstra, W.W. Synergistic effects of interferon gamma and 
tumour necrosis factor alpha on T84 cell function. Gut 45, 191-198 (1999). 
17. Bruewer, M., et al. Proinflammatory cytokines disrupt epithelial barrier function by 
apoptosis-independent mechanisms. Journal of immunology 171, 6164-6172 (2003). 
18. Utech, M., et al. Mechanism of IFN-gamma-induced endocytosis of tight junction proteins: 
myosin II-dependent vacuolarization of the apical plasma membrane. Molecular biology of 
the cell 16, 5040-5052 (2005). 
19. Tong, J., Wang, Y., Chang, B., Zhang, D. & Wang, B. Y-27632 inhibits ethanol-induced increase 
in intestinal epithelial barrier permeability. Mol Med Rep 9, 2357-2361 (2014). 
20. Elamin, E., Masclee, A., Dekker, J. & Jonkers, D. Ethanol disrupts intestinal epithelial tight 
junction integrity through intracellular calcium-mediated Rho/ROCK activation. American 
journal of physiology. Gastrointestinal and liver physiology 306, G677-685 (2014). 
21. Leverrier, Y. & Ridley, A.J. Apoptosis: caspases orchestrate the ROCK 'n' bleb. Nature cell 
biology 3, E91-93 (2001). 
CHAPTER IV 
121 
22. Ozdemir, D., et al. The effect of Rho kinase inhibitor Y-27632 on endotoxemia-induced 
intestinal apoptosis in infant rats. Journal of molecular histology 43, 81-87 (2012). 
23. Davies, S.P., Reddy, H., Caivano, M. & Cohen, P. Specificity and mechanism of action of some 
commonly used protein kinase inhibitors. The Biochemical journal 351, 95-105 (2000). 
24. Knipe, R.S., Tager, A.M. & Liao, J.K. The Rho kinases: critical mediators of multiple profibrotic 
processes and rational targets for new therapies for pulmonary fibrosis. Pharmacological 
reviews 67, 103-117 (2015). 
25. Van der Sluis, M., et al. Muc2-deficient mice spontaneously develop colitis, indicating that 
MUC2 is critical for colonic protection. Gastroenterology 131, 117-129 (2006). 
26. Bradley, P.P., Priebat, D.A., Christensen, R.D. & Rothstein, G. Measurement of cutaneous 
inflammation: estimation of neutrophil content with an enzyme marker. The Journal of 
investigative dermatology 78, 206-209 (1982). 
27. Wang, H.B., Wang, P.Y., Wang, X., Wan, Y.L. & Liu, Y.C. Butyrate enhances intestinal epithelial 
barrier function via up-regulation of tight junction protein Claudin-1 transcription. Digestive 
diseases and sciences 57, 3126-3135 (2012). 
28. Sanda, T., et al. Growth inhibition of multiple myeloma cells by a novel IkappaB kinase 
inhibitor. Clinical cancer research : an official journal of the American Association for Cancer 
Research 11, 1974-1982 (2005). 
29. Wirtz, S. & Neurath, M.F. Mouse models of inflammatory bowel disease. Advanced drug 
delivery reviews 59, 1073-1083 (2007). 
30. Strober, W., Fuss, I.J. & Blumberg, R.S. The immunology of mucosal models of inflammation. 
Annual review of immunology 20, 495-549 (2002). 
31. Neurath, M.F. Cytokines in inflammatory bowel disease. Nature reviews. Immunology 14, 
329-342 (2014). 
32. Goretsky, T., et al. p53 mediates TNF-induced epithelial cell apoptosis in IBD. The American 
journal of pathology 181, 1306-1315 (2012). 
33. Schnoor, M., Louis, N.A. Inflammatory Mediators Contributing to Intestinal Epithelial Cell 
Apoptosis and Barrier Disruption in IBD. J Clin Cell Immunol (2011). 
34. Williams, J.M., et al. A mouse model of pathological small intestinal epithelial cell apoptosis 
and shedding induced by systemic administration of lipopolysaccharide. Disease models & 
mechanisms 6, 1388-1399 (2013). 
35. Vandenbroucke, R.E., et al. Matrix metalloproteinase 13 modulates intestinal epithelial 
barrier integrity in inflammatory diseases by activating TNF. EMBO molecular medicine 5, 
932-948 (2013). 
36. Vandenbroucke, R.E., et al. Matrix metalloproteinase 13 modulates intestinal epithelial 
barrier integrity in inflammatory diseases by activating TNF. EMBO molecular medicine 5, 
1000-1016 (2013). 
37. Hindryckx, P., Laukens, D. Intestinal Barrier Dysfunction: The Primary Driver of IBD? in 
Inflammatory Bowel Disease - Advances in Pathogenesis and Management (ed. Karoui, S.) 23-
40 (InTech Europe, Rijeka, Croatia, 2012). 
38. Holvoet, T., Devriese, S., Castermans, K., Boland, S., Leysen, D, Vandewynckel Y., Devisscher, 
L., Van den Bossche, L., Van Welden, S., Dullaers, M., De Rycke, R., Geboes, K., Bourin, A., 
Defert, O., Hindryckx, P., De Vos, M., Laukens, D. Treatment of intestinal fibrosis in 
experimental inflammatory bowel disease via the pleiotropic actions of a local Rho kinase 
inhibitor.  (2016). 
39. Ishizaki, T., et al. Pharmacological properties of Y-27632, a specific inhibitor of rho-associated 
kinases. Molecular pharmacology 57, 976-983 (2000). 
40. Nagatoya, K., et al. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with 
unilateral ureteral obstruction. Kidney international 61, 1684-1695 (2002). 
41. Tada, S., et al. A selective ROCK inhibitor, Y27632, prevents dimethylnitrosamine-induced 
hepatic fibrosis in rats. Journal of hepatology 34, 529-536 (2001). 
CHAPTER IV 
122 
42. Bei, Y., et al. Long-term treatment with fasudil improves bleomycin-induced pulmonary 
fibrosis and pulmonary hypertension via inhibition of Smad2/3 phosphorylation. Pulmonary 
pharmacology & therapeutics 26, 635-643 (2013). 
43. Thia, K.T., Sandborn, W.J., Harmsen, W.S., Zinsmeister, A.R. & Loftus, E.V., Jr. Risk factors 
associated with progression to intestinal complications of Crohn's disease in a population-
based cohort. Gastroenterology 139, 1147-1155 (2010). 
44. Bettenworth, D. & Rieder, F. Medical therapy of stricturing Crohn's disease: what the gut can 
learn from other organs - a systematic review. Fibrogenesis & tissue repair 7, 5 (2014). 
 
 
  
 
 
 
CHAPTER V 
T84 MONOLAYERS ARE SUPERIOR TO CACO-2 AS A 
MODEL SYSTEM OF COLONOCYTES 
 
 
 
 
 
 
 
 
 
 
 
Taken from 
Devriese S., et al. T84 monolayers are superior to Caco-2 as a model system of colonocytes. 
Accepted for publication in Histochemistry and Cell Biology (2017).
CHAPTER V 
125 
T84 monolayers are superior to Caco-2 as a model system of colonocytes 
 
Authors 
Sarah Devriese1, Lien Van den Bossche1, Sophie Van Welden1, Tom Holvoet1, Iris Pinheiro2, Pieter 
Hindryckx1, Martine De Vos1, Debby Laukens1 
 
Affiliations 
1Department of Gastroenterology, Ghent University, 9000 Gent, Belgium 
2ProDigest BVBA, Technologiepark 3, 9052 Gent, Belgium 
 
Corresponding author 
Debby Laukens, Department of Gastroenterology, Ghent University Hospital, De Pintelaan 185, 
0MRB2, 9000 Ghent, Belgium, debby.laukens@ugent.be, Tel.: +32 9 332 20 64, Fax.: +32 9 332 49 84 
 
Abbreviations 
ALPI, alkaline phosphatase, intestinal; ANPEP, alanyl aminopeptidase, membrane; CFTR, cystic 
fibrosis transmembrane conductance regulator; DDP4, dipeptidyl peptidase 4; DMEM, Dulbecco's 
Modified Eagle Medium; FBS, fetal bovine serum; HMBS, hydroxymethyl-bilane synthase; LCT, 
lactase; MCT1, monocarboxylate transporter 1; MGAM, maltase-glucoamylase; MS4A12, membrane 
spanning 4-domains A12; NaB, sodium butyrate; NRQs, normalised relative quantities; OPLS, 
orthogonal partial least squares; PCA, principle component analysis; qRT-PCR, quantitative real-time 
PCR; SEM, standard error of the mean; SI, sucrase-isomaltase; TEER, transepithelial electrical 
resistance; TEM, transmission electron microscopy; VIP, variable importance for the projection.  
CHAPTER V 
126 
Abstract 
Colonic adenocarcinoma-derived Caco-2 and T84 epithelial cell lines are frequently used as in vitro 
model systems of functional epithelial barriers. Both are utilised interchangeably despite evidence 
that differentiated Caco-2 cells are more reminiscent of small intestinal enterocytes than of 
colonocytes, whereas differentiated T84 cells are less well characterised. The aim of this study was 
therefore to further characterise and compare differentiated Caco-2 and T84 cells. The objectives 
were to: (1) compare the brush border morphology, (2) measure the expression of enterocyte- and 
colonocyte-specific genes and (3) compare their response to butyrate, which is dependent on the 
monocarboxylate transporter 1 (MCT1), an apical protein expressed primarily in colonocytes. T84 
microvilli were significantly shorter than those of Caco-2 cells, which is a characteristic difference 
between small intestinal enterocytes and colonocytes. Also, enterocyte-associated brush border 
enzymes expressed in differentiated Caco-2 cells were not increased during T84 maturation, 
whereas colonic markers such as MCT1 were more abundant in differentiated T84 cells compared to 
differentiated Caco-2 cells. Consequently, T84 cells displayed a dose-responsive improvement of 
barrier function towards butyrate, which was absent in Caco-2 cells. We conclude that differentiated 
Caco-2 and T84 cells have distinct morphological, biochemical and functional characteristics, 
suggesting that T84 cells do not acquire the biochemical signature of mature small intestinal 
enterocytes like Caco-2 cells, but retain much of their original colonic characteristics throughout 
differentiation. These findings can help investigators select the appropriate intestinal epithelial cell 
line for specific in vitro research purposes. 
 
Keywords 
colonocyte, enterocyte, differentiation, epithelial cells, MCT1  
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Introduction 
Both T84 and Caco-2 cells are human intestinal epithelial cell lines derived from a colorectal 
adenocarcinoma, with the T84 cell line originating from a lung metastasis, whereas the Caco-2 cell 
line is derived from the primary tumor site. Caco-2 and T84 cells are, when cultured, the only two 
intestinal epithelial cell lines known to differentiate spontaneously at confluence into a monolayer of 
structurally and functionally mature absorptive epithelial cells. This maturation is completed within a 
time-course of two to three weeks and monolayer integrity is usually assessed by measuring the 
transepithelial electrical resistance (TEER).1-4 The differentiated phenotype is characterised by a 
columnar, polarised cell morphology, the formation of tight junctions separating the apical from the 
basolateral membrane compartments, and the appearance of a microvilli-studded apical brush 
border.3 For this reason, differentiated T84 and Caco-2 monolayers are both well-established in vitro 
model systems of human intestinal epithelium and are frequently used to study absorption, 
metabolism, bioavailability of drugs, electrolyte transport, and the effect of compounds on epithelial 
barrier integrity.5-8 Despite the fact that both cell lines are used interchangeably4, evidence suggests 
that differentiated Caco-2 cells closely resemble small intestinal enterocytes9 while mature T84 cells 
are more reminiscent of undifferentiated crypt cells10. However, comparative analysis and a clear 
characterisation of these cell lines is lacking. Here, we further investigated to what extent mature 
T84 and Caco-2 cells differ from each another in terms of the genes typically expressed by small 
intestinal enterocytes and colonocytes.  
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Materials and Methods 
Cell culture. Both Caco-2 (HTB-37) and T84 cells (CCL-248) were obtained from the American Type 
Culture Collection (Manassas, VA, USA). Caco-2 cells were grown in Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). T84 cells were grown in 
DMEM/Nutrient Mixture F-12 supplemented with 5% FBS. All media and supplements were 
purchased from Life Technologies (Gent, Belgium). Cells were incubated at 37°C in a humidified 
atmosphere of air/CO2 (95:5, v/v) with three medium changes per week. 
Transmission electron microscopy (TEM) and determination of microvillus length. Caco-2 and T84 
cells were seeded on 24-well, 0.4 µm pore diameter, semipermeable inserts (Greiner Bio-One, 
Vilvoorde, Belgium) at a density of 105 cells per well and cultured for two weeks. After this period, 
the integrity of the monolayer was evaluated by measuring the TEER using a Millicell ERS-2 
Voltohmmeter (Merck Millipore, Billerica, MA, USA). Next, the inserts were fixed in 
glutaraldehyde/paraformaldehyde and rinsed overnight in 0.1 M sodium cacodylate buffer (pH 7.4). 
Slices were post-fixed in 1% buffered osmium tetroxide (Merck, Summit, NJ, USA), dehydrated in a 
series of alcohol and embedded in Epon (Aurion, Wageningen, The Netherlands). Semi-thin (1 mm) 
sections, stained with toluidine blue, facilitated orientation of the tissue. Ultra-thin (90 nm) sections 
were cut, contrasted with uranyl acetate and lead citrate and examined in a Zeiss transmission 
electron microscope 900 at 50kV (Carl Zeiss, Oberkochen, Germany). The mean microvillus length 
was calculated from ten separate measurements of microvilli on TEM images of Caco-2 and T84 
apical brush borders (× 12.000). 
RNA extraction. Caco-2 and T84 cells were seeded in 12-well plates (Greiner Bio-One) at a density of 
106 cells/well and allowed to differentiate for 7, 14 or 21 days. For the undifferentiated conditions, 
106 cells were collected prior to passaging of subconfluent cultures. Each condition was performed in 
triplicate. Total RNA was extracted using the Qiagen RNeasy Mini Kit (Qiagen, Venlo, The 
Netherlands). Concentration and purity was determined using nanodrop technology (BioPhotometer 
Plus, Eppendorf, Rotselaar, Belgium). All samples exhibited an OD260/OD280 ratio between 1.8 and 
2.1. 
Quantitative Real-Time PCR (qRT-PCR). One microgram of total RNA was converted to single 
stranded cDNA by reverse transcription using the iScript™ cDNA synthesis kit (Bio-Rad, Temse, 
Belgium) according to the manufacturer’s instructions. The cDNA was diluted to a concentration of 5 
ng/µl and 15 nanogram was used in qRT-PCR with SYBR Green (SensiMix™ SYBR No-ROX kit, GC 
biotech, Alphen a/d Rijn, The Netherlands) and 250 nM of each primer. A two-step program was 
performed on the LightCycler 480 (Roche, Vilvoorde, Belgium). Cycling conditions were 95°C for 10 
min, 45 cycles of 95°C for 10 s and 60°C for 1 min. All reactions were performed in duplicate. Melting 
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curve analysis confirmed primer specificities. The PCR efficiency of each primer pair was calculated 
using a standard curve of reference cDNA. Amplification efficiency was determined using the 
formula 10-1/slope and primer pairs were selected based on an efficiency of 90-110%. Primer pair 
sequences and their efficiencies are listed in Table 1. Expression data were calculated relative to the 
mean of the overall expression level and normalised to the expression of the hydroxymethyl-bilane 
synthase (HMBS) reference gene (expressed as normalised relative quantities, NRQs). 
Predictive modelling using SIMCATM software. The qRT-PCR data for Caco-2 and T84 cells were used 
to construct a prediction model using SIMCATM 14 software (Umetrics, Malmö, Sweden). 
Multivariate data analysis was performed by means of unsupervised principle component analysis 
(PCA), i.e. without a priori knowledge of the data set, in order to visualise the natural 
interrelationship (including grouping and detection of outliers) among the observed mRNA levels of 
all enterocyte- and colonocyte-specific genes (ALPI, LCT, SI, MGAM, DDP4, ANPEP, CFTR, SLC16A1, 
and MS4A12) analysed for Caco-2 and T84 cells at different stages of maturation (subconfluent = day 
0 and one, two or three weeks post-confluency; i.e. day 7, 14 and 21, respectively). Using the qRT-
PCR data for Caco-2 and T84 cells at day 21 only, a second model, the orthogonal partial least 
squares (OPLS) model, was computed. This model separates the systematic variation in X (i.e. 
differentiation markers tested) into two elements: one that is linearly related or predictive to Y (i.e. 
differentiated Caco-2 or T84 phenotype) and one that is orthogonal or unrelated to Y. The validity of 
the OPLS model was verified by considering two different quality parameters: the R2 and Q2 
parameters. R2 corresponds to the predictive and orthogonal variation in X that is explained by the 
model and is a measure for the goodness of fit. Q2 refers to the goodness of prediction calculated by 
full cross-validation. R2 = 1 indicates perfect description of the data by the model, whereas Q2 = 1 
indicates perfect predictability. According to the SIMCA users’ guide, Q2 > 0.5 is admitted for good 
predictability.11 The obtained R2 and Q2 values were 0.998 and 0.993, respectively, indicating a well-
fitted, reliable model. A corresponding S-plot was constructed to reveal the significance of each of 
the selected differentiation markers with respect to the differentiation status of either Caco-2 or T84 
cells. Additionally, VIP-values (variable importance for the projection, VIP), summarising the most 
important X-variables that contribute to Y, were calculated. VIP-values larger than 1 indicate 
“important”, discriminatory X-variables. 
Butyrate dose-response. Caco-2 and T84 cells were seeded in semipermeable inserts (24-well, 0.4 
µm pore diameter, Greiner Bio-One) at a density of 80.000 cells per well. Starting on day 2 after 
seeding, developing monolayers were stimulated apically with a dose-range (0.5 mM to 8 mM, 2-fold 
dilution) of sodium butyrate (NaB) (Sigma-Aldrich, Diegem, Belgium). Evolution of monolayer 
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integrity was evaluated on day 2 and day 9 post-seeding by measuring the TEER. Cell culture medium 
was changed three times per week. Each condition was performed in triplicate. 
Statistical analysis. Statistical analysis was performed using GraphPad Prism software (GraphPad, La 
Jolla, CA, USA) and SPSS Statistics version 22.0 (IBM SPSS Statistics, Armonk, NY, USA). Normality of 
the data was determined using the Kolmogorov-Smirnoff test. Differences between groups were 
analysed using an unpaired Student’s t-test for independent samples in case of normally distributed 
data (applying the Welch’s correction in case of unequal variances) or the Mann-Whitney statistic if 
the data were not normally distributed. Two-tailed probabilities were calculated and p-values less 
than 0.05 were considered statistically significant. Values are presented as the mean ± standard 
error of the mean (SEM).  
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Results 
Differentiated T84 cells have shorter microvilli than differentiated Caco-2 cells 
T84 and Caco-2 cells were grown on semi-permeable membranes, which improves morphological 
differentiation of the monolayers by allowing access of fluids, ions and nutrients to both the apical 
and basolateral compartments.3 Two-week old monolayers with TEER values of 700 Ohm.cm2 or 
higher were analysed by transmission electron microscope. Both cells lines exhibited a fully 
differentiated phenotype, i.e. a monolayer of adherent columnar absorptive epithelial cells with an 
apical brush border (Figure 1A). However, the microvilli on the T84 cells are approximately three 
times shorter than those on the Caco-2 cells (p < 0.0001, Figure 1B), which is in accordance with the 
in vivo observation that the small intestinal brush border is studded with long, densely packed 
microvilli, whereas the absorptive cells of the colon have short, irregular microvilli.12 
 
Figure 1. Microvillus length in fully differentiated Caco-2 and T84 monolayers. (A) Detail TEM images (× 
12.000) of the apical brush border of Caco-2 and T84 monolayers. (B) Difference in average microvillus length 
between Caco-2 and T84 cells. Data represent the mean ± SEM of 10 microvilli/cell type. ***p < 0.001. 
Differentiated Caco-2 cells express enterocyte-specific genes, whereas differentiated T84 cells 
express colonocyte-specific genes 
T84 and Caco-2 cells were grown in standard cell culture plates and left to differentiate for 7, 14 or 
21 days. Functional differentiation was assessed through evaluation of the mRNA levels of a set of 
enterocyte- and colonocyte-specific differentiation markers (Table 1); brush border-associated 
enzymes1-3,13,14 (alkaline phosphatase, intestinal (ALPI), sucrase-isomaltase (SI), lactase (LCT), alanyl 
aminopeptidase, membrane (ANPEP), dipeptidyl peptidase 4 (DDP4) and maltase-glucoamylase 
(MGAM)), a brush border-associated chloride channel6,10,15 (cystic fibrosis transmembrane 
conductance regulator, CFTR), and the colonocyte markers membrane spanning 4-domains A12 
(MS4A12)16 and monocarboxylate transporter 1 (MCT1 or SLC16A1)17. 
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PCA analysis revealed that a distinct differentiation marker expression profile already exists between 
Caco-2 and T84 cells prior to the start of differentiation, which further persists throughout the 
different stages of maturation (Figure 2A). The significance of each differentiation marker, with 
respect to the phenotype of fully differentiated Caco-2 and T84 cells, was demonstrated by the OPLS 
model using the day 21 mRNA levels for all markers analysed. The resulting S-plot (Figure 2B) 
demonstrated that all brush border-associated enzymes, except MGAM, are highly specific to the 
differentiated Caco-2 phenotype while on the other hand, MS4A12 is strongly associated with 
mature T84 cells. This observation was confirmed by the corresponding VIP-scores of ≥ 1 that 
identified LCT, SI and DDP4 as the most important markers contributing to a differentiated Caco-2 
phenotype, and MS4A12 as the marker most characteristic of the differentiated T84 phenotype. 
 
Figure 2. PCA and OPLS plots based on enterocyte and colonocyte-specific gene expression data in Caco-2 
and T84 cells. (A) PCA scatter plot visualising the grouping among Caco-2 and T84 cells before (day 0) and 
during (days 7 to 21) differentiation, based on the observed mRNA levels for all differentiation markers 
analysed. (B) The S-plot for the OPLS model revealing the predictiveness of all markers tested in relation to the 
differentiated (day 21) Caco-2 or T84 phenotype. Caco-2-specific markers are situated in the upper-right corner 
of the plot and T84-specific markers in the lower-left corner. Markers with a VIP-score of 1 or higher are 
highlighted in black, markers with a VIP-score below 1 are highlighted in grey. 
qRT-PCR analysis of these selected differentiation markers confirmed the Caco-2-specific, 
differentiation-induced expression of brush border-associated hydrolases LCT, SI, DDP4, ALPI and, to 
a lesser degree, ANPEP (Figure 3A-E). Their mRNA levels at day 0 are already considerably higher in 
Caco-2 than in T84 cells (except for ANPEP), and also the differentiation-induced increase in their 
expression is substantially greater in Caco-2 than in T84 monolayers. Exceptions are MGAM and 
CFTR (Figure 3F-G), whose pre-differentiation levels are similar in both cell lines and whose 
expression is significantly upregulated during Caco-2 as well as T84 differentiation. For the 
colonocyte-specific markers, we observed that MS4A12 is expressed almost exclusively in 
differentiated T84 monolayers (Figure 3H) and that MCT1 mRNA levels, although not induced upon 
differentiation, are also consistently higher in T84 than in Caco-2 cells (Figure 3I). 
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Figure 3. Expression of enterocyte- and colonocyte-specific genes in T84 and Caco-2 cells before and after 
differentiation. (A-I) LCT, SI, DDP4, ALPI, ANPEP, MGAM, CFTR, MCT1 and MS4A12 mRNA levels in Caco-2 and 
T84 cells measured before (day 0) and after (day 21) differentiation. Data represent the mean ± SEM of 3 
replicates/group. *p < 0.05, **p < 0.01, ***p < 0.001. NRQs, normalised relative quantities; NS, not significant. 
T84 monolayers are more responsive to butyrate throughout maturation 
The observed difference in MCT1 levels between Caco-2 and T84 cells is of interest since MCT1 is 
responsible for apical transport of butyrate, a short-chain fatty acid produced during colonic 
microbial fermentation of dietary fiber.18 In colonocytes, butyrate functions mainly as an energy 
source but is also known to promote epithelial differentiation19, which is reflected by an improved 
barrier tightness20-22. In order to evaluate whether the observed difference in MCT1 expression 
between colonocyte-like T84 cells and enterocyte-like Caco-2 cells also translates to a functional 
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difference, we performed a dose-response experiment in which developing monolayers of T84 and 
Caco-2 cells were stimulated apically with a dose-range of butyrate. The evolution of monolayer 
integrity was monitored through intermediate TEER measurements. Only developing T84 
monolayers showed a dose-response to butyrate as well as a higher temporal increment in TEER 
upon stimulation with butyrate compared to Caco-2 cells.  
 
Figure 4. Dose-response effect of butyrate on developing T84 and Caco-2 monolayers. (A) T84 and (B) Caco-2 
developing monolayers were stimulated apically with a dose-range of butyrate (0.5 mM to 8 mM, 2-fold 
dilution), starting 2 days after seeding. TEER was measured at day 2 and day 9 post-seeding and is expressed as 
the fold change in TEER on day 9 versus day 2. Data represent the mean ± SEM of 3 replicates/group. NaB, 
sodium butyrate; TEER, transepithelial electrical resistance. 
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Discussion 
A differentiated enterocyte is characterised by a columnar cell morphology, interlocking junctional 
complexes, and the presence of apical microvilli.3 In this context, an enterocyte is usually defined as 
a specialised absorptive epithelial cell responsible for nutrient intake, as opposed to other 
specialised cells like goblet, Paneth and neuroendocrine cells, which are also present in the epithelial 
lining of the gut. In vivo, enterocyte differentiation occurs during migration from the crypts to the 
surface epithelium in case of colonocytes, or to the villus tip in small intestinal enterocytes.23 This 
differentiation is mimicked spontaneously in vitro by two cell lines; Caco-2 and T84.4 
Although both are derived from a colonic tumor, they display different functional and morphological 
phenotypes upon differentiation. We observed that expression of an array of brush border 
hydrolases, unique to the small intestine, is upregulated only during Caco-2 differentiation, whereas 
the expression of typical colonic markers, like MS4A12 and MCT1, are specific to differentiated T84 
cells. This is in line with previous observations from Bolte et al. who showed that Caco-2 cells 
express higher amounts of the brush border hydrolases ALPI, SI and DDP4 than T84 cells, suggesting 
a more pronounced small intestinal enterocytic differentiation compared to T84 cells.4 Although 
Caco-2 monolayers clearly differentiate to small intestinal-like cells, they still express low but 
detectable levels of MS4A12 as well as MCT1, albeit it to a lesser degree than T84 monolayers. This 
means that Caco-2 cells, even after complete differentiation, still retain residues of their colonic 
origin. The coexistence of enterocyte and colonocyte characteristics in this cell line has also been 
recognised previously.24 On the other hand, the characterisation of the differentiated T84 phenotype 
is less ambiguous. The absence of small intestinal hydrolase expression, their shorter microvilli, their 
functional response to butyrate in correspondence with the higher MCT1 levels in this cell line, and 
their previously documented electrical parameters and ion transport activities – including 
electrogenic chloride secretion – define mature T84 cells as most akin in structure and function to 
colonic crypt cells.6,10 
The reason why differentiated Caco-2 cells display this small intestinal hydrolase expression and 
differentiated T84 cells do not, is probably due to the fact that Caco-2 cells were derived from the 
primary colonic tumor site, whereas T84 cells were isolated from a lung metastasis. Cells at the 
primary tumor site dedifferentiate through activation of the embryonic “epithelial-mesenchymal 
transition” program to allow cancer cell motility, dissemination and, ultimately, metastasis at a 
distant site.25 However, metastases of most common human cancers often show a redifferentiation 
in the sense of a mesenchymal-epithelial (re-)transition, probably to allow growth and 
colonisation.26 Metastatic cells, like T84, are therefore more differentiated than primary tumor cells, 
like Caco-2, where dedifferentiation is accompanied by re-expression of a fetal-like gene pattern, 
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which, in the case of the human fetal colon, includes transient expression of small bowel 
enzymes.3,24 
Based on both morphological and biochemical characteristics, we conclude that Caco-2 and T84 cells 
show a distinct pattern of differentiation towards enterocytes and colonocytes, respectively. 
Researchers should be aware of these distinctive features when selecting the most appropriate 
intestinal epithelial cell line for a specific in vitro experiment. 
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Tables 
Table 1. Primers for qRT-PCR analysis. 
Gene symbol Forward (5’-3’) Reverse (3’-5’) E (%) 
HMBS GGCAATGCGGCTGCAA GGGTACCCACGCGAATCAC 101 
ALPI AGTTATCCTGCTCCCCACCTCCGG GAAGGTCCAACGGCAGGACACCT 92 
LCT CTGACCTCTTCGCCGACTATG TGGTGGGGAAGCTCCTTGA 108 
SI TCCAGCTACTACTCGTGTGAC CCCTCTGTTGGGAATTGTTCTG 101 
MGAM ACAGCCCGGTTGAAAAATCTG CAGCAGCATTTCCACTGAAGG 108 
DDP4 CCTTCTACTCTGATGAGTCACTGC GTGCCACTAAGCAGTTCCATCTTC 100 
ANPEP GACGCCACCTCTACCATCAT CCCACTTGATGTTGGCTTTC 93 
CFTR CCCACGCTTCAGGCACGAAGG GCCTGAGGGGCCAGTGACAC 91 
SLC16A1 CACTTAAAATGCCACCAGCA AGAGAAGCCGATGGAAATGA 85 
MS4A12 TTGGAGTTCTTCGTAGCTTGTG CAGGACAGACATATTGGTTGTGG 98 
E, efficiency. 
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Chronic inflammation in IBD is associated with severe microbial dysbiosis and both conditions affect, 
directly or indirectly, the integrity of the intestinal epithelial barrier. During this research, we 
investigated two different pathways involved in the maintenance and regulation of intestinal 
epithelial barrier function; luminal butyrate production and ROCK function (Figure 1). In this chapter, 
we will discuss the main research outcomes from chapters III - V and elaborate on the relevance of 
these results for the future treatment of IBD. 
 
Figure 1. Targeting intestinal epithelial dysfunction in IBD. Intestinal epithelial dysfunction in IBD is 
characterised by ROCK-mediated internalisation of TJ constituents, reduced expression of TJ proteins, and 
activation of pro-inflammatory signalling pathways like NF-κB. The aim of this thesis was to reduce acute 
cytokine-induced TJ dysfunction and epithelial inflammation by means of two barrier-protective and anti-
inflammatory mechanisms; (1) increasing colonic butyrate levels through administration of butyrate-producing 
Butyricicoccus pullicaecorum 25-3
T
 bacteria, and (2) local ROCK inhibition using the AMA0825 compound. IBD; 
inflammatory bowel disease, TJ; tight junction, ROCK; Rho-associated kinase, MAM; mucosa-associated 
microbiota. 
PROTECTING THE GUT EPITHELIUM FROM INFLAMMATION-INDUCED DYSFUNCTION IN IBD 
The resolution of impaired intestinal epithelial barrier integrity is crucial to mucosal healing. 
Therapeutic strategies aimed at the preservation of an intact epithelial barrier, which could not only 
prolong remission but also prevent the initial development and subsequent flare-ups of the disease - 
as opposed to the current immunosuppressive drugs that mainly act by reducing the severity of 
active episodes - make for a compelling prospect. During this research, we investigated two possible 
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ways to promote mucosal healing and to preserve intestinal epithelial barrier integrity: butyrate 
supplementation by means of the Butyricicoccus pullicaecorum 25-3T butyrate-producer, and local 
ROCK inhibition using the AMA0825 compound. 
1. Preserving barrier integrity in IBD through administration of Butyricicoccus pullicaecorum 25-3T 
As described in the introduction, various alterations in the composition of the gut microbiome have 
been reported in IBD patients. The most consistent observation is a reduced bacterial diversity 
characterised by an increase in bacteria from the Proteobacteria phylum and a decrease of 
Bacteroidetes and Firmicutes, two dominant phyla within the human gut microbiome.1,2 The loss of 
Firmicutes is primarily due to the depletion of species belonging to the bacterial order Clostridiales, 
particularly members of clostridial clusters IV and XIVa.1,3 The exact relevance of dysbiosis in IBD 
pathogenesis remains obscure; is it simply a consequence of the inflammatory process or is it an 
active primary driver contributing to the onset and/or perpetuation of inflammation? 
Arguments for a causative role of dysbiosis predisposing to active disease is supported by 
observations such as the persistence of a dysbiotic signature during clinical remission in UC, 
characterised by a low diversity and a temporal instability, and a decrease in bacterial richness prior 
to relapse.4,5 A subclinical dysbiosis has also been reported in unaffected relatives of UC and CD 
patients6,7, suggesting that an initial abnormal gut microbial composition might, in combination with 
genetic factors and unknown environmental triggers, contribute to initiation and progression of IBD. 
Since the commensal microbiota is critical to induce a tolerogenic environment in the gut mucosa, it 
seems likely that an imbalance in the healthy microbiota may render the host more susceptible to 
exaggerated effector immune responses.8 
The existence of a disease-associated dysbiosis has prompted research into the modulation of the 
gut microbial composition using probiotics as a treatment option in IBD. Probiotics are preparations 
of live microorganisms that, when administered in sufficient amounts, can confer a health benefit to 
the host through competitive inhibition of harmful microbes, production of barrier-protective 
metabolites like SCFAs, and interaction with lamina propria immune cells to stimulate an anti-
inflammatory response.1,9 
During this research, we focussed on the therapeutic potential of one bacterial strain in particular; 
Butyricicoccus pullicaecorum 25-3T. This butyrate-producing clostridial cluster IV species was isolated 
from the caecal content of a broiler chicken10,11 and is currently being considered as an interesting 
pre-clinical candidate for probiotic therapy in inflammatory intestinal disorders such as IBD, given the 
known barrier-protective and anti-inflammatory properties of butyrate. 
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In chapter III, we found that 16S rRNA expression for the genus Butyricicoccus was significantly 
decreased in the colonic mucosa of UC patients with active disease compared to healthy controls, 
which is in accordance with the previously described reduced abundance of the same genus in stool 
samples of IBD patients compared to healthy subjects.12 The mucosa-adherent properties of this 
genus are in agreement with a study published by Nava and Stappenbeck, which also identified 
Butyricicoccus as an autochthonous microbe predominantly colonising the mucosa-associated 
surface of the colon.13 The detection and quantification of Butyricicoccus in the mucosal 
compartment is a physiologically relevant observation. Despite the low abundance of this genus 
among the autochthonous bacteria associated with the human colonic mucosa (1-2%)13, the 
restoration of depleted mucosa-associated bacterial groups that normally reside in close proximity to 
the apical surface of the colonic epithelium are more likely to have an impact on host metabolism 
and cellular homeostasis since their biogeographical localisation facilitates host access to their 
metabolites. Also, mucosa-associated microbial communities have developed a symbiotic 
relationship with the human mucosa, which has allowed them to colonise this intestinal niche, as 
opposed to the transient microbiota of the fecal stream. This natural association of mucosa-adherent 
microbes with the intestinal epithelium might promote a more successful re-colonisation upon oral 
supplementation as a probiotic. This knowledge also emphasises the relevance of investigating not 
only the fecal, but also the mucosal disease-associated microbial dysbiosis. 
Interestingly, mucosal Butyricicoccus activity negatively correlated with the CLDN1 mRNA levels 
observed in biopsies, whereas stimulation of Caco-2 monolayers with butyrate reduced CLDN1 
protein expression and coincided with a restoration of the TNF/IFNγ-induced loss of barrier integrity. 
Most importantly, B. pullicaecorum 25-3T conditioned medium decreased CLDN1 levels in inflamed 
UC biopsies ex vivo. The beneficial effect of reducing CLDN1 expression seems counter-intuitive, 
however, CLDN1 levels are elevated during active IBD14,15 as well as in experimental colitis16, and its 
intestinal epithelial overexpression renders mice more susceptible to colitis and impairs their 
recovery.17 This is explained by the fact that, besides its function as a traditional TJ protein involved 
in the maintenance of intestinal barrier integrity, CLDN1 also plays a key role in the regulation of 
intestinal epithelial homeostasis by activating Notch-signalling, which induces colonocyte 
proliferation and inhibits goblet cell differentiation. Notch activation is also a frequent an early event 
in Wnt-induced intestinal tumorigenesis. This Notch activation is maintained throughout neoplastic 
transformation and acts downstream from the hyperactivated Wnt/β-catenin signalling cascade, 
which in itself also induces a Tcf (T-cell factor)/Lef (lymphoid enhancer factor)-mediated imbalance 
between cell proliferation and differentiation that further triggers tumorigenesis.18 Interestingly, 
CLDN1 has been identified as a target gene modulated by β-catenin/Tcf/Lef signalling and, 
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conversely, CLDN1 may also regulate β-catenin activity.19,20 Indeed, increased CLDN1 expression has 
been reported in primary and metastatic colon carcinomas, with frequent mislocalisation of the 
protein from the membrane to the cytoplasm and nucleus.14,20 Also, intestinal epithelial CLDN1 
overexpression in the adenomatous polyposis coli (APC)min mouse model of intestinal tumorigenesis 
significantly increases colon tumor growth as well as frequency while decreasing survival. Tumors in 
these mice also demonstrate elevated levels of Wnt- and Notch signalling.21 All this evidence 
combined supports the notion of CLDN1 as an oncogenic protein that aids in colonic neoplastic 
progression via upregulation of the Notch- and Wnt/β-catenin signalling pathways. Besides its 
upregulation in sporadic colon carcinomas, CLDN1 expression is also elevated in IBD-associated 
dysplasia.14 The connection between inflammation and tumorigenesis is well-established and IBD is a 
known risk factor for the development of colon cancer.22 The pro-inflammatory cytokine TNF is a key 
mediator of chronic inflammation in IBD but is also involved in epithelial-mesenchymal transition 
(EMT) and regulation of malignant progression of epithelial tumors by controlling cell migration, 
invasion and metastasis.23 Bhat et al. recently demonstrated that CLDN1 promotes TNF-induced EMT 
and migration in HT-29 colorectal adenocarcinoma cells, highlighting the key role of deregulated 
CLDN1 expression in the progression and metastasis of inflammation-induced colon cancer.24 The use 
of B. pullicaecorum 25-3T to reduce CLDN1 levels during mucosal inflammation would therefore not 
only benefit the maintenance of epithelial integrity but also further downstream pathways 
responsible for colonic epithelial cell transformation. 
Additional arguments for a barrier-protective and anti-inflammatory effect of B. pullicaecorum 25-3T 
were provided by Eeckhaut et al. who reported that B. pullicaecorum 25-3T conditioned medium 
prevented the loss of transepithelial resistance (as a measure of barrier integrity), and the increase in 
IL-8 secretion induced by TNF and IFNγ in Caco-2 monolayers.12 Also, oral administration of live B. 
pullicaecorum 25-3T bacteria resulted in a significant protective effect in TNBS-colitic rats, which was 
at least equivalent to the effect of F. prausnitzii based on macroscopic and histological criteria, and 
decreased intestinal MPO, TNF and IL-12 levels.12 
The future of Butyricicoccus pullicaecorum 25-3T in probiotic therapy for IBD 
Butyrate-producing anaerobic bacteria, in particular those belonging to clostridial clusters IV and 
XIVa, were previously proposed as novel probiotic candidates for the treatment of IBD.25 As discussed 
above, considerable evidence for a barrier-protective effect of the clostridial member B. 
pullicaecorum 25-3T already exists.12,26 Below, we will discuss how evidence from other work 
performed with B. pullicaecorum 25-3T further underscores the suitability of this butyrate-producer 
as a probiotic candidate for application in IBD therapy. 
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First of all, B. pullicaecorum 25-3T has been shown to be safe for human consumption. This is of 
particular importance given the fact that B. pullicaecorum 25-3T is of non-human origin, which is 
atypical for a probiotic strain, and because it is the first strain of the Butyricicoccus genus that is 
being considered as a probiotic. Steppe et al. evaluated the safety of B. pullicaecorum 25-3T for use in 
humans and found no adverse effects in acute and repeated oral dose toxicity tests performed in 
rats.27 The complete B. pullicaecorum 25-3T genome was sequenced and was found to contain no 
virulence factors, one gene related to harmful metabolites, and 52 sequences with high similarity to 
antimicrobial and toxic compound resistance genes, which did not correspond with a resistant 
phenotype. B. pullicaecorum 25-3T did show actual resistance against aminoglycosides and 
trimethoprim.27 These results show that B. pullicaecorum 25-3T is a non-pathogenic strain, but carries 
antibiotic resistance genes, a concern that should be further investigated to determine to what 
extent these sequences are actually linked with high minimum inhibitory concentrations, acquired 
resistance, and whether these sequences are horizontally transferable to other gut bacteria. 
Furthermore, in a placebo-controlled cross-over randomised intervention study, daily oral intake of 
B. pullicaecorum 25-3T capsules for four weeks was well-tolerated in 30 healthy subjects and did not 
induce adverse effects. The probiotic intervention induced changes in metabolic activity, although no 
effect was observed on fecal butyrate levels.28 
The therapeutic application of B. pullicaecorum 25-3T in patients will occur through oral ingestion. 
This means that B. pullicaecorum 25-3T, an obligate anaerobe, must pass the environment of the 
upper gastro-intestinal (GI) tract, which might affect its viability. Geirnaert et al. demonstrated that 
B. pullicaecorum 25-3T bacteria are intrinsically tolerant to the harsh conditions of the stomach and 
small intestine (pH, bile acids, oxygen).29 During acidic stomach conditions, B. pullicaecorum 25-3T 
loses cultivability but remains viable and active. Apparently, this is a sort of survival mechanism to 
cope with harsh environmental conditions because, once the acid stress factor disappears during 
small intestinal simulation, B. pullicaecorum 25-3T resuscitates and becomes cultivable again. As for 
the higher oxygen levels during upper GI passage, B. pullicaecorum 25-3T has been shown to reduce 
riboflavin to dihydroriboflavin, which in turn reduces O2 to H2O.
30 This is a bacterial mechanism that 
allows strict anaerobes to survive moderate oxygen concentrations in their environment through 
oxygen reduction via an extracellular redox mediator. Adding riboflavin or another redox mediator to 
the B. pullicaecorum 25-3T probiotic formulation would be an option to increase the number of viable 
cells that reach the colon. 
Administration of B. pullicaecorum 25-3T to patients will occur through oral intake of capsules 
containing freeze-dried bacteria. Geirnaert et al. have shown that enteric coating of hydroxypropyl 
methylcellulose capsules with cellulose acetate phthalate better protected bacteria from acid gastric 
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conditions, resulting in the delivery of more cultivable bacteria and a higher butyrate production 
during colonic simulation, compared to uncoated capsules.31 Another way of bypassing the stress-
effect of the upper GI environment on the bacteria, as well as improving the shelf life of the probiotic 
product, would be the use of spores. Sporulation genes were detected in the genome of B. 
pullicaecorum 25-3T 32, however, induction of sporulation has not yet been successful. 
A way to increase the success rate of probiotic intervention, is the administration of B. pullicaecorum 
25-3T as part of a mixture of several probiotic species that would form a stable, co-dependent 
community (“collaborome”), as opposed to the administration of a single bacterial strain. A 
multispecies mix of butyrate-producers has been shown to have the highest success rate in terms of 
increased butyrate production and colonisation capacity in mucus- and lumen-associated CD 
microbiota.33 
As a general comment, we would like to point out that B. pullicaecorum 25-3T - and by extension 
other butyrate-producing commensals- do not solely secrete butyrate and that a butyrate-specific 
effect of treatment with B. pullicaecorum 25-3T was not demonstrated explicitly for either the 
conditioned medium in active UC biopsies and TNF/IFNγ-stimulated Caco-2 monolayers, nor for the 
live bacteria in the TNBS-induced colitis. Other secreted bacterial metabolites may also be important. 
For example, a 15 kDa protein named microbial anti-inflammatory molecule (MAM) produced by F. 
prausnitzii, a butyrate-producing Firmicute deficient in CD34, was identified as being able to block the 
NF-κB pathway in IECs and alleviate experimental colitis in mice.35 
In addition, B. pullicaecorum 25-3T could also exert its effects indirectly by inducing a shift in the gut 
microbial composition through stimulating the colonisation and proliferation of other beneficial 
bacteria that could have a protective effect during inflammatory epithelial dysfunction. Future 
studies will be needed to identify exactly how B. pullicaecorum 25-3T exerts its beneficial effects by 
identifying its targets and mechanism of action.  
The last step in exploring the potential application of B. pullicaecorum 25-3T as a probiotic treatment 
for IBD, are clinical trials in which safety, dose range determination, indication, possible side effects, 
efficacy, and effectiveness are evaluated. If a probiotic effect is confirmed in humans, additional 
studies would be essential to unravel its mechanism of action and targets. 
Finally, the future use of B. pullicaecorum 25-3T in IBD patients would most likely be in combination 
with conventional immunosuppressive medication as an add-on therapy, and probably restricted to 
periods of remission to prevent relapse, since administration of large quantities of live bacteria to 
patients in whom intestinal permeability is already increased, is probably ill-advised. Probiotic 
therapy during quiescent disease in order to maintain remission is also recommended based on 
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evidence from the limited clinical trials on probiotics in IBD so far, which demonstrate that selected 
bacterial species can prevent relapse and, in a select few cases only, treat mild to moderately active 
UC.36,37 Based on these trials, evidence for the use of probiotics in IBD is also more substantiated for 
UC than for CD.9,38  
2. Preventing epithelial dysfunction in IBD through targeted local ROCK inhibition 
Besides modulating TJ gene expression using butyrate-producing probiotics, another way of 
preserving epithelial barrier integrity, is by targeting the inflammation-induced ROCK-mediated TJ 
destruction and IEC apoptosis. 
In chapter V, we investigated the effect of ROCK inhibition on intestinal epithelial dysfunction. 
Previous studies using Y-27632, a compound that is widely used as a selective ROCK inhibitor, 
reported an ameliorating effect on ethanol-induced increase in Caco-2 barrier permeability39,40, IFNγ-
induced TJ protein endocytosis41, and endotoxemia-induced IEC apoptosis in rats42. In this work, we 
used the newly developed AMA0825 compound; a ROCK1/2 inhibitor optimised to have a localised 
action in the intestine due to its degradation upon contact with esterase activity in the blood, which 
minimises systemic exposure. ROCK-selectivity and potency of AMA0825 was demonstrated by its 
limited cross-reactivity with other kinases (PKC δ, ε and θ) and its extremely low inhibitory 
concentrations (< 0.05 nM). AMA0825 efficiently inhibited in vitro ROCK activity at nM 
concentrations, as measured by a reduction in MLC phosphorylation. In vivo, oral administration of 
AMA0825 resulted in colonic drug levels that were above the functionally active concentrations, and 
local ROCK activity was reduced in mice treated with AMA082543, proving that localised ROCK 
inhibition by AMA0825 is feasible. Surprisingly, AMA0825 did not ameliorate in vitro TNF/IFNγ-
induced loss of barrier integrity, epithelial NF-κB activation or colonocyte apoptosis, and did not 
attenuate in vivo intestinal permeability or the ensuing mucosal inflammatory response. Apparently, 
specifically inhibiting ROCK activity is not an appropriate target for attenuating the acute stages of 
inflammation-induced intestinal epithelial dysfunction. We therefore have to conclude that the 
barrier-protective and anti-inflammatory effects observed for Y-27632 are off-target effects. Indeed, 
this was elaborated on in a paper by Davies et al., who demonstrated that Y-27632 also inhibits other 
kinases.44 For example, Y-27632 inhibits PKC-related protein kinase 2 with a potency similar to that 
for ROCK2, as well as three other protein kinases (mitogen-and stress-activated protein kinase 1, 
MAPK-activated protein kinase 1b and phosphorylase kinase) with IC50 values 10- to 50-fold higher 
than those for ROCK2. Several of these protein kinases are also known to be involved in TJ regulation 
and are triggered by diverse pathological conditions.45 The key to unravelling the involvement of a 
particular kinase in the formation and disassembly of TJs, both under normal and pathological 
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conditions, therefore lies in the use of inhibitory compounds that are highly selective to the kinase 
under investigation. 
A role for local ROCK inhibition in the treatment of fibrostenotic Crohn’s disease 
Although beyond the scope of the epithelial dysfunction investigated during this research, our lab 
recently demonstrated a role for ROCK inhibition using AMA0825 in the prevention and reversal of 
intestinal fibrosis in two different mouse models. On a cellular level, AMA0825 prevented the 
transforming growth factor β-induced transition of fibroblasts to myofibroblasts by reducing the 
activation of the myocardin-related transcription factor and p38 mitogen-activated protein kinase 
signalling pathways. In addition, AMA0825 potentiated autophagy in these cells.43 Intestinal fibrosis 
is a common complication of CD and ultimately results in luminal (sub)obstruction with surgical 
resection of the afflicted bowel segment as the only treatment option. With up to one third of CD 
patients developing an end-stage fibrotic disease46 and the lack of any available drug to halt 
intestinal fibrosis in IBD47, there is a clear unmet need for anti-fibrotic therapies. Localised ROCK 
inhibition using AMA0825 thus represents a promising, novel anti-fibrotic strategy for the prevention 
and treatment of fibrosis in CD patients. 
IMPROVING KNOWLEDGE ON T84 AND CACO-2 MONOLAYERS AS MODEL SYSTEMS OF HUMAN 
INTESTINAL EPITHELIUM 
During the optimisation of the cell culture models of intestinal barrier dysfunction, as well as in the 
literature, the Caco-2 and T84 colonic epithelial cell lines were used for the in vitro modelling of 
human intestinal epithelium, since they both differentiate spontaneously at confluence into a 
monolayer of structurally and functionally mature absorptive epithelial cells. Since we found 
increasing evidence that differentiated Caco-2 cells closely resembled small intestinal enterocytes, 
while mature T84 cells were less described, we tried to further define the differences between these 
two intestinal epithelial cell lines. In chapter V, we demonstrated that differentiated T84 monolayers 
have - in contrast to differentiated Caco-2 monolayers - shorter microvilli, a lack of brush border-
associated enzyme expression, exhibit high levels of colon-specific markers, and show a dose-
responsive improvement of barrier function towards butyrate. This led us to conclude that 
differentiated Caco-2 and T84 cells each have distinct morphological, biochemical and functional 
characteristics, suggesting that T84 cells do not acquire the signature of mature small intestinal 
enterocytes like Caco-2 cells, but retain much of their original colonic characteristics throughout 
differentiation. These findings can be used by investigators to better select the appropriate intestinal 
epithelial cell line for specific in vitro research purposes. 
In the context of the work performed during this thesis, either cell line would suit experiments 
examining basic cellular processes like kinase-mediated TJ dynamics or experiments with a simple 
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read-out, such as measuring TEER. This is because both of the examples above pertain to general 
characteristics of intestinal epithelium, which are met by both Caco-2 and T84 monolayers. Research 
in which the use of Caco-2 monolayers is more appropriate are, for example, studies investigating the 
interaction of apical IEC membranes with certain food components, such as proteins and simple 
carbohydrates, which would require the expression of brush border-associated digestive enzymes as 
well as transporters for the subsequent uptake of their degradation products. The colonocyte-like 
T84 cell line would be the model of choice for investigating epithelial responses to probiotic 
metabolites such as butyrate. Although butyrate-producing commensals are by no means unique to 
the colonic environment, cfr. the detection of F. prausnitzii on resected ileal CD mucosa34, the bulk of 
available butyrate in humans is produced during dietary fiber fermentation in the large intestine, 
which harbours significant populations of butyrate-producing species.48,49 These bacteria naturally 
and abundantly reside in the colonic lumen or mucosa and, as such, are in close proximity to 
colonocytes in particular. Therefore, interactions between the intestinal epithelium and butyrate-
producing probiotic candidates would be best approximated in vitro by using the T84 cell line. Also 
epithelial responses to potential barrier-protective and anti-inflammatory metabolites from these 
probiotic candidates are best studied in T84 cells, since the epithelial expression of receptors and 
transporters for these metabolites is probably highest in T84 colonocytes. 
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TAKE-HOME MESSAGES 
In this thesis, we have highlighted the intestinal permeability associated with inflammation in IBD, 
and the importance of restoring epithelial barrier integrity as a key treatment goal in clinical disease 
management. Restoring an intact epithelial barrier under inflammatory conditions was attempted by 
modulating two pathways; increasing in situ butyrate levels through probiotic treatment with B. 
pullicaecorum 25-3T, and inhibition of epithelial ROCK activity using the AMA0825 local ROCK 
inhibitor. We also further characterised T84 and Caco-2 differentiated monolayers, two frequently 
used models of intestinal epithelium in this thesis. 
Our research provided the following insights:  
1. Butyricicoccus pullicaecorum 25-3T is a probiotic candidate with barrier-protective potential 
 Butyricicoccus is a mucosa-associated microbe and its activity is reduced in UC patients with 
active disease 
 Butyricicoccus activity negatively correlates with CLDN1 gene expression 
 reduction of CLDN1 expression is associated with restoration of barrier integrity 
 B. pullicaecorum 25-3T conditioned medium reduces CLDN1 gene expression 
 
2. ROCK inhibition is not a target for attenuating inflammation-induced epithelial dysfunction 
 ROCK inhibition does not prevent the inflammation-induced intestinal epithelial barrier 
dysfunction or the associated inflammatory response 
 ROCK inhibition prevents and reverses intestinal fibrosis via effects that combine a reduction 
in fibroblast activation with an increase in the autophagic response in these cells 
 
3. T84 monolayers are superior to Caco-2 as a models system for colonocytes 
 Caco-2 monolayers express enterocyte-specific genes, whereas T84 monolayers express 
colonocyte-specific genes including MCT1, the main transporter for butyrate 
 T84 barrier function improves in response to butyrate in a dose-dependent manner, which is 
not the case for Caco-2 cells  
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